amnog-prod-bucket1000truemedia/001_Analyse-AbD-Beschluss-Zolgensma-2022-02-01.pdf2025-12-03T11:45:08.376Z"26c4694ccd0dfe30b93ebd9499da95ab"36889STANDARD2206203922062039Normalmedia/002_Analyse-AbD-Beschluss-Tecartus-2022-07-21.pdf2025-12-03T11:45:08.941Z"feb645b303531eafb49561c40a6c2e8d"34386STANDARD2206203922062039Normalmedia/003_Analyse-AbD-Beschluss-Risdiplam-2022-07-21.pdf2025-12-03T11:45:08.465Z"6e80479198ff4fe4494653087c23cfa2"37497STANDARD2206203922062039Normalmedia/004_Analyse-AbD-Beschluss-Etranacogen_Dezaparvovec-2022-08-30.pdf2025-12-03T11:45:09.150Z"42d0d973df756f88d9919dd2f5313d3d"128364STANDARD2206203922062039Normalmedia/005_Analyse-AbD-Beschluss-Valoctocogen_Roxaparvovec_-2023-03-16.pdf2025-12-03T11:45:09.747Z"268110352306f11eeb59f881551f16ae"128066STANDARD2206203922062039Normalmedia/2011-01-01-D-001_Ticagrelor_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:40.746Z"f656f9afcc473de4b7595044fb7d74ec"767907STANDARD2206203922062039Normalmedia/2011-01-27_Modul4A_Belimumab.pdf2025-12-03T11:02:14.367Z"638bee725d72c299be8a4def61400233"5113983STANDARD2206203922062039Normalmedia/2011-04-15-D-003_Cabazitaxel_IQWiG-Nutzenbewertung.PDF2025-12-03T11:01:43.150Z"8fb7f488ede12b1488b2463cc6c8f046"582579STANDARD2206203922062039Normalmedia/2011-04-15-D-004_Fingolimod_IQWiG-Nutzenbewertung.PDF2025-12-03T11:01:50.654Z"811414affb6e82aefef9070e9e5c31bf"576913STANDARD2206203922062039Normalmedia/2011-04-15-D-024_Regadenoson_Nutzenbewertung.pdf2025-12-03T11:01:51.547Z"d6d3c7296cba7e21b2c8905cf6065c3c"13475STANDARD2206203922062039Normalmedia/2011-05-01-D-005_Eribulin_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:55.274Z"5342255f3949069834b2eec4d32e4d24"458150STANDARD2206203922062039Normalmedia/2011-05-01-D-006_Collagenase_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:54.487Z"777faa2ca563d9b85020b9e514f0922e"315553STANDARD2206203922062039Normalmedia/2011-05-15-D-007_Aliskiren-Amlodipin_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:59.943Z"443eba36d228ba257eb30debd8136086"214562STANDARD2206203922062039Normalmedia/2011-05-15-D-008_Retigabin_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:58.665Z"f7a254ef92cc33c0d61621a147d2441a"218837STANDARD2206203922062039Normalmedia/2011-06-15-D-009_Apixaban_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:52.553Z"1c6e514e35fea6ead44109f1cc51de1f"611068STANDARD2206203922062039Normalmedia/2011-06-30_Modul1_Ticagrelor.pdf2025-12-03T11:01:39.632Z"8b869c2063dfea9413b8ec18eef3e954"253884STANDARD2206203922062039Normalmedia/2011-06-30_Modul4-A_Ticagrelor.pdf2025-12-03T11:01:41.886Z"24d52a38d6bee24ece76453078c14ce8"4386678STANDARD2206203922062039Normalmedia/2011-07-01-D-010_Cannabis-Sativa_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:08.662Z"2d0c86ce3d44b6e7ad770e9ed9fdc7f4"371967STANDARD2206203922062039Normalmedia/2011-07-27-D-012_Belimumab_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:15.253Z"3dbe4c52da6ed6d531c8a6ae4e1cbbf5"341572STANDARD2206203922062039Normalmedia/2011-07-29-D-013_Fampridin_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:08.667Z"ad504ac0e607ffe3c240c66e3ef30580"289911STANDARD2206203922062039Normalmedia/2011-08-01-D-014_Ipilimumab_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:14.204Z"0f992c6f292942de4368062be9eb0904"479825STANDARD2206203922062039Normalmedia/2011-08-01-D-018_Bromfenac_Nutzenbewertung.pdf2025-12-03T11:01:39.057Z"2cbade73dd94198fe2b79df094986b2d"14200STANDARD2206203922062039Normalmedia/2011-08-18_35a_Freistellung_2011-F-004.pdf2025-12-03T11:22:49.670Z"9ae2148e1ae59b121caa1e09de371481"57344STANDARD2206203922062039Normalmedia/2011-08-18_35a_Freistellung_2011-F-004_TrG.pdf2025-12-03T11:22:50.356Z"b9e17559b392c087b011322cfb9c3116"32625STANDARD2206203922062039Normalmedia/2011-08-18_35a_HMG-CoA-Reduktasehemmer_BAnz.pdf2025-12-03T11:01:34.845Z"148e2a1fbe95750380e9bf9c51bb3f8f"240375STANDARD2206203922062039Normalmedia/2011-08-18_35a_HMG-CoA-Reduktasehemmer_TrG.pdf2025-12-03T11:01:34.707Z"7884bf7c96a2599efbdc7c7faa3c5797"973185STANDARD2206203922062039Normalmedia/2011-08-29_Modul1_Boceprevir.pdf2025-12-03T11:01:37.452Z"54576230f7adcbfcc4784623b6d49ac9"144199STANDARD2206203922062039Normalmedia/2011-08-29_Modul4A_Boceprevir.pdf2025-12-03T11:01:37.708Z"5a4351397f45dcfe34a155cca655518b"1573028STANDARD2206203922062039Normalmedia/2011-09-01-D-015_Boceprevir_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:37.792Z"b13753409ed65fe3889006c45e164f32"688167STANDARD2206203922062039Normalmedia/2011-09-07_Modul1_Pirfenidon.pdf2025-12-03T11:01:34.945Z"f5d83747d64564dc8748861d16fcb1b0"213866STANDARD2206203922062039Normalmedia/2011-09-14_Modul4A_Pirfenidon.pdf2025-12-03T11:01:35.773Z"7f55fd993c25ecf14b045e550b9eb511"1633032STANDARD2206203922062039Normalmedia/2011-09-15-D-020_Pirfenidon_IQWiG-Nutzenbewertung.pdf2025-12-03T11:01:35.573Z"808cf85e4cdb7bf7be4b370207c40c27"515791STANDARD2206203922062039Normalmedia/2011-09-16_Modul1_Cabazitaxel.pdf2025-12-03T11:01:42.561Z"74427a83e7658f5a28891763ff16f65a"441360STANDARD2206203922062039Normalmedia/2011-09-16_Modul4_Cabazitaxel.pdf2025-12-03T11:01:42.387Z"a567a6ebcdf42cd819f5ea127aa3be8c"1135429STANDARD2206203922062039Normalmedia/2011-09-21_Modul1_Fingolimod.pdf2025-12-03T11:01:49.966Z"3f52f9a0d3a3c99c7ed3b3db031c213e"917490STANDARD2206203922062039Normalmedia/2011-09-21_Modul4_Fingolimod.pdf2025-12-03T11:02:07.450Z"583b38db3a34b42a290f6da886a7df8e-4"33220896STANDARD2206203922062039Normalmedia/2011-09-28_Modul1_Linagliptin.pdf2025-12-03T11:01:37.595Z"ef321b8e37763a822f937cf9ebee3fbf"143255STANDARD2206203922062039Normalmedia/2011-09-28_Modul4A_Linagliptin.pdf2025-12-03T11:01:39.728Z"9a688158df0b2980d747a5593c30d70c"5948289STANDARD2206203922062039Normalmedia/2011-09-30_Modul1_Abirateronacetat.pdf2025-12-03T11:01:34.643Z"80d9eac0641cf6711e40be2327f3b089"183642STANDARD2206203922062039Normalmedia/2011-09-30_Modul4A_Abirateronacetat.pdf2025-12-03T11:01:35.205Z"3c406dd180fcdcd27933af0a031b14cf"3646864STANDARD2206203922062039Normalmedia/2011-10-01-D-021_Linagliptin_IQWiG-Nutzenbewertung.PDF2025-12-03T11:01:37.707Z"82cd8539dfbd91883300ca0a92497d06"235101STANDARD2206203922062039Normalmedia/2011-10-01-D-023_Abirateronacetat_IQWiG-Nutzenbewertung.PDF2025-12-03T11:01:34.900Z"ba374a6a76d223254a848b3a8d4c7322"566584STANDARD2206203922062039Normalmedia/2011-10-14_Modul1_Telaprevir.pdf2025-12-03T11:01:56.558Z"9b50b3852f63a020e16eae726be07c61"153231STANDARD2206203922062039Normalmedia/2011-10-14_Modul4A_Telaprevir.pdf2025-12-03T11:01:58.192Z"9631275a1ff8deb158a8b2f6155836ca"5405793STANDARD2206203922062039Normalmedia/2011-10-15-D-022_Telaprevir_IQWiG-Nutzenbewertung.PDF2025-12-03T11:01:57.400Z"b7d4941f0962b88c91616e64294458a2"889434STANDARD2206203922062039Normalmedia/2011-10-27_Modul1_Eribulin.pdf2025-12-03T11:01:54.941Z"7b4001038e47305797c28be3844cb714"403738STANDARD2206203922062039Normalmedia/2011-10-27_Modul4A_Eribulin.pdf2025-12-03T11:01:56.356Z"99be6e7f2128d3b292129820a4dd0b33"1250616STANDARD2206203922062039Normalmedia/2011-11-01_Modul1_Xiapex.pdf2025-12-03T11:01:54.091Z"dfab6a63843c3028f7e1b330c1c21523"277593STANDARD2206203922062039Normalmedia/2011-11-01_Modul4A_Xiapex.pdf2025-12-03T11:01:56.458Z"16a74418825e445148a9a4ef6b37221a"4565347STANDARD2206203922062039Normalmedia/2011-11-07_Modul1_Retigabin.pdf2025-12-03T11:01:57.661Z"ff7d3c3e2329f406cc53debaf96678fb"137068STANDARD2206203922062039Normalmedia/2011-11-07_Modul4A_Retigabin.pdf2025-12-03T11:01:59.083Z"e3c53ae270209f6493d9c86945b4d19c"4403791STANDARD2206203922062039Normalmedia/2011-11-11_Modul1_Rasilamlo.pdf2025-12-03T11:02:01.458Z"e749535ffd1684b4e39b391339e39d0d"1106654STANDARD2206203922062039Normalmedia/2011-11-11_Modul4A_Rasilamlo.pdf2025-12-03T11:02:02.274Z"6ef19ef26f0b71f1b1c6b1513e1f1f0c"6001503STANDARD2206203922062039Normalmedia/2011-12-05_Modul1_Apixaban.pdf2025-12-03T11:01:51.846Z"2924e3526ccdf45c4278f8a9334cd348"204390STANDARD2206203922062039Normalmedia/2011-12-05_Modul4A_Apixaban.pdf2025-12-03T11:01:54.144Z"b469292bd07352dd28538aadf0b627ed"2483720STANDARD2206203922062039Normalmedia/2011-12-12_Modul1_Tafamidis.pdf2025-12-03T11:02:00.106Z"dad285a4d6a69b9fe439e6d1d31d9a7f"163852STANDARD2206203922062039Normalmedia/2011-12-12_Modul4A_Tafamidis.pdf2025-12-03T11:02:04.299Z"bacf38957452479c756add64172c253a"1652468STANDARD2206203922062039Normalmedia/2011-12-15-D-025_Tafamidis_20Meglumin_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:00.361Z"3604829a17c10a5acf3d9b2036646713"523228STANDARD2206203922062039Normalmedia/2011-12-15_AM-RL-XII_Ticagrelor_BAnz.pdf2025-12-03T11:01:39.723Z"454bd7505d4b6e38b48e586003473a92"261756STANDARD2206203922062039Normalmedia/2011-12-15_AM-RL-XII_Ticagrelor_TrG.pdf2025-12-03T11:01:39.842Z"ddb7d15f9fd0fd97a3de0c885dc7131d"119683STANDARD2206203922062039Normalmedia/2011-12-28_Modul1_THC-CBD.pdf2025-12-03T11:02:07.051Z"593082fba61e12efd275e101c283e55f"423034STANDARD2206203922062039Normalmedia/2011-12-28_Modul4_A_THC-CBD.pdf2025-12-03T11:02:09.984Z"adc83de68e980983f4ae98cbd1de3b10"2622670STANDARD2206203922062039Normalmedia/2012-01-05_Modul1_Emtricitabin-Rilpivirin-Tenofovirdisoproxil.pdf2025-12-03T11:02:02.293Z"336a291058b6f93cfac1b53e9894525c"410608STANDARD2206203922062039Normalmedia/2012-01-10_Modul4A_Emtricitabin-Rilpivirin-Tenofovirdisoproxil.pdf2025-12-03T11:02:10.698Z"0e333bc6396b81b8f10c9edf332fca2c"2778091STANDARD2206203922062039Normalmedia/2012-01-13_Modul1_Belatacept.pdf2025-12-03T11:02:11.068Z"e10ad73e004046ecb0380762d3695fa5"353074STANDARD2206203922062039Normalmedia/2012-01-13_Modul4A_Belatacept.pdf2025-12-03T11:02:13.248Z"7b9e39dafff6c173239b4d6baa74ed11"2706668STANDARD2206203922062039Normalmedia/2012-01-15-D-026_Rilpivirin-Emtricitabin-Tenofovir_Addendum_.pdf2025-12-03T11:02:03.341Z"a327ec7d067eb96ba65287df0cbebaa5"330050STANDARD2206203922062039Normalmedia/2012-01-15_D-026_Rilpivirin-Emtricitabin-Tenofovir_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:02.957Z"90f83d1cb93a1363d9f9f8a30891ba95"273272STANDARD2206203922062039Normalmedia/2012-01-15_D-027_Rilpivirin_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:02.868Z"f67c47f0e2da464b74e5f2839b9ab318"545914STANDARD2206203922062039Normalmedia/2012-01-15_Modul1_Rilpivirin.pdf2025-12-03T11:02:03.779Z"eb6c93c3147e87c3d02dc9aea56a113f"173891STANDARD2206203922062039Normalmedia/2012-01-15_Modul4A_Rilpivirin.pdf2025-12-03T11:02:03.908Z"90f70086d453015ecf6d003d361522dc"3266961STANDARD2206203922062039Normalmedia/2012-01-19_AM-RL-XII_Bromfenac_BAnz.pdf2025-12-03T11:01:39.839Z"e8236449d521b3432469502b398d686c"281254STANDARD2206203922062039Normalmedia/2012-01-19_AM-RL-XII_Bromfenac_TrG.pdf2025-12-03T11:01:38.956Z"85dbf173c486e3417a057b9532b983a0"111174STANDARD2206203922062039Normalmedia/2012-01-27_Modul1_Belimumab.pdf2025-12-03T11:02:13.257Z"4151b7888ce90b3c9d993753cf5cd5da"241218STANDARD2206203922062039Normalmedia/2012-01-30_Modul1_Ipilimumab.pdf2025-12-03T11:02:14.454Z"61e7b726d2291e5227617346e62cee61"314180STANDARD2206203922062039Normalmedia/2012-01-30_Modul4A_Ipilimumab.pdf2025-12-03T11:02:17.157Z"6fe9d091afde94c5e8ddc6a730eca8d2"1728189STANDARD2206203922062039Normalmedia/2012-02-01_Modul1_Fampyra.pdf2025-12-03T11:02:06.074Z"1df821bb1d7764d305d063facedc05e4"170135STANDARD2206203922062039Normalmedia/2012-02-01_Modul4_Fampyra.pdf2025-12-03T11:02:07.062Z"12dc6416ee02750cf1d7f202128dcf80"4789077STANDARD2206203922062039Normalmedia/2012-02-17_Modul1_Vemurafenib.pdf2025-12-03T11:02:17.457Z"105c8d2fa29680f94cbba3b8acbea394"228006STANDARD2206203922062039Normalmedia/2012-02-17_Modul4A_Vemurafenib.pdf2025-12-03T11:02:19.526Z"5780ff2e25bd7d833288def0e8aeba60"3487431STANDARD2206203922062039Normalmedia/2012-03-01_AM-RL-XII_Boceprevir_BAnz.pdf2025-12-03T11:01:37.048Z"78cf37435581df23e8504091ca162516"311636STANDARD2206203922062039Normalmedia/2012-03-01_AM-RL-XII_Boceprevir_TrG.pdf2025-12-03T11:01:37.251Z"72386675403fb4227e6a1d4d63d3090d"57629STANDARD2206203922062039Normalmedia/2012-03-14_Modul1_Vandetanib.pdf2025-12-03T11:02:16.680Z"1488738022d4be4f5750806251004ebe"187397STANDARD2206203922062039Normalmedia/2012-03-14_Modul4A_Vandetanib.pdf2025-12-03T11:02:16.909Z"d102df4b8d93848addc0f3a3afbaa425"2121235STANDARD2206203922062039Normalmedia/2012-03-15-D-029_Vemurafenib_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:17.378Z"1702bd7d7a267979a1de2945aea3a967"691217STANDARD2206203922062039Normalmedia/2012-03-15-D-030_Vandetanib_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:16.559Z"e87cd1f3e04e5845770dfbe6cb4c3a71"297515STANDARD2206203922062039Normalmedia/2012-03-15_AM-RL-XII_Azilsartan_20medoxomil_BAnz.pdf2025-12-03T11:01:41.358Z"400c87fc1356f701f21177bb17c2a33a"336109STANDARD2206203922062039Normalmedia/2012-03-15_AM-RL-XII_Azilsartan_medoxomil_TrG.pdf2025-12-03T11:01:42.475Z"078a920002aa730be0edb282ccaca866"2899304STANDARD2206203922062039Normalmedia/2012-03-15_AM-RL-XII_Pirfenidon_BAnz.pdf2025-12-03T11:01:35.974Z"bf3276a2772c9040809616ddd9f3042c"343080STANDARD2206203922062039Normalmedia/2012-03-15_AM-RL-XII_Pirfenidon_TrG.pdf2025-12-03T11:01:36.043Z"3642d3e2f6c6c9b1c7909a3f1824a755"58762STANDARD2206203922062039Normalmedia/2012-03-15_Information_zur_zVT_Vemurafenib.pdf2025-12-03T11:02:17.049Z"f3dd7408e405c4c0a698c76fa8c18d47"420480STANDARD2206203922062039Normalmedia/2012-03-15_Informationen_zur_zVT_Vandetanib.pdf2025-12-03T11:02:16.604Z"cad42c748e0287e7b93f78d96367ce2c"196498STANDARD2206203922062039Normalmedia/2012-03-15_Informationen_zur_zVT_Vandetanib_Wx6nXRs.pdf2026-03-21T13:50:23.308Z"cad42c748e0287e7b93f78d96367ce2c"196498STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Abirateron_BAnz.pdf2025-12-03T11:01:33.767Z"05ca2332974fed7c38cd9e6e146a8236"361558STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Abirateron_TrG.pdf2025-12-03T11:01:33.584Z"aa37ce6f684350bf21e5f7742aeb60ab"88233STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Cabazitaxel_BAnz.pdf2025-12-03T11:01:41.375Z"f73b67c8fb9ce4dd211adee426cbc634"371183STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Cabazitaxel_TrG.pdf2025-12-03T11:01:41.575Z"b8268c90ae03b3500921ae6d33ad1f8d"83376STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Fingolimod_BAnz.pdf2025-12-03T11:01:51.568Z"3cbb77c9ea5c1ce1ed0454022d390367"2171718STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Fingolimod_TrG.pdf2025-12-03T11:01:51.051Z"400732cb129ae9a1619c1b5d18d35b59"103035STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Linagliptin_BAnz.pdf2025-12-03T11:01:38.259Z"c2fb2d6c8026edf08316a95d23dc24c5"362447STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Linagliptin_TrG.pdf2025-12-03T11:01:38.546Z"87ac03e440d8e0620f685b41ce919128"90586STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Regadenoson_BAnz.pdf2025-12-03T11:01:51.450Z"90d87727e1ed4fb60827bf764aeb7890"340817STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Regadenoson_TrG.pdf2025-12-03T11:01:51.278Z"0658f0b8c8407cd845e053a5649f311f"73394STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Telaprevir_BAnz.pdf2025-12-03T11:01:58.115Z"a3d78d1fc56185819d9babfeb4f05fe3"392226STANDARD2206203922062039Normalmedia/2012-03-29_AM-RL-XII_Telaprevir_TrG.pdf2025-12-03T11:01:56.564Z"cdb6dd9c403cdb0dc0b5f1b622bd980e"70274STANDARD2206203922062039Normalmedia/2012-04-19_AM-RL-XII_Collagenase_BAnz.pdf2025-12-03T11:01:53.752Z"6b6543878404a0816995453d0607a526"291397STANDARD2206203922062039Normalmedia/2012-04-19_AM-RL-XII_Collagenase_TrG.pdf2025-12-03T11:01:53.770Z"279244c29354b6935d92f4fb1797a92f"86574STANDARD2206203922062039Normalmedia/2012-04-19_AM-RL-XII_Eribulin.pdf2025-12-03T11:01:55.240Z"4ec1c0d65443211039a7577128901f30"397262STANDARD2206203922062039Normalmedia/2012-04-19_AM-RL-XII_Eribulin_TrG.pdf2025-12-03T11:01:55.748Z"5d4e6669595ff10851cbdd9a1aae4848"99691STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-35a_Freistellung-Malariamittel.pdf2025-12-03T11:22:52.557Z"10cd18839b39fb99e68115154e734184"28195STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-35a_Freistellung-Malariamittel_TrG.pdf2025-12-03T11:22:53.441Z"5a48679d868d2aefce8ec171520a8df3"50072STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-35a_Freistellung_Beta-Lactam-Antibiotika.pdf2025-12-03T11:22:47.946Z"271911db14ba2fda7c609c222f38344e"28243STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-35a_Freistellung_Beta-Lactam-Antibiotika_TrG.pdf2025-12-03T11:22:47.870Z"9d2eec4b7b3cf9e94b6989b5cbfdcfcd"50123STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-XII_Aliskiren-Amlodipin_BAnz.pdf2025-12-03T11:01:58.858Z"057f8acff3b6410480d41c20a4ccffa2"280350STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-XII_Aliskiren-Amlodipin_TrG.pdf2025-12-03T11:01:58.881Z"c049684966706b6385c5c60b41827ab7"100673STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-XII_Retigabin_BAnz.pdf2025-12-03T11:01:58.787Z"66d9511045a62b87aba556b58ee8fe09"264458STANDARD2206203922062039Normalmedia/2012-05-03_AM-RL-XII_Retigabin_TrG.pdf2025-12-03T11:01:58.991Z"7e49becd06c44ffeb408a9935f75f777"86835STANDARD2206203922062039Normalmedia/2012-05-29_Wortprotokoll_Belatacept.pdf2025-12-03T11:02:11.044Z"bd11dac183fc4885ed5e3d81ea882e3e"163161STANDARD2206203922062039Normalmedia/2012-05-29_Wortprotokoll_Emtricitabin_Rilpivirin_Tenofovirdisoproxil.pdf2025-12-03T11:02:03.483Z"eea6ba312bae456af7832f2395b9128f"158627STANDARD2206203922062039Normalmedia/2012-05-29_Wortprotokoll_Rilpivirin.pdf2025-12-03T11:02:02.226Z"1b7c66f4394b63c01f275caed990f643"70511STANDARD2206203922062039Normalmedia/2012-06-07_AM-RL-XII_Apixaban_BAnz.pdf2025-12-03T11:01:52.740Z"1be2d16cfcb637c04b2ccaff86e5a7fc"349721STANDARD2206203922062039Normalmedia/2012-06-07_AM-RL-XII_Apixaban_TrG.pdf2025-12-03T11:01:53.157Z"0881a9f60248fe4cddcbf593871cf527"103285STANDARD2206203922062039Normalmedia/2012-06-07_AM-RL-XII_Tafamidis_BAnz.pdf2025-12-03T11:02:01.268Z"0e2d49238e702fa9c32cbfcce2883414"264763STANDARD2206203922062039Normalmedia/2012-06-07_AM-RL-XII_Tafamidis_TrG.pdf2025-12-03T11:02:00.539Z"6f268591655cd52bc2cbf67c1b09a3e8"61267STANDARD2206203922062039Normalmedia/2012-06-11_Modul1_Pasireotid.pdf2025-12-03T11:02:19.554Z"2a632b6b471ada9a56eba31bebd88ac1"278750STANDARD2206203922062039Normalmedia/2012-06-11_Modul4A_Pasireotid.pdf2025-12-03T11:02:19.858Z"d8bd7c317d1dad284f344c872dce90f6"964362STANDARD2206203922062039Normalmedia/2012-06-12_Wortprotokoll_Belimumab.pdf2025-12-03T11:02:14.347Z"99a1897d96accd5964b0813f18669ff9"414768STANDARD2206203922062039Normalmedia/2012-06-12_Wortprotokoll_Fampridin.pdf2025-12-03T11:02:07.246Z"d5f9bf6f35446a16a983b169d3f397a7"484175STANDARD2206203922062039Normalmedia/2012-06-12_Wortprotokoll_Ipilimumab.pdf2025-12-03T11:02:14.161Z"c889c6742d6524748ee34e257735a03f"152176STANDARD2206203922062039Normalmedia/2012-06-21_AM-RL-XII_Extrakte_20aus_20Cannabis_BAnz.pdf2025-12-03T11:02:08.463Z"63d8ef10c5eacac176c0e9eb09d0f64e"297220STANDARD2206203922062039Normalmedia/2012-06-21_AM-RL-XII_Extrakte_20aus_20Cannabis_TrG.pdf2025-12-03T11:02:08.456Z"7f14d3c36558d7e766bcada59e78ccd9"109589STANDARD2206203922062039Normalmedia/2012-07-01-D-033_Nutzenbewertung_Tegafur-Gimeracil-Oteracil.pdf2025-12-03T11:02:21.158Z"308b7f404f94d5bc71e2fcc24b91e694"227910STANDARD2206203922062039Normalmedia/2012-07-01_Informationen_zur_zVT_Tegafur-Gimeracil-Oteracil.pdf2025-12-03T11:02:22.961Z"5ae5e04e673542162d87b0f0213725c2"684411STANDARD2206203922062039Normalmedia/2012-07-05_AM-RL-XII_Belatacept_BAnz.pdf2025-12-03T11:02:11.841Z"30f0656b293908323f814d347dac746f"301783STANDARD2206203922062039Normalmedia/2012-07-05_AM-RL-XII_Belatacept_TrG.pdf2025-12-03T11:02:11.950Z"0ccfb55100133414cfe5e4e4aaae63c2"95607STANDARD2206203922062039Normalmedia/2012-07-05_AM-RL-XII_Emtricitabin-Rilpivirin-Tenofovir_BAnz.pdf2025-12-03T11:02:04.857Z"b388378587b55acb1db3d5290e622280"283374STANDARD2206203922062039Normalmedia/2012-07-05_AM-RL-XII_Emtricitabin-Rilpivirin-Tenofovir_TrG.pdf2025-12-03T11:02:04.301Z"d7ce042481a477f909082e408b92fb9e"117676STANDARD2206203922062039Normalmedia/2012-07-05_AM-RL-XII_Rilpivirin_BAnz.pdf2025-12-03T11:02:01.684Z"97435cf58b0519958a767f03e48ecc3c"277440STANDARD2206203922062039Normalmedia/2012-07-05_AM-RL-XII_Rilpivirin_TrG.pdf2025-12-03T11:02:01.773Z"4a877b23cb651019015e1db40d90757f"114209STANDARD2206203922062039Normalmedia/2012-07-15-D-011_Belatacept_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:10.851Z"fbec363c96a8ab04deed2dacce227d52"600504STANDARD2206203922062039Normalmedia/2012-07-24_Wortprotokoll_Vandetanib.pdf2025-12-03T11:02:16.647Z"bc5da15b953bc55fc02c4b60e3fb7a50"469938STANDARD2206203922062039Normalmedia/2012-07-24_Wortprotokoll_Vemurafenib.pdf2025-12-03T11:02:17.443Z"e067b182cbda0a522e692325f59dc30d"485253STANDARD2206203922062039Normalmedia/2012-08-02_AM-RL-XII_Belimumab_BAnz.pdf2025-12-03T11:02:13.192Z"f60530263b5ba7d0390287aa02f44d45"297576STANDARD2206203922062039Normalmedia/2012-08-02_AM-RL-XII_Belimumab_TrG.pdf2025-12-03T11:02:13.239Z"f2b9e9a4ee534aaf34ea93fb017c79c7"130072STANDARD2206203922062039Normalmedia/2012-08-02_AM-RL-XII_Fampridin_BAnz.pdf2025-12-03T11:02:05.619Z"b66ccb5526feecd604ead574aab6a0aa"267450STANDARD2206203922062039Normalmedia/2012-08-02_AM-RL-XII_Fampridin_TrG.pdf2025-12-03T11:02:05.590Z"ce1da3fc242f0d0d70399b166b47b404"92380STANDARD2206203922062039Normalmedia/2012-08-02_AM-RL-XII_Ipilimumab_BAnz.pdf2025-12-03T11:02:14.177Z"8cf76fb1dfd6d65ccf1b3e6f3536defe"289606STANDARD2206203922062039Normalmedia/2012-08-02_AM-RL-XII_Ipilimumab_TrG.pdf2025-12-03T11:02:14.199Z"562585076435e5aad00001fe1fe90fd4"116276STANDARD2206203922062039Normalmedia/2012-08-13_Modul1_Ivacaftor.pdf2025-12-03T11:02:22.345Z"5655da8fe42083cad31c7d1e3d31ebdc"416712STANDARD2206203922062039Normalmedia/2012-08-13_Modul4A_Ivacaftor.pdf2025-12-03T11:02:25.768Z"f96dd3d4c7076fe3c5e6e8ee3f3f4a35"4167541STANDARD2206203922062039Normalmedia/2012-08-30_Analyse-Schiedsspruch-Bromfenac.pdf2025-12-03T11:45:10.252Z"1116a032b0dec30d8280f7829c1b0c48"114067STANDARD2206203922062039Normalmedia/2012-08-30_Modul1_Linagliptin.pdf2025-12-03T11:02:23.560Z"03ed9c550ebc7514e35a38c2e6cfb5af"188320STANDARD2206203922062039Normalmedia/2012-08-30_Modul4A_Linagliptin.pdf2025-12-03T11:02:25.838Z"3c0d1c99e83c84f55666a27c5c6578b6"3667442STANDARD2206203922062039Normalmedia/2012-08-30_Schiedsspruch_1-12_Bromfenac_Yellox_002.pdf2025-12-03T11:45:12.454Z"5df75d0095306e157cec09cc91e87a01"3218845STANDARD2206203922062039Normalmedia/2012-09-01_Informationen_zur_zVT_Lingaliptin_5b_D-035.pdf2025-12-03T11:02:24.067Z"b64ed6e0167bddfe4f0826b29a846219"434067STANDARD2206203922062039Normalmedia/2012-09-06_AM-RL-XII_Vandetanib_BAnz.pdf2025-12-03T11:02:15.943Z"9fa8f064c9b063275ff4b9bc7f610697"80713STANDARD2206203922062039Normalmedia/2012-09-06_AM-RL-XII_Vandetanib_TrG.pdf2025-12-03T11:02:16.075Z"6bba65c955ea2ce31fa543b4fa1252ed"93495STANDARD2206203922062039Normalmedia/2012-09-06_AM-RL-XII_Vemurafenib_BAnz.pdf2025-12-03T11:02:21.449Z"f6b65013749b472f73539e14aa7d9565"290478STANDARD2206203922062039Normalmedia/2012-09-06_AM-RL-XII_Vemurafenib_TrG.pdf2025-12-03T11:02:17.644Z"72ca91a78448113d245f2c79640ab080"105881STANDARD2206203922062039Normalmedia/2012-09-07_Modul1_Perampanel.pdf2025-12-03T11:02:26.962Z"15426b80441b2b2def07d3f53c81360c"216584STANDARD2206203922062039Normalmedia/2012-09-07_Modul1_Ruxolitinib.pdf2025-12-03T11:02:32.752Z"45c47df7774bc367930d03be53a2743a"290735STANDARD2206203922062039Normalmedia/2012-09-07_Modul4A_Perampanel.pdf2025-12-03T11:02:27.792Z"79a5305e358b8d9308a1e61ece81efd1-2"8627928STANDARD2206203922062039Normalmedia/2012-09-07_Modul4A_Ruxolitinib.pdf2025-12-03T11:02:34.683Z"2a8be8c2f9b59a2be2523b033192d1e3"2892213STANDARD2206203922062039Normalmedia/2012-09-15_Informationen_zur_zweckmaessigen_Vergleichstherapie-Perampanel.pdf2025-12-03T11:02:26.740Z"0982ee79215a24d1b65504570ca97c0e"101193STANDARD2206203922062039Normalmedia/2012-09-15_Nutzenbewertung_G-BA_Ruxolitinib.pdf2025-12-03T11:02:32.419Z"5bab2f300784d3ec65d84353f6f61537"2368064STANDARD2206203922062039Normalmedia/2012-09-17_Nutzenbewertung_G-BA-2.pdf2025-12-03T11:02:19.573Z"11a38864392a71a696ef4384a6f1d5e3"465022STANDARD2206203922062039Normalmedia/2012-09-27_Modul1_Aclidiniumbromid.pdf2025-12-03T11:02:28.846Z"71b60c07c700fc8601e3c89698fffc32"447698STANDARD2206203922062039Normalmedia/2012-09-27_Modul1_Axitinib.pdf2025-12-03T11:02:29.460Z"7df85ddcc2832f761405a3ca49f58e4c"319424STANDARD2206203922062039Normalmedia/2012-09-27_Modul4A_Aclidiniumbromid.pdf2025-12-03T11:02:33.001Z"34da28126b3b8d7b83049e2c3df97069-2"12932878STANDARD2206203922062039Normalmedia/2012-10-01_Informationen_zur_zVT_D-038_Aclidiniumbromid.pdf2025-12-03T11:02:28.051Z"8ba98d1eff9a04ecbe3c45f8880fc6a5"663981STANDARD2206203922062039Normalmedia/2012-10-01_Informationen_zur_zVT_D-039_Axitinib.pdf2025-12-03T11:02:29.475Z"5c2d7da2f588c30e81428c9e1bd15835"247896STANDARD2206203922062039Normalmedia/2012-10-23_Wortprotokoll_end_Pasireotid.pdf2025-12-03T11:02:21.049Z"f0d4ea3eb6c0587fe25d54c791f1bc10"356156STANDARD2206203922062039Normalmedia/2012-10-31_Modul1_Brentuximabvedotin.pdf2025-12-03T11:02:41.263Z"46e339a75e135ffa1b1007e9e9196459"582287STANDARD2206203922062039Normalmedia/2012-10-31_Modul1_Decitabin.pdf2025-12-03T11:02:37.552Z"a60e8773cdfb0a2ef8735e48546ff634"140366STANDARD2206203922062039Normalmedia/2012-10-31_Modul4A_Brentuximabvedotin.pdf2025-12-03T11:02:43.151Z"ecfedb075369ca3ccef253f02714f957"1821470STANDARD2206203922062039Normalmedia/2012-10-31_Modul4A_Decitabin.pdf2025-12-03T11:02:37.290Z"02f6084f627bb7265e967e42198ac326"1682031STANDARD2206203922062039Normalmedia/2012-10-31_Modul4B_Brentuximabvedotin.pdf2025-12-03T11:02:43.085Z"01d61f1d9164a133ed474d91afd9c7a1"1758855STANDARD2206203922062039Normalmedia/2012-11-01_Nutzenbewertung_G-BA_Decitabin.pdf2025-12-03T11:02:39.524Z"89e02bc65d45c7af764723c701fc7739"3918014STANDARD2206203922062039Normalmedia/2012-11-06_Wortprotokoll_Tegafur-Gimeracil-Oteracil.pdf2025-12-03T11:02:21.447Z"92505df9308ae5dd2105ddb3a0a27ac7"180194STANDARD2206203922062039Normalmedia/2012-11-07_Modul1_Crizotinib.pdf2025-12-03T11:02:32.894Z"404cb1ac438647be7c81ed8a9b34692c"155199STANDARD2206203922062039Normalmedia/2012-11-07_Modul4A_Crizotinib.pdf2025-12-03T11:02:33.172Z"930f5342114bda5409676fc72e87178e"3710199STANDARD2206203922062039Normalmedia/2012-11-14_Modul1_Saxagliptin-Metformin.pdf2025-12-03T11:02:38.955Z"3580f84ada2c49d45de95e564972742d"239760STANDARD2206203922062039Normalmedia/2012-11-14_Modul4A_Komboglyze.pdf2025-12-03T11:02:40.588Z"2e95cd9e2a2c808c17fbbdcb3488a7c8"2167775STANDARD2206203922062039Normalmedia/2012-11-14_Modul4B_Komboglyze.pdf2025-12-03T11:02:42.876Z"7ac0ff908f6ac73e36987751f8264b0b"1180568STANDARD2206203922062039Normalmedia/2012-11-15-D-040_Crizotinib_Addendum.pdf2025-12-03T11:02:35.059Z"cf1b0c82f67343d4a76a6ad4ee35b203"192074STANDARD2206203922062039Normalmedia/2012-11-15-D-041_Saxagliptin-Metformin_Addendum.pdf2025-12-03T11:02:39.880Z"26ec94d7d96423107d99c38946418251"428096STANDARD2206203922062039Normalmedia/2012-11-15_Informationen_zur_zVT_Crizotinib_D-040.pdf2025-12-03T11:02:33.868Z"77a47780c4971d392302df58741a5582"868098STANDARD2206203922062039Normalmedia/2012-11-15_Informationen_zur_zVT_D-041.pdf2025-12-03T11:02:39.471Z"070c7cabefa520c4bb520aa980854c45"447537STANDARD2206203922062039Normalmedia/2012-11-15_Nutzenbewertung_G-BA.pdf2025-12-03T11:02:24.703Z"0e664c61b7f0490e4bc3eea84ac8469f"2373684STANDARD2206203922062039Normalmedia/2012-11-22_Modul1_Dapagliflozin.pdf2025-12-03T11:02:46.911Z"c8313c0b71b3b4bd607b01b142fb5262"402215STANDARD2206203922062039Normalmedia/2012-11-29_A12-11_Linagliptin_Erneute_20Nutzenbewertung_20_C2_A7_2035a_20Absatz_205b_20SGB_20V.pdf2025-12-03T11:02:24.722Z"876187eaecbf40a366a4ad107484647d"494197STANDARD2206203922062039Normalmedia/2012-12-01_Informationen_zur_zVT_D-044_Pixantron.pdf2025-12-03T11:02:44.846Z"a236ef0ec7397a44e39e65311e0d9353"606818STANDARD2206203922062039Normalmedia/2012-12-01_Informationen_zur_zVT_D-047_Lingaliptin_neu_AWG.pdf2025-12-03T11:02:42.965Z"9724d3df68440d56c7a6e5d1e6542f0b"446364STANDARD2206203922062039Normalmedia/2012-12-01_Nutzenbewertung_G-BA_Brentuximab_D-037.pdf2025-12-03T11:02:42.636Z"44e9625cf205a83389c49bc24196cc0f"2949445STANDARD2206203922062039Normalmedia/2012-12-06_AM-RL-XII_Pasireotid_BAnz.pdf2025-12-03T11:02:19.378Z"96359877ed962f8f4827874d2a14d5e1"106553STANDARD2206203922062039Normalmedia/2012-12-06_AM-RL-XII_Pasireotid_TrG.pdf2025-12-03T11:02:19.595Z"f7c40a2a25f047f0c9e5a52555f6d649"92027STANDARD2206203922062039Normalmedia/2012-12-06_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_2.pdf2025-12-03T11:02:19.514Z"66f7f0e3350778f6249121b2a7c228c4"144281STANDARD2206203922062039Normalmedia/2012-12-12_Modul1_Aflibercept.pdf2025-12-03T11:02:46.248Z"fa2fee52a639bcb777af5eaa988d83db"609059STANDARD2206203922062039Normalmedia/2012-12-12_Modul4_Aflibercept.pdf2025-12-03T11:02:47.116Z"b1115b5ed57b25cb659afafc1477d7a0"7448357STANDARD2206203922062039Normalmedia/2012-12-13_A12-12_Perampanel_Nutzenbewertung_20_C2_A7_2035a_20SGB_20V.pdf2025-12-03T11:02:30.342Z"2b700060d044c341dc213696aa10c9fc"487665STANDARD2206203922062039Normalmedia/2012-12-13_Modul4A_Dapagliflozin.pdf2025-12-03T11:02:51.724Z"56ecf786d0b3581d42d0f30ee5c5af4d"5682253STANDARD2206203922062039Normalmedia/2012-12-13_Modul4B_Dapagliflozin.pdf2025-12-03T11:02:54.970Z"0df664fa3ffe51045e03ab1912abedc0-2"13500668STANDARD2206203922062039Normalmedia/2012-12-13_Modul4C_Dapagliflozin.pdf2025-12-03T11:02:51.968Z"22de687628f3724be00ff2ecd229cd97"3480855STANDARD2206203922062039Normalmedia/2012-12-13_Modul4D_Dapagliflozin.pdf2025-12-03T11:02:51.509Z"f8d8be9a521a1b8621eac6f5cc302795"2807522STANDARD2206203922062039Normalmedia/2012-12-14_Modul1_Apixaban.pdf2025-12-03T11:01:49.829Z"d6e543c2118ac8bf3fd2e045b0c35cbc"284340STANDARD2206203922062039Normalmedia/2012-12-14_Modul4B_Apixaban.pdf2025-12-03T11:01:49.845Z"ff25991ae109331b55449878c798f676"4116703STANDARD2206203922062039Normalmedia/2012-12-14_Modul4C_Apixaban.pdf2025-12-03T11:01:48.581Z"f03b0328a7c79e588feea1ca5395e336"2473836STANDARD2206203922062039Normalmedia/2012-12-15-D-045_Dapagliflozin_Addendum.pdf2025-12-03T11:02:47.155Z"0ab7d22d60c2573a6479cb082ddf6a3d"230021STANDARD2206203922062039Normalmedia/2012-12-15_Informationen_zur_2VT_Dapagliflozin_D-045.pdf2025-12-03T11:02:47.486Z"0e84e9e5d9237c0d63b8f212c6523dfa"446709STANDARD2206203922062039Normalmedia/2012-12-15_Informationen_zur_zVT_D-052_Aflibercept.pdf2025-12-03T11:02:48.447Z"1d3ce3e86e56a6458e7c89f6559ad319"97563STANDARD2206203922062039Normalmedia/2012-12-15_Nutzenbewertung_IQWiG-35a__Aflibercept.pdf2025-12-03T11:02:47.012Z"fc9f1bee45d87c8fa9fbc75a1c48fc53"399008STANDARD2206203922062039Normalmedia/2012-12-20_Tegafur-Gimeracil-Oteracil_BAnz.pdf2025-12-03T11:02:21.542Z"c111f51a5e98a548fc28d08734b25fa0"173710STANDARD2206203922062039Normalmedia/2012-12-20_Tegafur-Gimeracil-Oteracil_TrG.pdf2025-12-03T11:02:21.482Z"39e42b1928f38f350318f6268334b8df"195854STANDARD2206203922062039Normalmedia/2012-12-21_A12-13_Aclidiniumbromid_Nutzenbewertung_20_C2_A735a_20SGB_20V.pdf2025-12-03T11:02:27.791Z"8c2e11d40eaba111ac4bb1ee51080f35"481642STANDARD2206203922062039Normalmedia/2012-12-21_A12-14_Axitinib_Nutzenbewertung-__35a.pdf2025-12-03T11:02:29.655Z"a86b981889af0c01ce319cbe1a8580e4"628615STANDARD2206203922062039Normalmedia/2012_09_27_Modul4A_Axitinib.pdf2025-12-03T11:02:31.388Z"b9fad5192c7bcc05edc6584fac091818"4669514STANDARD2206203922062039Normalmedia/2012_11_20_Modul1_Pixantron.pdf2025-12-03T11:02:44.251Z"69f760bce0329d04a780ab5ba5e54f35"204415STANDARD2206203922062039Normalmedia/2012_11_20_Modul4_Pixantron.pdf2025-12-03T11:02:45.785Z"4a1c72ebd63387583e338a81e7e66c29"2628516STANDARD2206203922062039Normalmedia/2013-01-01_Informationen_zur_zVT_Apixaban_D-053.pdf2025-12-03T11:01:51.403Z"16e1b7eb0ad5820ed299cf05e4dd082a"482196STANDARD2206203922062039Normalmedia/2013-01-08_Wortprotokoll_20Ivacaftor.pdf2025-12-03T11:02:23.457Z"9e9123c602a676eebfc76a314ecee132"342142STANDARD2206203922062039Normalmedia/2013-01-08_Wortprotokoll_Linagliptin.pdf2025-12-03T11:02:25.040Z"b85f72238608b1ed381b7c933e91b65a"514638STANDARD2206203922062039Normalmedia/2013-01-11_Modul1_Ingenolmebutat_Gel.pdf2025-12-03T11:02:53.532Z"ca739fbd18a6c25c2bd45a23d7be136d"385901STANDARD2206203922062039Normalmedia/2013-01-11_Modul4A_Ingenolmebutat.pdf2025-12-03T11:03:01.763Z"e1586bfaf05f3883b45422305ccb7d58"7330121STANDARD2206203922062039Normalmedia/2013-01-14_Modul1_Abirateronacetat.pdf2025-12-03T11:02:10.089Z"c87ae7e731edb005d4179d1d7d8d94da"485025STANDARD2206203922062039Normalmedia/2013-01-14_Modul1_Fidaxomicin.pdf2025-12-03T11:02:51.882Z"483a0fac294e422f1e7bdeb94fd6cb72"174420STANDARD2206203922062039Normalmedia/2013-01-14_Modul4A_Abirateronacetat.pdf2025-12-03T11:02:10.473Z"d836ba97b23da79487789094dcfa85ce"3164396STANDARD2206203922062039Normalmedia/2013-01-14_Modul4A_Fidaxomicin.pdf2025-12-03T11:02:53.549Z"dd83f31258b7e18b07cb15347324699a"2154232STANDARD2206203922062039Normalmedia/2013-01-15-D-051_Fidaxomicin_Addendum.pdf2025-12-03T11:02:51.774Z"102803e0231832f833c25aba71e6b085"219503STANDARD2206203922062039Normalmedia/2013-01-15-D-056_Abirateronacetat_Addendum.pdf2025-12-03T11:02:10.120Z"a87b733290c60539a7d8708e74a24085"173035STANDARD2206203922062039Normalmedia/2013-01-15_Informationen_zur_zVT_Abirateronacetat.pdf2025-12-03T11:02:10.797Z"136d3b97831159671da617900cfbebe8"869990STANDARD2206203922062039Normalmedia/2013-01-15_Informationen_zur_zweckmaessigen_Vergleichstherapie_D-046_Ingenolmebutat.pdf2025-12-03T11:02:53.529Z"91f4c1eea8a63369801b9a7746ea29dd"330547STANDARD2206203922062039Normalmedia/2013-01-15_Informationen_zur_zweckmaessigen_Vergleichstherapie_Fidaxomicin.pdf2025-12-03T11:02:50.656Z"26f38bd590520471d92cfdb567c8e86b"684988STANDARD2206203922062039Normalmedia/2013-01-29_Wortprotokoll_Perampanel.pdf2025-12-03T11:02:26.495Z"d89143a5114d851c599efcfae6bb7aa1"202764STANDARD2206203922062039Normalmedia/2013-01-29_Wortprotokoll_Ruxolitinib.pdf2025-12-03T11:02:34.362Z"24d64b241a35de49e05c0468a4ba2447"246432STANDARD2206203922062039Normalmedia/2013-02-07_AM-RL-XII_Ivacaftor_BAnz.pdf2025-12-03T11:02:21.544Z"76fc05e2625cebcf7bbf110edf88fa39"157076STANDARD2206203922062039Normalmedia/2013-02-07_AM-RL-XII_Ivacaftor_TrG.pdf2025-12-03T11:02:21.945Z"b9aa13298c9fbc4f7cc7d78e19529eef"88580STANDARD2206203922062039Normalmedia/2013-02-07_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_Ivacaftor.pdf2025-12-03T11:02:23.263Z"6993c67f56ae3b654d506313c04f4054"162965STANDARD2206203922062039Normalmedia/2013-02-11_Axitinib_end_Wortprotokoll.pdf2025-12-03T11:02:29.540Z"a672cf978a749170eca128d8b5309aa3"113353STANDARD2206203922062039Normalmedia/2013-02-11_Wortprotokoll_end_Aclidiniumbromid.pdf2025-12-03T11:02:27.783Z"1c071d075f2aafe2bb8966b6ed0a97ea"153040STANDARD2206203922062039Normalmedia/2013-02-13_A12-15_Crizotinib_Nutzenbewertung_20_C2_A7_2035a_20SGB_20V.pdf2025-12-03T11:02:33.840Z"15494622405dab3ae7d7b162dc28dc63"575422STANDARD2206203922062039Normalmedia/2013-02-13_A12-16_Saxagliptin-Metformin_Nutzenbewertung_20_C2_A7_2035a_20SGB_20V.pdf2025-12-03T11:02:39.191Z"093fee27b21824755966fefe1d7c4ad9"331042STANDARD2206203922062039Normalmedia/2013-02-21_AM-RL-XII_Linagliptin_BAnz.pdf2025-12-03T11:02:24.765Z"947eb2895db9dfd2074e8d10ddd8978f"273671STANDARD2206203922062039Normalmedia/2013-02-21_AM-RL-XII_Linagliptin_TrG.pdf2025-12-03T11:02:24.692Z"9923206d2feb40ed89530dd5e42aac13"111132STANDARD2206203922062039Normalmedia/2013-02-26_Analyse-Schiedsspruch-Retigabin.pdf2025-12-03T11:45:10.448Z"db510997e6778c700a9281750c68c5bd"116346STANDARD2206203922062039Normalmedia/2013-02-26_Schiedsspruch_3-12-Retigabin_Trobalt_003.pdf2025-12-03T11:45:12.371Z"187147171d8164221ca0ff1295c4d06f"2849049STANDARD2206203922062039Normalmedia/2013-02-27_A12-17_Pixantron-Nutzenbewertung_20_C2_A7_35a_SGB.pdf2025-12-03T11:02:43.971Z"e0bbb318434d63443e96b2fa3a5e6aae"294007STANDARD2206203922062039Normalmedia/2013-03-01_Informationen-zur-zweckmaessigen-Vergleichstherapie_Aflibercept.pdf2025-12-03T11:02:56.161Z"093d01abfc6ed699f7d02138a1ed4e94"228266STANDARD2206203922062039Normalmedia/2013-03-01_Modul1_Aflibercept.pdf2025-12-03T11:02:54.443Z"5a0f3e07545d71279de4702b2532671f"154818STANDARD2206203922062039Normalmedia/2013-03-01_Modul4_Aflibercept.pdf2025-12-03T11:02:55.254Z"4ee40c655d72d33aeaffb95063040585"2258519STANDARD2206203922062039Normalmedia/2013-03-01_Nutzenbewertung_Linagliptin_Neues_AWG_G-BA.pdf2025-12-03T11:02:43.168Z"d5920f1c4ede8f39540c1923086872a1"173863STANDARD2206203922062039Normalmedia/2013-03-04_Modul1_Pertuzumab.pdf2025-12-03T11:03:00.708Z"9d5f7b6b6759080c87b7e3f0ce26d1c9"276528STANDARD2206203922062039Normalmedia/2013-03-04_Modul4A_Pertuzumab.pdf2025-12-03T11:03:02.412Z"4d27341710d4a20762069c89fb407c23"3269592STANDARD2206203922062039Normalmedia/2013-03-06_Modul1_Saxagliptin.pdf2025-12-03T11:03:03.078Z"b3029bf8518822b218a069bbf99261b3"346256STANDARD2206203922062039Normalmedia/2013-03-07_AM-RL-XII_Perampanel_BAnz.pdf2025-12-03T11:02:27.739Z"5d7f2ed06a809592a9d0a098e7ba664b"93734STANDARD2206203922062039Normalmedia/2013-03-07_AM-RL-XII_Perampanel_TrG.pdf2025-12-03T11:02:26.158Z"03dcb0dbc02c0b5bdf3b968fda5a7caf"92501STANDARD2206203922062039Normalmedia/2013-03-07_AM-RL-XII_Ruxolitinib_BAnz.pdf2025-12-03T11:02:32.413Z"0ddb2d64406097a595910e30b993ae4a"162679STANDARD2206203922062039Normalmedia/2013-03-07_AM-RL-XII_Ruxolitinib_TrG.pdf2025-12-03T11:02:31.394Z"c597ca6f44c60ec8fb1ec2c98a156ea3"263348STANDARD2206203922062039Normalmedia/2013-03-07_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_2_.pdf2025-12-03T11:02:31.544Z"4352a389e4ca42e3f474b63875e3e867"120907STANDARD2206203922062039Normalmedia/2013-03-07_Modul1_Vandetanib.pdf2025-12-03T11:02:57.742Z"6ade3b2aff43de79835ff2c3ff1212e7"186778STANDARD2206203922062039Normalmedia/2013-03-07_Modul4A_Vandetanib.pdf2025-12-03T11:03:00.618Z"aaf8171429e5fadfa68eeee6c94fe8f3"5418489STANDARD2206203922062039Normalmedia/2013-03-12_Dapagliflozin_Nutzenbewertung_IQWiG-35a.pdf2025-12-03T11:02:47.448Z"1a00244c1f7a1209725fb8133494203a"548787STANDARD2206203922062039Normalmedia/2013-03-12_Decitabin_Wortprotokoll.pdf2025-12-03T11:02:37.862Z"634ee2ce0bb42fffbabb5bf3c950ac4d"151352STANDARD2206203922062039Normalmedia/2013-03-14_Analyse-Schiedsspruch-Extrakt-Cannabis-sativa.pdf2025-12-03T11:45:10.858Z"cc5052b9afd3c784b10b312dbcff4630"113524STANDARD2206203922062039Normalmedia/2013-03-14_Modul1_Lixisenatid.pdf2025-12-03T11:02:55.458Z"9f0ee3c256e6c682c079fdd5825c4fa5"508575STANDARD2206203922062039Normalmedia/2013-03-14_Modul4A_Lixisenatid.pdf2025-12-03T11:03:01.600Z"45dc50c44654e31a6f0bb15b76f6ccf6-2"10788924STANDARD2206203922062039Normalmedia/2013-03-14_Schiedsspruch_4-12_Extrakt-aus-Cannabis-sativa_Sativex_004.pdf2025-12-03T11:45:13.085Z"da4d85050d39cef04beb9b65113e2d2e"2960890STANDARD2206203922062039Normalmedia/2013-03-15-D-059_Vandetanib_5b_Addendum.pdf2025-12-03T11:02:57.876Z"6c787248def1da168969ac52301fcdce"159889STANDARD2206203922062039Normalmedia/2013-03-15_Informationen_zur_zVT_Lixisenatid_D-061.pdf2025-12-03T11:02:56.074Z"a2e32340967f064c4b4e89c5a64d5390"440284STANDARD2206203922062039Normalmedia/2013-03-15_Modul4A_Komboglyze.pdf2025-12-03T11:03:07.268Z"c5200cd908f5a21beacd1508547b3453"2397402STANDARD2206203922062039Normalmedia/2013-03-15_Modul_1_Komboglyze.pdf2025-12-03T11:03:06.470Z"48fa461e5b0d41289c798c454001a60c"198049STANDARD2206203922062039Normalmedia/2013-03-21_AM-RL-XII_Aclidiniumbromid_BAnz.pdf2025-12-03T11:02:26.486Z"42779737bf71e179b3154c39e35addc6"126062STANDARD2206203922062039Normalmedia/2013-03-21_AM-RL-XII_Aclidiniumbromid_TrG.pdf2025-12-03T11:02:26.905Z"48a48f52f56bf8d0d1edcf7b9a6245bd"110575STANDARD2206203922062039Normalmedia/2013-03-21_AM-RL-XII_Axitinib.pdf2025-12-03T11:02:29.949Z"1eb88c815899b64891c6f272447c819c"111444STANDARD2206203922062039Normalmedia/2013-03-21_AM-RL-XII_Axitinib_TrG.pdf2025-12-03T11:02:33.176Z"f2b78bb8fc0ebcf5532503727d8852a2"129411STANDARD2206203922062039Normalmedia/2013-03-25_Modul1_Vildagliptin-Metformin.pdf2025-12-03T11:03:13.667Z"9ace6029909004e72688debb8485fc7d"395937STANDARD2206203922062039Normalmedia/2013-03-25_Modul1_Vildagliptin.pdf2025-12-03T11:03:14.946Z"a82a41dbc752cc64a68fc8317ac90eae"411940STANDARD2206203922062039Normalmedia/2013-03-25_Modul4A_Vildagliptin-Metformin.pdf2025-12-03T11:03:16.372Z"d3325461c87562682ea761af07bec318"6358226STANDARD2206203922062039Normalmedia/2013-03-25_Modul4A_Vildagliptin.pdf2025-12-03T11:03:19.844Z"262580327d330c8693ca8678ceae449e-2"8668271STANDARD2206203922062039Normalmedia/2013-03-26_Modul1_Sitagliptin-Metformin.pdf2025-12-03T11:03:13.167Z"d539160777ebf306c5a1f773ca376a86"884698STANDARD2206203922062039Normalmedia/2013-03-26_Modul1_Sitagliptin.pdf2025-12-03T11:03:09.563Z"8b73d53e3bd5027c6437695987451a8d"1199747STANDARD2206203922062039Normalmedia/2013-03-26_Modul4A_Sitagliptin-Metformin.pdf2025-12-03T11:03:11.987Z"187b795aadd74917743e60613aa5648d"2739544STANDARD2206203922062039Normalmedia/2013-03-26_Modul4A_Sitagliptin.pdf2025-12-03T11:03:11.921Z"96a08c71e245c790936788175102578f"6349162STANDARD2206203922062039Normalmedia/2013-03-26_Modul4B_Sitagliptin-Metformin.pdf2025-12-03T11:03:11.578Z"3942800a3715551fb11c61d7a22279d0"1506124STANDARD2206203922062039Normalmedia/2013-03-26_Modul4B_Sitagliptin.pdf2025-12-03T11:03:13.134Z"13ed2bc0668a6c0ce8ce0058bec7923b"2752516STANDARD2206203922062039Normalmedia/2013-03-26_Modul4C_Sitagliptin-Metformin.pdf2025-12-03T11:03:11.644Z"29fc3de0993139da148cf428cf3969ba"1241936STANDARD2206203922062039Normalmedia/2013-03-26_Modul4C_Sitagliptin.pdf2025-12-03T11:03:11.131Z"6efd331e5b59cbac106a18a9c2205713"1380223STANDARD2206203922062039Normalmedia/2013-03-26_Modul4D_Sitagliptin.pdf2025-12-03T11:03:11.077Z"1410d2a66309c388206539820b6c6292"1483135STANDARD2206203922062039Normalmedia/2013-03-26_Modul4E_Sitagliptin.pdf2025-12-03T11:03:09.556Z"19560561730ab9ec73416fce3922e68f"1243757STANDARD2206203922062039Normalmedia/2013-03-26_Wortprotokoll_Crizotinib.pdf2025-12-03T11:02:34.045Z"9741039a1bec0ec27820512556cc024b"152259STANDARD2206203922062039Normalmedia/2013-03-26_Wortprotokoll_Saxagliptin_Metformin.pdf2025-12-03T11:02:39.563Z"f799327782157d5a85421d5302be365b"189898STANDARD2206203922062039Normalmedia/2013-03-27_A12-20_Apixaban-neues-AWG_Nutzenbewertung-IQWiG.pdf2025-12-03T11:01:52.070Z"060e39eb87fa5c3eecb887104ca7c4b4"920480STANDARD2206203922062039Normalmedia/2013-03-27_Modul4A_Saxagliptin.pdf2025-12-03T11:03:02.386Z"5ac2ccf0c78a7a3b0a7b09a835b44833"4630659STANDARD2206203922062039Normalmedia/2013-03-27_Modul4B_Saxagliptin.pdf2025-12-03T11:03:03.175Z"fe231315dcd67080b0815465ef5d3e16"2969705STANDARD2206203922062039Normalmedia/2013-03-27_Modul4C_Saxagliptin.pdf2025-12-03T11:03:04.489Z"67f98a5c492670522926393b0ba4d1fe"2576450STANDARD2206203922062039Normalmedia/2013-03-27_Modul4D_Saxagliptin.pdf2025-12-03T11:03:03.042Z"99115a242f8baf083c09c7d056046e44"2442221STANDARD2206203922062039Normalmedia/2013-03-28_Modul1_Colestilan.pdf2025-12-03T11:02:34.770Z"c9a73be72e20c3299114ceea4569bc58"494866STANDARD2206203922062039Normalmedia/2013-03-28_Modul4A_Colestilan.pdf2025-12-03T11:02:40.273Z"146b6a7b05e1f02d69337a81a0d17a44"8012751STANDARD2206203922062039Normalmedia/2013-04-01-D-048_Vildagliptin_Metformin_Addendum.pdf2025-12-03T11:03:14.050Z"858d22e73c1868c5a7f8cc17e69984d3"295639STANDARD2206203922062039Normalmedia/2013-04-01-D-049_Vildagliptin_Addendum.pdf2025-12-03T11:03:15.860Z"f8deff1f26a0a34bbf4f7e7337dd6743"227338STANDARD2206203922062039Normalmedia/2013-04-01-D-055_Sitagliptin_Metformin_Addendum.pdf2025-12-03T11:03:18.245Z"f7178562330caecd0f76dad7a0a99579"260334STANDARD2206203922062039Normalmedia/2013-04-01-D-057_Pertuzumab_Addendum.pdf2025-12-03T11:03:06.553Z"9246799118600a69159f4e78374ea4cb"80582STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Colestilan.pdf2025-12-03T11:02:36.256Z"efc53bfbb58389d5298ce77c88e291a9"272494STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Pertuzumab.pdf2025-12-03T11:03:06.579Z"136a786a2c3aa301c3c5a44228b90947"1039622STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Saxaliptin_D-050.pdf2025-12-03T11:03:04.419Z"489f5368dd872c66da375b37f1b7c6bf"945422STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Saxaliptin_Metformin_neu_D-06_AWG.pdf2025-12-03T11:03:05.655Z"145c9353a4be01aa43c247e30622398a"942518STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Sitagliptin_D-054.pdf2025-12-03T11:03:08.974Z"0df239db47822021740c552a12462a71"963417STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Sitagliptin_Metformin_D-055.pdf2025-12-03T11:03:12.965Z"019a9acc2cfc766da635e9c9b8352d5f"945176STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Vildagliptin_D-049.pdf2025-12-03T11:03:15.649Z"9f0877b053f232c22f25284fc748f44d"437632STANDARD2206203922062039Normalmedia/2013-04-01_Informationen_zur_zVT_Vildagliptin_Metformin_D-048.pdf2025-12-03T11:03:13.371Z"605c5a245741adf14e7f01e7bf1a4f41"436916STANDARD2206203922062039Normalmedia/2013-04-08_Wortprotokoll_Brentuximab_20Vedotin.pdf2025-12-03T11:02:41.173Z"4e3ba45ff86cd97820caff8641413d22"132274STANDARD2206203922062039Normalmedia/2013-04-08_Wortprotokoll_Linagliptin.pdf2025-12-03T11:02:45.742Z"2e87d3369b0235c6102e85202e61e4e3"208748STANDARD2206203922062039Normalmedia/2013-04-08_Wortprotokoll_Pixantron.pdf2025-12-03T11:02:44.342Z"306975cd7cbb44937947ed0b6213f342"126625STANDARD2206203922062039Normalmedia/2013-04-11_A13-04_Ingenolmebutat_Nutzenbewertung-IQWiG.pdf2025-12-03T11:02:54.255Z"3ed7f81cfe2cdc0c0c055b8d3ea4eeac"301365STANDARD2206203922062039Normalmedia/2013-04-11_A13-05_Fidaxomicin_Nutzenbewertung-IQWiG.pdf2025-12-03T11:02:52.944Z"56362225946b799e0793028bfce7b02e"470326STANDARD2206203922062039Normalmedia/2013-04-11_A13-06_Abirateronacetat_neues-Anwendungsgebiet_Nutzenbewertung-IQWiG.pdf2025-12-03T11:02:10.678Z"c16e35326ded200e4904f84f0af699d1"479506STANDARD2206203922062039Normalmedia/2013-04-23_Wortprotokoll_Aflibercept.pdf2025-12-03T11:02:48.764Z"c53b72f1a1eb3d64d62cb010149391ee"154731STANDARD2206203922062039Normalmedia/2013-04-23_Wortprotokoll_Dapagliflozin_.pdf2025-12-03T11:02:47.747Z"e7412ae3bcc728e75ae04999fcabbf64"200163STANDARD2206203922062039Normalmedia/2013-04-26_Modul1_Bosutinib.pdf2025-12-03T11:03:17.554Z"ce984352ec4d5c64327c221756c6f4a1"464272STANDARD2206203922062039Normalmedia/2013-04-26_Modul4A_Bosutinib.pdf2025-12-03T11:03:22.249Z"2c2351d8aaac19e304de88f82e934790"2638571STANDARD2206203922062039Normalmedia/2013-04-29_Modul1_Ocriplasmin.pdf2025-12-03T11:03:20.965Z"020a7d2c397ff69a6c20cca1bdd15670"493065STANDARD2206203922062039Normalmedia/2013-04-29_Modul4A_Ocriplasmin.pdf2025-12-03T11:03:24.445Z"7f5b97b1ea176032b5ee3df1f191c6e0"6255900STANDARD2206203922062039Normalmedia/2013-04-30_Modul1A_Linaclotid.pdf2025-12-03T11:03:18.912Z"fe01f4bd292aaa09c0b37f4361944f70"514895STANDARD2206203922062039Normalmedia/2013-04-30_Modul4A_Linaclotid.pdf2025-12-03T11:03:23.479Z"2fe00c1cb64de9bbdf36fd72228c2efd"6574299STANDARD2206203922062039Normalmedia/2013-05-01_Informationen_20zur_20zVT_Ocriplasmin_D-066.pdf2025-12-03T11:03:21.143Z"d8290255b6c6587d9464a3b04dba72c7"120482STANDARD2206203922062039Normalmedia/2013-05-01_Informationen_zur_zVT_D-065_Linaclotid.pdf2025-12-03T11:03:18.799Z"e392017ef2156db76042da5b9f299edc"137249STANDARD2206203922062039Normalmedia/2013-05-01_Nutzenbewertung_G-BA_Bosutinib.pdf2025-12-03T11:03:18.813Z"d041142ef5d2b2032bfb13ecc771adb6"1123393STANDARD2206203922062039Normalmedia/2013-05-02_AM-RL-XII_Crizotinib_BAnz.pdf2025-12-03T11:02:35.759Z"2e7e5b31ef6662575aaccc530c91a323"190719STANDARD2206203922062039Normalmedia/2013-05-02_AM-RL-XII_Crizotinib_TrG.pdf2025-12-03T11:02:34.056Z"a525f25699a0e2f1a2db6fba8f5d9eb7"106645STANDARD2206203922062039Normalmedia/2013-05-02_AM-RL-XII_Decitabin_BAnz.pdf2025-12-03T11:02:37.267Z"e25425a4878cb27da338819533894d57"127626STANDARD2206203922062039Normalmedia/2013-05-02_AM-RL-XII_Decitabin_TrG.pdf2025-12-03T11:02:37.451Z"caed60c1d4a778ef68fddfd436934e79"111875STANDARD2206203922062039Normalmedia/2013-05-02_AM-RL-XII_Saxagliptin_20Metformin_BAnz.pdf2025-12-03T11:02:39.388Z"da08f4d80319208b72277674daea778d"151647STANDARD2206203922062039Normalmedia/2013-05-02_AM-RL-XII_Saxagliptin_20Metformin_TrG.pdf2025-12-03T11:02:39.868Z"ad3e8a244c6af44d1ba9e8b91fa4b382"158913STANDARD2206203922062039Normalmedia/2013-05-02_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_Kopie_2.pdf2025-12-03T11:02:37.945Z"8e269f6e183bce3e40f246c211a78cc1"122699STANDARD2206203922062039Normalmedia/2013-05-07_Wortprotokoll_end_Apixaban.pdf2025-12-03T11:01:50.006Z"ec3528bd0f27ba9f6897ff3cef1003da"365476STANDARD2206203922062039Normalmedia/2013-05-16_AM-RL-XII_Brentuximab.pdf2025-12-03T11:02:41.554Z"5eb2f692b406e451ee4c0aafc9783ae6"165607STANDARD2206203922062039Normalmedia/2013-05-16_AM-RL-XII_Brentuximab_TrG.pdf2025-12-03T11:02:40.542Z"de96eaf3cb0b42ae12b6919d2c04f735"150883STANDARD2206203922062039Normalmedia/2013-05-16_AM-RL-XII_Linagliptin-neues-AWG_BAnz.pdf2025-12-03T11:02:42.644Z"6ef201e6f98be3e4ca68798fd1c1dbdd"224688STANDARD2206203922062039Normalmedia/2013-05-16_AM-RL-XII_Linagliptin-neues-AWG_TrG.pdf2025-12-03T11:02:42.599Z"2933be3a881d35499c3d9681521ed01a"91997STANDARD2206203922062039Normalmedia/2013-05-16_AM-RL-XII_Pixantron_BAnz.pdf2025-12-03T11:02:44.966Z"2f3f10265000766de4a6ddf15610b241"292005STANDARD2206203922062039Normalmedia/2013-05-16_AM-RL-XII_Pixantron_TrG.pdf2025-12-03T11:02:44.761Z"9ded16734e1c26ee80ded5f0e9b46641"133730STANDARD2206203922062039Normalmedia/2013-05-16_Bewertung_Therapiekosten_Patientenzahlen_IQWiG.pdf2025-12-03T11:02:40.957Z"8715ae9eda5c12286a415d0e1759007e"154880STANDARD2206203922062039Normalmedia/2013-05-27_Wortprotokoll_Ingenolmebutat.pdf2025-12-03T11:02:53.746Z"a1b769198dad24a065403fa624252d91"349408STANDARD2206203922062039Normalmedia/2013-05-27_Wortprotokoll_end_Abirateronacetat.pdf2025-12-03T11:02:12.244Z"960cf6d3a8f0b09020033dd80aaad79a"121026STANDARD2206203922062039Normalmedia/2013-05-27_Wortprotokoll_end_Fidaxomicin.pdf2025-12-03T11:02:51.628Z"d91b30b1991df230d9c67c7641f69df0"191240STANDARD2206203922062039Normalmedia/2013-05-29_A13-08_Aflibercept-Zaltrap_Nutzenbewertung-IQWiG.pdf2025-12-03T11:02:54.431Z"abe92c886d65743cf99d6c35b9923cbd"391133STANDARD2206203922062039Normalmedia/2013-05-29_Analyse-Schiedsspruch-Perampanel_2-13.pdf2025-12-03T11:45:11.655Z"39136f6334b5e9dfbacac8678fd3aca6"113587STANDARD2206203922062039Normalmedia/2013-05-29_Analyse-Schiedsspruch-Vemurafenib.pdf2025-12-03T11:45:11.557Z"473538958db94a347a91ab0a66c7ffee"113286STANDARD2206203922062039Normalmedia/2013-05-29_Schiedsspruch_1-13_Vemurafenib_Zelboraf_005.pdf2025-12-03T11:45:12.573Z"6bc3a6e52c4858afa673b963e044a89a"2315804STANDARD2206203922062039Normalmedia/2013-05-30_Modul1_Lisdexamfetamindimesilat.pdf2025-12-03T11:03:24.748Z"59cbaf7f11e9432df86148945ebb9b40"476946STANDARD2206203922062039Normalmedia/2013-05-30_Modul4A_Lisdexamfetamindimesilat.pdf2025-12-03T11:03:24.850Z"493c7d4719e86e362b36c39a0aa216ef"6560956STANDARD2206203922062039Normalmedia/2013-06-01_Informationen_zur_zVT_Lisdexamfetamindimesilat.pdf2025-12-03T11:03:25.551Z"3c06763dae3c8e9efce0d0233ba012b5"704014STANDARD2206203922062039Normalmedia/2013-06-06_AM-RL-XII_Aflibercept_BAnz.pdf2025-12-03T11:02:45.867Z"12c890050a44d22affe6636a65f8700a"94428STANDARD2206203922062039Normalmedia/2013-06-06_AM-RL-XII_Aflibercept_TrG.pdf2025-12-03T11:02:48.042Z"a91019ee83d4662463ac7a7b03297bdf"84718STANDARD2206203922062039Normalmedia/2013-06-06_AM-RL-XII_Dapagliflozin_BAnz.pdf2025-12-03T11:02:47.959Z"eadabf419253c216049410f43fdab8b9"164873STANDARD2206203922062039Normalmedia/2013-06-06_AM-RL-XII_Dapagliflozin_TrG.pdf2025-12-03T11:02:48.340Z"df5d12f9594546943630b2e9d7a812fa"174293STANDARD2206203922062039Normalmedia/2013-06-13_D-059_Vandetanib_5b_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:58.153Z"65380d10fa4494b666b6f980a2ca5959"503110STANDARD2206203922062039Normalmedia/2013-06-13_D-061_Lixisenatid_IQWiG-Nutzenbewertung.pdf2025-12-03T11:02:56.379Z"fc3634afa310efba6c3ca0309dc2f7cd"725842STANDARD2206203922062039Normalmedia/2013-06-14_Modul1_Elvitegravir-Cobicistat-Emtricitabin-Tenofovirdisoproxil.pdf2025-12-03T11:03:28.569Z"2f0e8d567e09634001a95af4bce3cbc3"554165STANDARD2206203922062039Normalmedia/2013-06-14_Modul4A_Elvitegravir-Cobicistat-Emtricitabin-Tenofovirdisoproxil.pdf2025-12-03T11:03:28.590Z"c533b8389c4c2075221e99ad6fafa6d4"4431073STANDARD2206203922062039Normalmedia/2013-06-14_Modul4B_Elvitegravir-Cobicistat-Emtricitabin-Tenofovirdisoproxil.pdf2025-12-03T11:03:29.659Z"6070e29e219bef57cbdeb387cb1d13ef"5567496STANDARD2206203922062039Normalmedia/2013-06-15-D-068_Elvitegravir_IQWiG_Nutzenbewertung.pdf2025-12-03T11:03:26.442Z"2b6df7b0b0efa2a234ae7b16bfdb0075"758436STANDARD2206203922062039Normalmedia/2013-06-15_Elvitegravir_Cobicistat_Emtricitabin_Tenofovirdisoproxil_B-017_Uebersicht_zVT.pdf2025-12-03T11:03:27.068Z"0375e241768f4cc2890c7e30b74c1fbb"668875STANDARD2206203922062039Normalmedia/2013-06-20_AM-RL-XII_Aclidiniumbromid_Aenderungsbeschluss_BAnz.pdf2025-12-03T11:02:27.939Z"ba2b80e606f6a4c1b31fdfe4b50ae077"90730STANDARD2206203922062039Normalmedia/2013-06-20_AM-RL-XII_Apixaban-neues-AWG_BAnz.pdf2025-12-03T11:01:48.684Z"f0562220adcc96f0fe584f6f613c2ac1"129900STANDARD2206203922062039Normalmedia/2013-06-20_AM-RL-XII_Apixaban-neues-AWG_TrG.pdf2025-12-03T11:01:48.582Z"ad93c8198536f0d9289fab94798bb294"142708STANDARD2206203922062039Normalmedia/2013-06-27_A13-01_Saxagliptin_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:03.202Z"5697f611e7c3d801971019ac10bec15c"618895STANDARD2206203922062039Normalmedia/2013-06-27_A13-02_Sitagliptin_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:09.856Z"47f77d8382189169bfd4d65ed4b2b6fb"1644643STANDARD2206203922062039Normalmedia/2013-06-27_A13-03_Sitagliptin-Metformin_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:11.979Z"efabe0539330ca48b24eeedf3c1eebdb"379017STANDARD2206203922062039Normalmedia/2013-06-27_A13-10_Pertuzumab_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:00.434Z"d17a08318535aec46637d3a7ca866524"484711STANDARD2206203922062039Normalmedia/2013-06-27_A13-12_Saxagliptin-Metformin_28neuesAWG_29_Nutzenbewertung-_C2_A735a-SGBV.pdf2025-12-03T11:03:06.658Z"01a54f7eb282f81e3515733c7307559b"278518STANDARD2206203922062039Normalmedia/2013-06-27_A13-15_Colestilan_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:02:35.457Z"d98139c9e5aa9c12b967498947d3877a"455784STANDARD2206203922062039Normalmedia/2013-06-27_A13-16_Vildagliptin_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:15.768Z"67857579214fda8d370bf771286f9924"622624STANDARD2206203922062039Normalmedia/2013-06-27_A13-17_Vildagliptin-Metformin_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:13.885Z"94da019dba2ebab5753957691dacf966"340904STANDARD2206203922062039Normalmedia/2013-07-01_Informationen_zur_zweckm_C3_A4_C3_9_-D-070_Figen_Vergleichstherapie.pdf2025-12-03T11:03:25.142Z"2053e4a5362d6ffc3fa34c48465b687e"432604STANDARD2206203922062039Normalmedia/2013-07-01_Nutzenbewertung_Nepafenac.pdf2025-12-03T11:03:24.224Z"d0e9ab87f974b3ebf758dd3e23940a00"82594STANDARD2206203922062039Normalmedia/2013-07-04_AM-RL-XII_Abirateronacetat-neuesAWG_BAnz.pdf2025-12-03T11:02:08.954Z"c36fab024b3fde84cb8fbc8ec83be306"122645STANDARD2206203922062039Normalmedia/2013-07-04_AM-RL-XII_Abirateronacetat-neuesAWG_TrG.pdf2025-12-03T11:02:11.560Z"1ceb0f54578f903bb738aab914993a31"294087STANDARD2206203922062039Normalmedia/2013-07-04_AM-RL-XII_Fidaxomicin_BAnz.pdf2025-12-03T11:02:50.259Z"45fc4210cb855b66ce4c2d2adaf94696"143802STANDARD2206203922062039Normalmedia/2013-07-04_AM-RL-XII_Fidaxomicin_TrG.pdf2025-12-03T11:02:50.257Z"6aa41f509c8b8b5d42651cac1e550277"118818STANDARD2206203922062039Normalmedia/2013-07-04_AM-RL-XII_Ingenolmebutat_BAnz.pdf2025-12-03T11:02:52.144Z"51e9f4fcbd836bc9ba80ce709aec65c0"143641STANDARD2206203922062039Normalmedia/2013-07-04_AM-RL-XII_Ingenolmebutat_TrG.pdf2025-12-03T11:02:52.751Z"47596348b8d59c1ba6a56d5152559c98"96132STANDARD2206203922062039Normalmedia/2013-07-09_Wortprotokoll_end_Aflibercept.pdf2025-12-03T11:02:54.432Z"bdab2ad2aff17e8407611f01637b3a31"160759STANDARD2206203922062039Normalmedia/2013-07-23_Wortprotokoll_Lixisenatid.pdf2025-12-03T11:02:56.172Z"692bb2d845830ce088adac097bd4a39d"106470STANDARD2206203922062039Normalmedia/2013-07-23_Wortprotokoll_Vandetanib.pdf2025-12-03T11:02:59.176Z"de323c37317285613355c9e9c0c46bd1"125045STANDARD2206203922062039Normalmedia/2013-07-30_A13-20_Ocriplasmin_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:21.181Z"dfc06730c779da617afec52bfc5b6942"709065STANDARD2206203922062039Normalmedia/2013-07-30_A13-21_Linaclotid_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:19.882Z"2a9e40d1d7e75e614283c7d537ff0387"332417STANDARD2206203922062039Normalmedia/2013-07-30_Modul1_Saxagliptin.pdf2025-12-03T11:23:02.850Z"1fa3254791bd1f79328a196dad0ee7d9"196769STANDARD2206203922062039Normalmedia/2013-07-31_Modul1_Vismodegib.pdf2025-12-03T11:03:32.149Z"f7fb03bb68c817c0e4cce4910bb80809"200861STANDARD2206203922062039Normalmedia/2013-07-31_Modul4A_Vismodegib.pdf2025-12-03T11:03:32.170Z"03a0d9073b8bac48651d3bd62db7cec0"3878932STANDARD2206203922062039Normalmedia/2013-08-01_Modul1_Ponatinib.pdf2025-12-03T11:03:29.574Z"ef14007f310400027d1e97aa05868564"234463STANDARD2206203922062039Normalmedia/2013-08-01_Modul4A_Ponatinib.pdf2025-12-03T11:03:29.871Z"85d8ffbe747a6f13514c1403943a26eb"3317554STANDARD2206203922062039Normalmedia/2013-08-01_Modul4B_Ponatinib.pdf2025-12-03T11:03:29.201Z"ea3ac43bf112ff67440e97a8f0104f0a"2368778STANDARD2206203922062039Normalmedia/2013-08-01_Nutzenbewertung_G-BA-Ponatinib.pdf2025-12-03T11:03:29.492Z"23fc5207fa0bc374fcb99a02fc4fd81b"864966STANDARD2206203922062039Normalmedia/2013-08-05_Wortprotokoll_Gliptine.pdf2025-12-03T11:03:04.159Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalmedia/2013-08-05_Wortprotokoll_Gliptine_Dm9XgbO.pdf2026-03-21T13:50:23.879Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalmedia/2013-08-05_Wortprotokoll_Gliptine_Sxya9D7.pdf2026-03-21T13:50:24.681Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalmedia/2013-08-05_Wortprotokoll_Gliptine_dP0A5Kh.pdf2026-03-21T13:50:24.431Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalmedia/2013-08-05_Wortprotokoll_Gliptine_rHn9hMI.pdf2026-03-21T13:50:23.607Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalmedia/2013-08-05_Wortprotokoll_Gliptine_uLzqjG6.pdf2026-03-21T13:50:24.179Z"9162436fff516d82b158d24f36915fb6"327869STANDARD2206203922062039Normalmedia/2013-08-05_Wortprotokoll_Pertuzumab.pdf2025-12-03T11:03:01.099Z"900565a251c8af4b18e7aa837e91903c"392531STANDARD2206203922062039Normalmedia/2013-08-09_Wortprotokoll_Colestilan.pdf2025-12-03T11:02:35.255Z"45f903af2540f4bc42ef41983c299f50"126898STANDARD2206203922062039Normalmedia/2013-08-15_AM-RL-35a_Einstellung-Retigabin.pdf2025-12-03T11:23:01.348Z"40bd8b2e502454679313eb0fbfb346f4"29402STANDARD2206203922062039Normalmedia/2013-08-15_AM-RL-35a_Einstellung-Retigabin_TrG.pdf2025-12-03T11:23:01.544Z"89b9aeac8c32c460967639c33cdd5edf"59753STANDARD2206203922062039Normalmedia/2013-08-15_AM-RL-XII_Aflibercept_BAnz.pdf2025-12-03T11:02:57.779Z"358187eb23ee03713e623b0fc4d92bca"165529STANDARD2206203922062039Normalmedia/2013-08-15_AM-RL-XII_Aflibercept_TrG.pdf2025-12-03T11:02:57.761Z"c98dd722e37106fdca379f93c5386d1d"145413STANDARD2206203922062039Normalmedia/2013-08-15_Informationen_zur_zVT_D-069_Vismodegib.pdf2025-12-03T11:03:30.347Z"436b80ceb0deeae52542b2b3922eb60f"401936STANDARD2206203922062039Normalmedia/2013-08-15_Nutzenbewertung-35a-SGB-V_Vismodegib.pdf2025-12-03T11:03:30.976Z"1a0db836bc3b8521d2e5a1ecb07fc2c6"299286STANDARD2206203922062039Normalmedia/2013-08-21_Modul4A_Saxagliptin.pdf2025-12-03T11:23:07.308Z"bbd171fde80f79b83579095bfcac7029"7037928STANDARD2206203922062039Normalmedia/2013-08-29_A13-24_Lisdexamfetamindimesilat_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:23.544Z"aa3c09541eb479ab09ba28a17e43968f"272104STANDARD2206203922062039Normalmedia/2013-08-29_Modul1_Enzalutamid.pdf2025-12-03T11:03:32.549Z"97d41adc1b3c366577be57ed7a752565"172039STANDARD2206203922062039Normalmedia/2013-08-29_Modul4A_Enzalutamid.pdf2025-12-03T11:03:33.783Z"daf129231c5b69ae621c6c4823eda9e9"2152185STANDARD2206203922062039Normalmedia/2013-08-30_Modul1_Pomalidomid.pdf2025-12-03T11:03:34.191Z"134fc10c1442f7e2a52077552221d11a"163981STANDARD2206203922062039Normalmedia/2013-08-30_Modul4A_Pomalidomid.pdf2025-12-03T11:03:34.082Z"9f07c1162955be8a1caf3f5cb7623558"1700714STANDARD2206203922062039Normalmedia/2013-09-01-D-073_Enzalutamid_Addendum.pdf2025-12-03T11:03:32.681Z"dee2951e1c07968c42782aa5ac86b8c4"303849STANDARD2206203922062039Normalmedia/2013-09-01_Informationen_zur_zVT_D-073_Enzalutamid.pdf2025-12-03T11:03:32.650Z"06f04c24d487a8b10457dcd95a4de27f"281264STANDARD2206203922062039Normalmedia/2013-09-01_Nutzenbewertung_G-BA_Pomalidomid.pdf2025-12-03T11:03:35.957Z"e6c2df5a7172fb8b944d36d9e92fae5d"823479STANDARD2206203922062039Normalmedia/2013-09-02_Modul1_Vemurafenib.pdf2025-12-03T11:03:35.451Z"907cc4232807dd9ff2bbb71eb9911986"450903STANDARD2206203922062039Normalmedia/2013-09-02_Modul4A_Vemurafenib.pdf2025-12-03T11:03:38.253Z"4107d08ee030da302eb19b27c2151bcb"4382620STANDARD2206203922062039Normalmedia/2013-09-05_AM-RL-XII_Lixisenatid_BAnz.pdf2025-12-03T11:02:54.930Z"6f9250e8ce15f9363201dbb8b9530eda"181802STANDARD2206203922062039Normalmedia/2013-09-05_AM-RL-XII_Lixisenatid_TrG.pdf2025-12-03T11:02:55.285Z"d898521d248c49b3fe6b8264936d34a1"177475STANDARD2206203922062039Normalmedia/2013-09-05_AM-RL-XII_Vandetanib_BAnz.pdf2025-12-03T11:02:59.345Z"9c32b1d7de465c0b06b5be6310eae7bc"133430STANDARD2206203922062039Normalmedia/2013-09-05_AM-RL-XII_Vandetanib_TrG.pdf2025-12-03T11:02:59.758Z"7486d496c6382b31df6c34546f2bc07d"137126STANDARD2206203922062039Normalmedia/2013-09-09_Bosutinib_Wortprotokoll.pdf2025-12-03T11:03:17.957Z"d6ea5d28786640defe7fb3988c350f60"87346STANDARD2206203922062039Normalmedia/2013-09-09_Wortprotokoll_End_Ocriplasmin.pdf2025-12-03T11:03:21.239Z"801a4491aeaf9467c5171e7c8417c689"201446STANDARD2206203922062039Normalmedia/2013-09-09_Wortprotokoll_end_Linaclotid.pdf2025-12-03T11:03:19.722Z"64d14a426a8389141e2ba1e6e6de33ed"234255STANDARD2206203922062039Normalmedia/2013-09-19_35a_Freistellung-Spinalanaesthesie.pdf2025-12-03T11:22:47.870Z"79eeef956ba09ced44398c730e53b879"28318STANDARD2206203922062039Normalmedia/2013-09-19_35a_Freistellung-Spinalanaesthesie_TrG.pdf2025-12-03T11:22:47.960Z"f1636da7a3ae2b67b0a03a37b4dfc0bd"52106STANDARD2206203922062039Normalmedia/2013-09-19_Modul1_Dabrafenib.pdf2025-12-03T11:03:42.277Z"027fe2a495a7770b27e415bbde41eb8a"290499STANDARD2206203922062039Normalmedia/2013-09-20_Modul1_Aflibercept.pdf2025-12-03T11:03:38.164Z"e37a836a169d2e737a6cc54144a778a4"550574STANDARD2206203922062039Normalmedia/2013-09-20_Modul4B_Aflibercept.pdf2025-12-03T11:03:40.504Z"c046dfe9d4d0061f0e85ea44f5c7d2a6"5344848STANDARD2206203922062039Normalmedia/2013-09-20_Modul4_Dabrafenib.pdf2025-12-03T11:03:46.334Z"dfed90caa39dd796ea9ab3059a382637"6359303STANDARD2206203922062039Normalmedia/2013-09-25_Modul1_Teriflunomid.pdf2025-12-03T11:03:46.166Z"fc09753623e070cb7914c61574d5ebcb"487964STANDARD2206203922062039Normalmedia/2013-09-26_Modul4A_Teriflunomid.pdf2025-12-03T11:03:42.116Z"66af6c1bb71c514c9e0d87e98015d9f1"5631350STANDARD2206203922062039Normalmedia/2013-09-30_Modul1_Regorafenib_mCRC.pdf2025-12-03T11:03:40.142Z"92206b64f26d80cdbdbd3291a75aae6a"522081STANDARD2206203922062039Normalmedia/2013-09-30_Modul4_Regorafenib_mCRC.pdf2025-12-03T11:03:45.611Z"1e740b1635c94680890b19f7ac88b5ed"2676916STANDARD2206203922062039Normalmedia/2013-10-01-D-076_Dabrafenib_Addendum.pdf2025-12-03T11:03:42.776Z"83f80576bd3a04ca55a591ab4899a973"133128STANDARD2206203922062039Normalmedia/2013-10-01-D-077_Regorafenib_Addendum.pdf2025-12-03T11:03:39.877Z"9313029b3d66f4e4abfd2689dc7b1ced"93373STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Colestilan_BAnz_WZ.pdf2025-12-03T11:02:34.562Z"b404012dc4c17fc4a6053b2ad1d930fc"127749STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Colestilan_TrG_WZ.pdf2025-12-03T11:02:36.046Z"be165c07ae60c92dedb7f5a273aa01ff"596864STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Pertuzumab_BAnz.pdf2025-12-03T11:02:59.755Z"e2bc63dfc4ab484ab6fe68ea228a046e"152298STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Pertuzumab_TrG.pdf2025-12-03T11:03:02.392Z"a86518d799ac1136afeb989002ce5e3b"145004STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Saxagliptin-Metformin_nAWG_BAnz.pdf2025-12-03T11:03:06.550Z"84b0c2fc263dbbd574cd07469d489a11"92603STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Saxagliptin-Metformin_nAWG_TrG.pdf2025-12-03T11:03:06.741Z"218e14e8ebc641bb30a09693261c48da"128933STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Saxagliptin_BAnz.pdf2025-12-03T11:03:04.309Z"456a2386ca06fdf317f0998442e84ba9"218814STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Saxagliptin_TrG.pdf2025-12-03T11:03:04.459Z"38ff13b44f5fa6855ba8703145ea8c93"195865STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Sitagliptin-Metformin_BAnz.pdf2025-12-03T11:03:11.259Z"b04b5362937ca53f6e1bda12a39c35a5"196541STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Sitagliptin-Metformin_TrG.pdf2025-12-03T11:03:11.826Z"79b8ca4b71e109b29e6068ba4971bea5"190645STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Sitagliptin_BAnz.pdf2025-12-03T11:03:08.881Z"0fd1970ab5cec7b56235b9b1597c5542"248061STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Sitagliptin_TrG.pdf2025-12-03T11:03:08.347Z"680c6ff998a4ea83eba269b26f698ee5"230893STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Vildagliptin-Metformin_BAnz.pdf2025-12-03T11:03:13.955Z"876b5548aaca1044e2843be3d5d4bbcb"343662STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Vildagliptin-Metformin_TrG.pdf2025-12-03T11:03:13.063Z"5d0b160a5ffd94a17d03f84ac8447af2"166577STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Vildagliptin_BAnz.pdf2025-12-03T11:03:15.811Z"07e65b110b19325d226d39f5f06a04d7"214592STANDARD2206203922062039Normalmedia/2013-10-01_AM-RL-XII_Vildagliptin_TrG.pdf2025-12-03T11:03:16.078Z"0bd61cd1d191e9b9c7feada2b1605e31"204712STANDARD2206203922062039Normalmedia/2013-10-01_Information_zur_zVT_-D-078_Teriflunomid.pdf2025-12-03T11:03:42.145Z"f13f52930337e2616dd382740ae717cd"359323STANDARD2206203922062039Normalmedia/2013-10-01_Information_zur_zVT_Dabrafenib.pdf2025-12-03T11:03:42.076Z"69d4efea370ff19f10f9023349d313cf"309181STANDARD2206203922062039Normalmedia/2013-10-01_Information_zur_zVT_Regorafenib.pdf2025-12-03T11:03:39.874Z"8c126ef488401c9742e7d147e0e190e0"353408STANDARD2206203922062039Normalmedia/2013-10-01_Information_zur_zVT_Vemurafenib-3.pdf2025-12-03T11:03:35.370Z"369ad3c59a457f322f9eb885c6ed4f2f"309208STANDARD2206203922062039Normalmedia/2013-10-01_Informationen_zur_zVT_D-080_Aflibercept_nAWG.pdf2025-12-03T11:03:38.244Z"6ba6d5a8921bdb23cac3d7d7bb454f0f"267797STANDARD2206203922062039Normalmedia/2013-10-08_Wortprotokoll_end_Lisdexamfetamindimesilat.pdf2025-12-03T11:03:24.942Z"c3919c7ba33c20082788c716fb3bd017"125074STANDARD2206203922062039Normalmedia/2013-10-17_AM-RL-XII_Bosutinib_BAnz.pdf2025-12-03T11:03:17.165Z"11aef40c1cc951a566b2062554820736"188703STANDARD2206203922062039Normalmedia/2013-10-17_AM-RL-XII_Bosutinib_TrG.pdf2025-12-03T11:03:17.058Z"46afbfb13c53474a8b034a8e0225f6f2"179665STANDARD2206203922062039Normalmedia/2013-10-17_AM-RL-XII_Linaclotid_BAnz.pdf2025-12-03T11:03:19.087Z"51b853d374819d0ac9fdb406e0355333"97151STANDARD2206203922062039Normalmedia/2013-10-17_AM-RL-XII_Linaclotid_TrG.pdf2025-12-03T11:03:20.564Z"acf458055f1475691e1eae071520817b"213925STANDARD2206203922062039Normalmedia/2013-10-17_AM-RL-XII_Ocriplasmin_BAnz.pdf2025-12-03T11:03:19.855Z"de1b4f534e57197aa54ba358ddf6e367"111471STANDARD2206203922062039Normalmedia/2013-10-17_AM-RL-XII_Ocriplasmin_TrG.pdf2025-12-03T11:03:20.568Z"6cbe46c084a76bdd46526f78f7cfdad0"144854STANDARD2206203922062039Normalmedia/2013-10-17_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG.pdf2025-12-03T11:03:18.645Z"ca55237d5deeae11d1be024b9bba8bce"128800STANDARD2206203922062039Normalmedia/2013-10-22_Wortprotokoll_end_Elvitegravir-Cobicistat-Emtricitabin-Tenof.pdf2025-12-03T11:03:26.453Z"6136ff7fd836705844706a96b15a4497"162060STANDARD2206203922062039Normalmedia/2013-11-04_Modul1_Indacaterol-Glycopyrronium.pdf2025-12-03T11:01:45.086Z"be024af70c566635537b286941b069e5"521294STANDARD2206203922062039Normalmedia/2013-11-04_Modul4A_Indacaterol-Glycopyrronium.pdf2025-12-03T11:01:48.850Z"b6637f2c37ea815b13380fd3c2684399-2"8919700STANDARD2206203922062039Normalmedia/2013-11-05_Wortprotokoll_Nepafenac.pdf2025-12-03T11:03:25.943Z"278506a5e75bdf263a637d215dd49c48"72846STANDARD2206203922062039Normalmedia/2013-11-14_AM-RL-XII_Lisdexamfetamin_BAnz.pdf2025-12-03T11:03:22.645Z"846952c8ab1ccb3395a98ea704af3acd"95665STANDARD2206203922062039Normalmedia/2013-11-14_AM-RL-XII_Lisdexamfetamin_TrG.pdf2025-12-03T11:03:22.648Z"7ad3b81d0d8974f18a595e18b6d0dd6a"96971STANDARD2206203922062039Normalmedia/2013-11-14_Modul1_Afatinib.pdf2025-12-03T11:01:46.770Z"f095ddead9b1ff8d50fd3105cdf6c522"555306STANDARD2206203922062039Normalmedia/2013-11-14_Modul4A_Afatinib.pdf2025-12-03T11:01:50.147Z"a511bffc37b433c63068c38256881434"5635526STANDARD2206203922062039Normalmedia/2013-11-15-D-081_Information-zur-zVT_Intacaterol_Glycopyrronium.pdf2025-12-03T11:01:45.354Z"58e4dfd70e9e4c1cd519f19d7c21d130"549042STANDARD2206203922062039Normalmedia/2013-11-15-D-082_Information-zur-zVT_Afatinib.pdf2025-12-03T11:01:47.178Z"df9fa0f6fecfbc4a102d9d932a3b0f97"912072STANDARD2206203922062039Normalmedia/2013-11-25_Modul1_Trastuzumab_Emtansin.pdf2025-12-03T11:03:50.444Z"70da8a8b7d2560069c5381ef962bd491"259618STANDARD2206203922062039Normalmedia/2013-11-25_Modul4A_Trastuzumab_Emtansin.pdf2025-12-03T11:03:52.447Z"429b68fb3aa037e16da1952b4c599e47"5410074STANDARD2206203922062039Normalmedia/2013-11-28_A13-33_Enzalutamid_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:32.784Z"88007c3bf248402501ef25f50c18b22a"715301STANDARD2206203922062039Normalmedia/2013-11-28_Schiedsspruch_2-13_Perampanel_Fycompa_006.pdf2025-12-03T11:45:13.484Z"2b2aa6c4348e632985f5a701805c6522"4299666STANDARD2206203922062039Normalmedia/2013-11-29_Modul1_Ipilimumab.pdf2025-12-03T11:03:44.275Z"ccd7803f43f47873c2f4d2b0fb020eba"321255STANDARD2206203922062039Normalmedia/2013-11-29_Modul4B_Ipilimumab.pdf2025-12-03T11:03:45.951Z"333d106f18518a732afa89e83d8ad141"4065569STANDARD2206203922062039Normalmedia/2013-12-05_35a_Freistellung_Defibrotid.pdf2025-12-03T11:22:48.658Z"7a00f5f86120bbcb832e120cf14a6740"28222STANDARD2206203922062039Normalmedia/2013-12-05_35a_Freistellung_Defibrotid_TrG.pdf2025-12-03T11:22:48.839Z"70379a01631086af9f693ea1782e5c34"51287STANDARD2206203922062039Normalmedia/2013-12-05_AM-RL-XII_Elvi_Cobi_Emtr_Teno_BAnz.pdf2025-12-03T11:03:25.858Z"0e6a28c318ad360ea48aaf2b56939f15"133858STANDARD2206203922062039Normalmedia/2013-12-05_AM-RL-XII_Elvi_Cobi_Emtr_Teno_TrG.pdf2025-12-03T11:03:25.958Z"57a7b679f32c604205a514c6170d8f99"162170STANDARD2206203922062039Normalmedia/2013-12-10_Wortprotokoll_Ponatinib.pdf2025-12-03T11:03:29.509Z"50881da8c0d574fad8253cf3acc6bdfa"195279STANDARD2206203922062039Normalmedia/2013-12-11_A13-34_Vemurafenib_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:36.255Z"fcd0be319aa55a5cb57fdf20b6cfc0f5"224883STANDARD2206203922062039Normalmedia/2013-12-13_Modul1_Radium-223-dichlorid_mCRPC.pdf2025-12-03T11:03:50.043Z"4f90777099c2561b1b6ed221fd1bf23f"524529STANDARD2206203922062039Normalmedia/2013-12-13_Modul4_Radium-223-dichlorid_mCRPC.pdf2025-12-03T11:03:51.697Z"327503f6b863c2726bb62a5c61a3d101-2"8673458STANDARD2206203922062039Normalmedia/2013-12-15_Info_zur_zVT_Ipilimumab.pdf2025-12-03T11:03:46.040Z"ab2b6300e289851922dd2707b823047c"617445STANDARD2206203922062039Normalmedia/2013-12-15_Info_zur_zVT_Lomitapid.pdf2025-12-03T11:03:46.116Z"e931d173be1ae3cb77918f136b2c8aa2"358205STANDARD2206203922062039Normalmedia/2013-12-15_Nutzenbewertung_D093_Lomitapid.pdf2025-12-03T11:03:46.916Z"bb29aed26370d0d1fe09d8a45186890d"356621STANDARD2206203922062039Normalmedia/2013-12-19_A13-36_Aflibercept-Eylea_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:38.096Z"bd3da27c2e209b6106ab813551419fe0"351831STANDARD2206203922062039Normalmedia/2013-12-19_A13-37_Regorafenib_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:40.402Z"4f631004f01df4fa3e2e2cb54cb8e4dc"743843STANDARD2206203922062039Normalmedia/2013-12-19_AM-RL-XII_Nepafenac_BAnz.pdf2025-12-03T11:03:24.852Z"3ea26deeb304a637822414d1f3fce85c"97992STANDARD2206203922062039Normalmedia/2013-12-19_AM-RL-XII_Nepafenac_TrG.pdf2025-12-03T11:03:25.365Z"2662385876bdabc6a8eefdffda36922f"86408STANDARD2206203922062039Normalmedia/2013-12-20_A13-38_Teriflunomid_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:40.698Z"ef70ca5066fcc41c640f6498e79dd45e"760907STANDARD2206203922062039Normalmedia/2013-12-23_A13-35_Dabrafenib_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:42.643Z"1d692f3270ddc47e6130b5883f254f58"690214STANDARD2206203922062039Normalmedia/2014-01-01_Emtricitabin_Rilpivirin_Tenofovir_D-089_Info_zur_20zVT.pdf2025-12-03T11:03:48.461Z"9f1b9cff059d6e1596eb4d5b33b2d94d"558164STANDARD2206203922062039Normalmedia/2014-01-01_Informationen_zur_zVT_Trastuzumab_Emtansin-DM1.pdf2025-12-03T11:03:51.516Z"ef0d72a9dbdffe77f8b5a8f77efafd53"392869STANDARD2206203922062039Normalmedia/2014-01-01_Nutzenbewertung-35a-SGBV_Trastuzumab-Emtansin.pdf2025-12-03T11:03:52.842Z"1f94a9c14208c22e24c08b1737c5b5f9"775847STANDARD2206203922062039Normalmedia/2014-01-01_Nutzenbewertung_Radium-223-dichlorid-SGB-V.pdf2025-12-03T11:03:50.057Z"f064a6fd0165e70585889e3dd9cfcb51"800250STANDARD2206203922062039Normalmedia/2014-01-01_Radium-223-dichlorid_2014-D-094_Informationen_zur_zVT.pdf2025-12-03T11:03:49.987Z"0f9c3a52e9256dd07d91e3385a114ccb"959740STANDARD2206203922062039Normalmedia/2014-01-02_Modul1_Emtricitabin-Rilpivirin-Tenofovirdisoproxil.pdf2025-12-03T11:03:47.859Z"cae7fd7a8b81b3280a29915828a493bb"472012STANDARD2206203922062039Normalmedia/2014-01-02_Modul4A_Emtricitabin-Rilpivirin-Tenofovirdisoproxil.pdf2025-12-03T11:03:49.175Z"78597405eeda82525311aa577c2d7a36"2375300STANDARD2206203922062039Normalmedia/2014-01-12_Wortprotokoll_end_Apixaban.pdf2025-12-03T11:04:51.678Z"ab958de2e4dae6a9e34ada7fb94ef527"150148STANDARD2206203922062039Normalmedia/2014-01-12_Wortprotokoll_end_Teduglutid.pdf2025-12-03T11:05:01.673Z"c91db67f76be94fa49effab95df25224"132963STANDARD2206203922062039Normalmedia/2014-01-13_Wortprotokoll_end_Enzalutamid.pdf2025-12-03T11:03:32.667Z"66d6cfc8b8196adf3339bfa62b195e51"108182STANDARD2206203922062039Normalmedia/2014-01-13_Wortprotokoll_end_Pomalidomid.pdf2025-12-03T11:03:35.172Z"8f6c42461d60bc49f5f1d506d9ea8a79"142078STANDARD2206203922062039Normalmedia/2014-01-13_Wortprotokoll_end_Vismodegib.pdf2025-12-03T11:03:36.153Z"756f7fb1bbf9e4ce840a8342600d4f55"167334STANDARD2206203922062039Normalmedia/2014-01-14_Modul1A_Turoctocog_alfa.pdf2025-12-03T11:03:52.570Z"3337dd9be9da3e6e87881c3f69739e30"161492STANDARD2206203922062039Normalmedia/2014-01-14_Modul4A_Turoctocog_alfa.pdf2025-12-03T11:03:53.965Z"e20365f935090bc64cef8e339d5ee90b"1377615STANDARD2206203922062039Normalmedia/2014-01-15_Information_zur_zVT_Turoctocog_alpha.pdf2025-12-03T11:03:52.855Z"4d494931c09d04c6a98ce8daf2f3062e"222583STANDARD2206203922062039Normalmedia/2014-01-15_Informationen_zur_zVT_D-098_Retigabin.pdf2025-12-03T11:03:53.754Z"18aa5343e1cfaa6e2cec3e0f1fc05b45"136413STANDARD2206203922062039Normalmedia/2014-01-15_Nutzenbewertung_D-098_Retigabin.pdf2025-12-03T11:03:54.053Z"653c1750e312012e6d0d8efd3c1918c6"95956STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Dapagliflozin_2012-12-15-D-045_TK_BAnz.pdf2025-12-03T11:02:50.165Z"87236ae17744dca0cb2bce20b0a4056c"105543STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Linaclotid_TK_BAnz.pdf2025-12-03T11:03:19.802Z"4e1b5129a511ba0c7ae18c2622fb4fa0"133984STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Linagliptin_5b_2012-09-01-D-035_TK_BAnz.pdf2025-12-03T11:02:24.847Z"f9b22a774ebcf83fd358c1e4e761f7cd"159150STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Linagliptin_nAWG_2012-12-01-D-047_TK_BAnz.pdf2025-12-03T11:02:42.780Z"11086b46e72bad0c3fa937f4d4ac8b04"151610STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Lixisenatid_2013-03-15-D-061_TK_BAnz.pdf2025-12-03T11:02:56.363Z"e16013b2240dd7d8914036cc58276ce9"187952STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Ponatinib_BAnz.pdf2025-12-03T11:03:28.787Z"d8524fa862bcb5521f398385d9196da6"128729STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Ponatinib_TrG.pdf2025-12-03T11:03:28.499Z"4056e9c7fdbedd43a7418b1b96bc55f4"141030STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Saxagliptin-Metformin-nAWG_2013-04-01-D-063_TK_BAnz.pdf2025-12-03T11:03:04.655Z"6f6ce18c3e8961608428d6a3675baafd"159726STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Saxagliptin-Metformin_Therapiek_BAnz.pdf2025-12-03T11:02:40.383Z"0ed0c378c3d274bd5bb32e145a420069"104250STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Saxagliptin_2013-04-01-D-050_TK_BAnz.pdf2025-12-03T11:03:04.410Z"517e8efc8cb62e7b8314d305741f1cd1"122193STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Sitagliptin_2013-04-01-D-054_TK_BAnz.pdf2025-12-03T11:03:09.043Z"ddea7189f8e2de4405efcc37fc1ac2b4"121528STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Sitagliptin_M_2013-04-01-D-055_TK_BAnz.pdf2025-12-03T11:03:14.143Z"a0b8894115dc305c65651062ccdd371b"112258STANDARD2206203922062039Normalmedia/2014-01-23_AM-RL-XII_Vildagliptin-Metformin_2013-04-01-D-048_TK_BAnz.pdf2025-12-03T11:03:16.469Z"2ca6fc7cf9a7bdfd7edbd579f49fb0bc"160456STANDARD2206203922062039Normalmedia/2014-01-23_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_1_.pdf2025-12-03T11:03:29.612Z"25a149e12edd506e89148a85bc162782"142261STANDARD2206203922062039Normalmedia/2014-01-28_Modul1_Macitentan.pdf2025-12-03T11:03:55.752Z"c726a6b8bb6ea8a2a4c31a7ba6fb395c"447311STANDARD2206203922062039Normalmedia/2014-01-28_Modul4A_Macitentan.pdf2025-12-03T11:03:58.188Z"52c99cdc079e3e80c96b636c0f87b558"5454486STANDARD2206203922062039Normalmedia/2014-01-28_Wortprotokoll_end_Vemurafenib.pdf2025-12-03T11:03:36.354Z"607c12586877a6d0fea2e273cd58d6d9"297894STANDARD2206203922062039Normalmedia/2014-02-01-D-091_Sofosbuvir_Addendum.pdf2025-12-03T11:03:58.587Z"640d70b69c300597205bcb220b77c462"126439STANDARD2206203922062039Normalmedia/2014-02-01_Nutzenbewertung_G-BA_Macitentan.pdf2025-12-03T11:03:56.362Z"5258c1952fd3a099a4f13d1cb1c6638e"1231885STANDARD2206203922062039Normalmedia/2014-02-03_Modul1_Dapagliflozin-Metformin.pdf2025-12-03T11:04:00.847Z"bb022cfc05b9e6eb5b313ad04eca59de"450883STANDARD2206203922062039Normalmedia/2014-02-03_Modul4A_Dapagliflozin-Metformin.pdf2025-12-03T11:04:02.966Z"9fb0dc85f0bf43f3c0314eb718cc13bd"1997437STANDARD2206203922062039Normalmedia/2014-02-03_Modul4B_Dapagliflozin-Metformin.pdf2025-12-03T11:04:02.766Z"c8c7691db488eb4aad8cae4c2dd02ddf"2495255STANDARD2206203922062039Normalmedia/2014-02-03_Modul4C_Dapagliflozin-Metformin.pdf2025-12-03T11:04:04.443Z"651c24956d17549db4cd67f343696548"764448STANDARD2206203922062039Normalmedia/2014-02-06_AM-RL-XII_Vismodegib_2013-08-15-D-069_BAnz.pdf2025-12-03T11:03:30.977Z"3e8e50a4f28311898928d7c6048514b3"160095STANDARD2206203922062039Normalmedia/2014-02-06_AM-RL-XII_Vismodegib_2013-08-15-D-069_TrG.pdf2025-12-03T11:03:31.043Z"9433abbc5b4299cee1f8f6fd2033b4ce"144785STANDARD2206203922062039Normalmedia/2014-02-07_Modul1_Dolutegravir.pdf2025-12-03T11:03:57.542Z"e1484a02735b50f59759df2d6656cd13"201798STANDARD2206203922062039Normalmedia/2014-02-07_Modul4A_Dolutegravir.pdf2025-12-03T11:03:59.558Z"195b2c2eb5d8bc1c69eda1fce02589e6-2"8917518STANDARD2206203922062039Normalmedia/2014-02-10-Wortprotokoll_end_Aflibercept.pdf2025-12-03T11:03:38.455Z"72f9d01e5dc16913ff872e066169f0b6"161624STANDARD2206203922062039Normalmedia/2014-02-10_Wortprotokoll_end_Regorafenib.pdf2025-12-03T11:03:40.340Z"6d15721392c6413c182f90667d4cfeab"206118STANDARD2206203922062039Normalmedia/2014-02-10_Wortprotokoll_end_Teriflunomid.pdf2025-12-03T11:03:42.267Z"6e1f7ae551fcc1a382f85930a6689caa"288311STANDARD2206203922062039Normalmedia/2014-02-10_Wortprotokoll_end_korr_Dabrafenib.pdf2025-12-03T11:03:43.840Z"ddc99416ec005e9deda5aeef88908961"227969STANDARD2206203922062039Normalmedia/2014-02-12_A13-40_Indacaterol-Glycopyrronium_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:01:45.360Z"d7000323712f4905bda72be629b58b35"465623STANDARD2206203922062039Normalmedia/2014-02-13_A13-41_Afatinib_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:01:47.883Z"5061d1e6f641644c9926cf9b091b798d"1037817STANDARD2206203922062039Normalmedia/2014-02-15-D-099_Informationen_zur_zweckmaessigen_Vergleichstherapie_Dolutegravir.pdf2025-12-03T11:04:00.543Z"c5d3316410527e2bf5765a6735d76384"756473STANDARD2206203922062039Normalmedia/2014-02-15_Informationen_zur_zVT_Dapagliflozin_Metformin_D-09.pdf2025-12-03T11:04:02.044Z"44f067a5d787938852a3b500a64b2fe8"1478612STANDARD2206203922062039Normalmedia/2014-02-19_Modul1_Canagliflozin.pdf2025-12-03T11:04:04.946Z"5a95e37eb62386bb66f664c85bd34d78"953404STANDARD2206203922062039Normalmedia/2014-02-19_Modul4A_Canagliflozin.pdf2025-12-03T11:04:04.424Z"7904d058724245cc0b3d51768cec9339"776999STANDARD2206203922062039Normalmedia/2014-02-19_Modul4B_Canagliflozin.pdf2025-12-03T11:04:07.493Z"12106ad3e7464335e890013f1265a931"4860317STANDARD2206203922062039Normalmedia/2014-02-19_Modul4C_Canagliflozin.pdf2025-12-03T11:04:05.763Z"0cf43010c27e1eff8d9367f7fc52cde9"879102STANDARD2206203922062039Normalmedia/2014-02-19_Modul4D_Canaglflozin.pdf2025-12-03T11:04:06.926Z"0594501b227e369ae8f64845e7e39ab1"2122871STANDARD2206203922062039Normalmedia/2014-02-19_Modul4E_Canagliflozin.pdf2025-12-03T11:04:06.151Z"e4958175b0ad4b17730d0a8c4cf60c26"882983STANDARD2206203922062039Normalmedia/2014-02-20_AM-RL-XII_Colestilan_Aenderungsbeschluss_BAnz.pdf2025-12-03T11:02:36.262Z"569e692728f3b8b0d332f1fa17de7133"138567STANDARD2206203922062039Normalmedia/2014-02-20_AM-RL-XII_Enzalutamid_2013-09-01-D-073_BAnz.pdf2025-12-03T11:03:31.145Z"3b5753cd482bd7ad73cb67341a6b10a1"99331STANDARD2206203922062039Normalmedia/2014-02-20_AM-RL-XII_Enzalutamid_2013-09-01-D-073_TrG.pdf2025-12-03T11:03:31.546Z"472a492846f1ff450e9651ce033d2f7c"129174STANDARD2206203922062039Normalmedia/2014-02-20_AM-RL-XII_Pomalidomid_2013-09-01-D-075_BAnz.pdf2025-12-03T11:03:33.860Z"a0ad245f91ad0421ae7b2ae77f44d224"141478STANDARD2206203922062039Normalmedia/2014-02-20_AM-RL-XII_Pomalidomid_2013-09-01-D-075_TrG.pdf2025-12-03T11:03:34.184Z"ea78bd0af5f17cb5c982d52ff8ccc7c1"221130STANDARD2206203922062039Normalmedia/2014-02-20_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_Kopie_4.pdf2025-12-03T11:03:34.245Z"b9da671d69112e08afe612618ec92f77"142957STANDARD2206203922062039Normalmedia/2014-03-06_AM-RL-XII_Vemurafenib_2013-09-15-D-074_BAnz.pdf2025-12-03T11:03:36.867Z"ad15ec80fbf3205ad49faeae16b3fad4"178246STANDARD2206203922062039Normalmedia/2014-03-06_AM-RL-XII_Vemurafenib_2013-09-15-D-074_TrG.pdf2025-12-03T11:03:37.042Z"a860a7cf452b729d48601b85daf51aed"114977STANDARD2206203922062039Normalmedia/2014-03-13_A13-44_Ipilimumab-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:45.210Z"4890a9feaccea5fecb1b5e41d3080a9d"416031STANDARD2206203922062039Normalmedia/2014-03-15-D-101_Canagliflozin_Addendum.pdf2025-12-03T11:04:04.396Z"6086c482c3f234662e7e8c547dbad23a"588183STANDARD2206203922062039Normalmedia/2014-03-15_Informationen_zur_zVT_Canagliflozin_D-101.pdf2025-12-03T11:04:07.346Z"abec5eca88bde4759b8fbe83e02fbd8f"1488392STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_BAnz.pdf2025-12-03T11:22:56.963Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_BRuNYH1.pdf2026-03-21T13:51:30.403Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_NbKqUHc.pdf2026-03-21T13:51:29.519Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_PHKzhjx.pdf2026-03-21T13:51:29.868Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_BAnz_Vwm9C0x.pdf2026-03-21T13:51:28.546Z"7e7733c3a93ee638c8eb27797d66283c"50603STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_TrG.pdf2025-12-03T11:22:57.457Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_TrG_NT2QP8L.pdf2026-03-21T13:51:29.351Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_TrG_OZaVoIQ.pdf2026-03-21T13:51:30.215Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_TrG_dxQF0ux.pdf2026-03-21T13:51:30.045Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalmedia/2014-03-17_35a_EinstellungBestandsmarkt_TrG_gszMm7f.pdf2026-03-21T13:51:29.683Z"2df830db77dcbe944c065cc50c32ac55"51422STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII-IX_KombiGluco-lwBeta2_Sympathomimetika_G1S3_BAnz.pdf2025-12-03T11:03:21.947Z"c34e74e37ac72fe0ebf424133f50e9ee"63613STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII-IX_KombiGluco-lwBeta2_Sympathomimetika_G1S3_TrG.pdf2025-12-03T11:03:25.176Z"8fc32f21a9c6e981f94d229c621fdedb"4782126STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII_Aflibercept-nAWG_2013-10-01-D-080_BAnz.pdf2025-12-03T11:03:37.866Z"177a06eb457d5fecd2b86caadbd433bd"100839STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII_Aflibercept-nAWG_2013-10-01-D-080_TrG.pdf2025-12-03T11:03:37.742Z"2e50d2cd22b441fae30344d989176697"153092STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII_Regorafenib_2013-10-01-D-077_BAnz.pdf2025-12-03T11:03:38.949Z"d417b81572c6f34ea8a3fee50bb8834e"122213STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII_Regorafenib_2013-10-01-D-077_TrG.pdf2025-12-03T11:03:39.759Z"d8b06c3ce5f196207236161ac264c908"230827STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII_Teriflunomid_2013-10-01-D-078_BAnz.pdf2025-12-03T11:03:40.771Z"f43c4ddbe268efe9a1daaee61a85c988"124874STANDARD2206203922062039Normalmedia/2014-03-20_AM-RL-XII_Teriflunomid_2013-10-01-D-078_TrG.pdf2025-12-03T11:03:41.067Z"b97d801cba4a36cefd349953dc2fa296"169420STANDARD2206203922062039Normalmedia/2014-03-25-Wortprotokoll_end_Indacaterol_Glycopyrronium.pdf2025-12-03T11:01:46.368Z"8be60b197e435e5c9863d4a3d4421eb4"188850STANDARD2206203922062039Normalmedia/2014-03-25_Wortprotokoll_end_Afatinib.pdf2025-12-03T11:01:47.247Z"19edf4f6dcb6dea6060f0b221fa65af4"275243STANDARD2206203922062039Normalmedia/2014-03-26_A14-11_Addendum-zum-Auftrag-A13-44_Ipilimumab-neues-Anwendungsgebiet.pdf2025-12-03T11:03:45.721Z"94c25f3e613cd070ee6f3fc5b8ea0d44"130187STANDARD2206203922062039Normalmedia/2014-03-28_A14-03_Rilpivirin-Emtricitabin-Tenofovir-neues-Anwendungsgebiet_Nutzenbewertu_Ng1kxDn.pdf2026-03-21T13:50:24.933Z"f7de27a9be4f2287cd7aabd14386d42f"329001STANDARD2206203922062039Normalmedia/2014-03-28_A14-03_Rilpivirin-Emtricitabin-Tenofovir-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:48.068Z"f7de27a9be4f2287cd7aabd14386d42f"329001STANDARD2206203922062039Normalmedia/2014-04-01-SofosbuvirModul1.pdf2025-12-03T11:03:58.348Z"92edc5d963262e856c5749af5305a7e9"412741STANDARD2206203922062039Normalmedia/2014-04-03_AM-RL-XII_Dabrafenib_2013-10-01-D-076_BAnz.pdf2025-12-03T11:03:41.245Z"a4e32e585849ed7e473c873b02398ae5"118734STANDARD2206203922062039Normalmedia/2014-04-03_AM-RL-XII_Dabrafenib_2013-10-01-D-076_TrG.pdf2025-12-03T11:03:41.742Z"bcf54b8200188a7a0683b7e27595be3b"284953STANDARD2206203922062039Normalmedia/2014-04-10_A14-04_Turoctocog_20alfa_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:03:53.160Z"50de2f0ebb9b6018038128a63023b4e4"299964STANDARD2206203922062039Normalmedia/2014-04-17_35a_Freistellung-2014-F-00.pdf2025-12-03T11:22:49.850Z"f932fc3387fa241f04b46c9d4a0e7c93"28406STANDARD2206203922062039Normalmedia/2014-04-17_35a_Freistellung-2014-F-00_TrG.pdf2025-12-03T11:22:49.670Z"2c8576063821610b22ad00e0510517cc"52092STANDARD2206203922062039Normalmedia/2014-04-17_35a_Freistellung-2014-F-00_TrG_XjN5pRp.pdf2026-03-21T13:51:46.537Z"2c8576063821610b22ad00e0510517cc"52092STANDARD2206203922062039Normalmedia/2014-04-17_35a_Freistellung-2014-F-00_jv13vS7.pdf2026-03-21T13:51:46.365Z"f932fc3387fa241f04b46c9d4a0e7c93"28406STANDARD2206203922062039Normalmedia/2014-04-24_Modul1_Riociguat.pdf2025-12-03T11:04:07.218Z"2a02db8f393af936da821fb1093f21cd"478509STANDARD2206203922062039Normalmedia/2014-04-24_Modul4A_Riociguat.pdf2025-12-03T11:04:09.590Z"e2a602941986e244cdf4e22e166b8e75"2183706STANDARD2206203922062039Normalmedia/2014-04-24_Modul4B_Riociguat.pdf2025-12-03T11:04:09.497Z"2b309ba21c7f2cc9397abc8264fecfd0"2480538STANDARD2206203922062039Normalmedia/2014-04-28_Modul1_Insulin_degludec.pdf2025-12-03T11:04:10.047Z"2a13f35fd2114b3acb1959a6a5e130be"620858STANDARD2206203922062039Normalmedia/2014-04-28_Modul4A_Insulin_degludec.pdf2025-12-03T11:04:09.953Z"b95958b74e2dba61f97e3471053fa0bf"1786786STANDARD2206203922062039Normalmedia/2014-04-28_Modul4B_Insulin_degludec.pdf2025-12-03T11:04:09.959Z"36cb29427015daa4a65e80af6a5214b6"3325943STANDARD2206203922062039Normalmedia/2014-04-28_Modul4C_Insulin_degludec.pdf2025-12-03T11:04:11.198Z"44ad02293da8b32d799e36e3876c8a18"2414309STANDARD2206203922062039Normalmedia/2014-04-28_Modul4D_Insulin_degludec.pdf2025-12-03T11:04:10.801Z"ed900f9f160ff71736ce19b3b5ad4742"2820567STANDARD2206203922062039Normalmedia/2014-04-29_Nutzenbewertung_20IQWiG_Sofosbuvir.pdf2025-12-03T11:03:58.469Z"476251442be8af651a1b365dcb8390c9"858856STANDARD2206203922062039Normalmedia/2014-04-29_Wortprotokoll_end_Ipilimumab_nAWG.pdf2025-12-03T11:03:45.652Z"f2efceb144a9c45ec1e6b590c72a5bd5"133269STANDARD2206203922062039Normalmedia/2014-04-29_Wortprotokoll_end_Lomitapid.pdf2025-12-03T11:03:47.972Z"e96e9e18de531400f740f0ad8f339ceb"122447STANDARD2206203922062039Normalmedia/2014-05-01-D-100__Dimethylfumarat_Addendum.pdf2025-12-03T11:04:10.805Z"ece54f8b4470d357a4997d64b7f8d330"158191STANDARD2206203922062039Normalmedia/2014-05-01_Informationen_zur_zVT_D-100_Dimethylfumarat.pdf2025-12-03T11:04:11.342Z"77e6963716480ce22fedc313f9ff4472"445935STANDARD2206203922062039Normalmedia/2014-05-01_Informationen_zur_zVT_Insulin_degludec_D-109.pdf2025-12-03T11:04:17.809Z"ca589657f70ccf14ea2118e386e54d76"2036948STANDARD2206203922062039Normalmedia/2014-05-01_Modul1_Dimethylfumarat.pdf2025-12-03T11:04:11.058Z"efc6dcaffa4e6279047ed7f195fc67d6"555936STANDARD2206203922062039Normalmedia/2014-05-01_Nutzenbewertung-35a-SGB-V_Dimethylfumarat.pdf2025-12-03T11:04:11.954Z"c29356ef6d51878bceb28b0b58bbd402"449403STANDARD2206203922062039Normalmedia/2014-05-01_Nutzenbewertung_G-BA_Riociguat.pdf2025-12-03T11:04:08.860Z"99d19ef911d09438f3605408fd63a56c"729008STANDARD2206203922062039Normalmedia/2014-05-02_Info_zur_zVT_Sofosbuvir.pdf2025-12-03T11:03:58.381Z"72ab106a60567f8995e74fa201a17fda"672924STANDARD2206203922062039Normalmedia/2014-05-06_Modul1_Perampanel.pdf2025-12-03T11:04:17.354Z"676a9169c605d2911d5ae5f25c18274b"450730STANDARD2206203922062039Normalmedia/2014-05-06_Modul4A_Perampanel.pdf2025-12-03T11:04:22.780Z"51928c5ff4a3843b53eb712282e4130e-2"12658388STANDARD2206203922062039Normalmedia/2014-05-07_Modul1_Cholsaeure.pdf2025-12-03T11:04:15.356Z"86366312eee37f91454f9b6fceb1a6aa"159868STANDARD2206203922062039Normalmedia/2014-05-07_Modul4A_Cholsaeure.pdf2025-12-03T11:04:15.875Z"2091f5d8fb0f0475a7a2e6d07f4b4116"853725STANDARD2206203922062039Normalmedia/2014-05-08_AM-RL-XII_Afatinib_2013-11-15-D-082_BAnz.pdf2025-12-03T11:01:48.132Z"1984925f71c5d40afac486923651df74"734737STANDARD2206203922062039Normalmedia/2014-05-08_AM-RL-XII_Afatinib_2013-11-15-D-082_TrG.pdf2025-12-03T11:01:49.977Z"8a97cb1b99a04c6733d79b0ea3ebca2b"168005STANDARD2206203922062039Normalmedia/2014-05-08_AM-RL-XII_Indacaterol-Glycopyrronium_2013-11-15-D-081_BAnz.pdf2025-12-03T11:01:44.480Z"7b5d9d825cba43523e10c734db6ce9b1"163407STANDARD2206203922062039Normalmedia/2014-05-08_AM-RL-XII_Indacaterol-Glycopyrronium_2013-11-15-D-081_TrG.pdf2025-12-03T11:01:44.528Z"85be18395203b6a6e4d10f42203d5568"145095STANDARD2206203922062039Normalmedia/2014-05-12_Wortprotokoll_Radium-223.pdf2025-12-03T11:03:49.683Z"dc86e7dc612f2a2cb42bc6918f10d6aa"239420STANDARD2206203922062039Normalmedia/2014-05-12_Wortprotokoll_Trastuzumab-Emtansin.pdf2025-12-03T11:03:51.298Z"e1073152779229c73e943d4072d8905d"372515STANDARD2206203922062039Normalmedia/2014-05-12_Wortprotokoll_end_Rilpivirin-Kombi.pdf2025-12-03T11:03:48.143Z"ce1237d65343913261dd8a877b46875c"108603STANDARD2206203922062039Normalmedia/2014-05-13_Nutzenbewertung_20IQWIG_Dolutegravir.pdf2025-12-03T11:03:59.620Z"beb96c76775aaca433db2b2e78b9b42a"800578STANDARD2206203922062039Normalmedia/2014-05-14_Modul1_Ruxolitinib.pdf2025-12-03T11:04:13.663Z"0a4ca1a743b52d65c4c1ee627436507a"425749STANDARD2206203922062039Normalmedia/2014-05-14_Modul4A_Ruxolitinib.pdf2025-12-03T11:04:17.128Z"ab32bdc8c9c89d96df9f19270c65c714"5595472STANDARD2206203922062039Normalmedia/2014-05-15_Informationen_zur_zVT_D-106_Perampanel.pdf2025-12-03T11:04:18.854Z"022659a2e695b650674dde71e6740cb6"216898STANDARD2206203922062039Normalmedia/2014-05-15_Nutzenbewertung_IQWiG_Dapagliflozin-Metformin.pdf2025-12-03T11:04:01.147Z"c35268e3065d896506e633e384749835"413523STANDARD2206203922062039Normalmedia/2014-05-18_Modul1_Elosulfase_alfa.pdf2025-12-03T11:04:21.983Z"7e0549fe152a124d6982fad98841432d"393021STANDARD2206203922062039Normalmedia/2014-05-18_Modul4A_Elosulfase_alfa.pdf2025-12-03T11:04:23.611Z"4a35ca4a9327fb486faa806bb857448a"2903857STANDARD2206203922062039Normalmedia/2014-05-21_Modul1_Simeprevir.pdf2025-12-03T11:04:22.849Z"e500276a43f0178f79cbe28f77244d31"242026STANDARD2206203922062039Normalmedia/2014-05-21_Modul4A_Simeprevir.pdf2025-12-03T11:04:27.553Z"372e5716d26b7b6921109aa448aef8f1-2"10033356STANDARD2206203922062039Normalmedia/2014-05-27_Modul1_Mirabegron.pdf2025-12-03T11:04:20.072Z"beacd417835cb54926bf7f18d88031db"254802STANDARD2206203922062039Normalmedia/2014-05-27_Modul4A_Mirabegron.pdf2025-12-03T11:04:22.829Z"3003afe39b06e1177e0ceb941cd79008"3851425STANDARD2206203922062039Normalmedia/2014-05-27_Wortprotokoll_end_Retigabin.pdf2025-12-03T11:03:53.646Z"77411e5c9bb781c525a907741e7049e8"134160STANDARD2206203922062039Normalmedia/2014-05-27_Wortprotokoll_end_Turoctocog-alfa.pdf2025-12-03T11:03:53.458Z"672dc2ba9a8767d97de42b9720832fb6"183594STANDARD2206203922062039Normalmedia/2014-06-01-D-110_Mirabegron_Addendum.pdf2025-12-03T11:04:20.151Z"ae2e94f402103a7a7faa4a41c5ffd9a0"78075STANDARD2206203922062039Normalmedia/2014-06-01-D-113_Simeprevir_Addendum.pdf2025-12-03T11:04:23.460Z"564ec44e127f5603f657aea28e6e213d"141033STANDARD2206203922062039Normalmedia/2014-06-01_Informationen_zur_zVT_Mirabegron.pdf2025-12-03T11:04:20.577Z"ead9c2111317553618800af8a5b39a3f"1070131STANDARD2206203922062039Normalmedia/2014-06-01_Informationen_zur_zVT_Simeprevir_B-018.pdf2025-12-03T11:04:23.878Z"5195f792a401fa3546a9c1c011dc645f"1019855STANDARD2206203922062039Normalmedia/2014-06-01_Nutzenbewertung-35a-SGB-V_Simeprevir.pdf2025-12-03T11:04:24.655Z"a7fc9a67d6ce841addc776e5fdb34536"1439589STANDARD2206203922062039Normalmedia/2014-06-02_Modul1_Fingolimod.pdf2025-12-03T11:04:28.975Z"69b77ca49d5913f69356a2ff83413c93"225121STANDARD2206203922062039Normalmedia/2014-06-05_AM-RL-XII_Ipilimumab_nAwg_2013-12-15-D-090_BAnz.pdf2025-12-03T11:03:44.246Z"9e0351fe8584eb1314d2743963d6a135"810036STANDARD2206203922062039Normalmedia/2014-06-05_AM-RL-XII_Ipilimumab_nAwg_2013-12-15-D-090_TrG.pdf2025-12-03T11:03:44.257Z"e3860537dafacecc7eac822d7e7f3675"307072STANDARD2206203922062039Normalmedia/2014-06-05_AM-RL-XII_Lomitapid_2013-12-15-D-093_BAnz.pdf2025-12-03T11:03:46.342Z"6849e49e46b35de48f8d472b9f8acd4f"143925STANDARD2206203922062039Normalmedia/2014-06-05_AM-RL-XII_Lomitapid_2013-12-15-D-093_TrG.pdf2025-12-03T11:03:48.463Z"c7b52cd51d5b79ee2bf40c24bf4cedb3"104907STANDARD2206203922062039Normalmedia/2014-06-10_Wortprotokoll_end_Macitentan.pdf2025-12-03T11:03:56.142Z"65868e8daa8dbdb36ef849e599ee6e9e"147778STANDARD2206203922062039Normalmedia/2014-06-10_Wortprotokoll_end_Sofosbuvir.pdf2025-12-03T11:03:59.277Z"f150b809ec1b44ff15fd8e2ba4173cb9"328296STANDARD2206203922062039Normalmedia/2014-06-12_Modul1_Siltuximab.pdf2025-12-03T11:04:27.640Z"5fe6e799238fd786650836c9d8cff10c"652739STANDARD2206203922062039Normalmedia/2014-06-12_Modul4A_Siltuximab.pdf2025-12-03T11:04:28.882Z"2aa2c64aeb61effe3c42dc2711f833a2"2969002STANDARD2206203922062039Normalmedia/2014-06-12_Nutzenbewertung_20IQWiG_Canagliflozin.pdf2025-12-03T11:04:05.341Z"718b98dc1386588e59b515a92e472070"654724STANDARD2206203922062039Normalmedia/2014-06-15_Info_zur_zVT_D-118_Insulin_degludec_nAWG.pdf2025-12-03T11:04:27.888Z"0acb3aa41a1679dd0ee50f1cc836e02a"1478891STANDARD2206203922062039Normalmedia/2014-06-15_Nutzenbewertung_G-BA-Siltuximab.pdf2025-12-03T11:04:27.306Z"6d3cdd1171831544821c6c4b66a15add"589550STANDARD2206203922062039Normalmedia/2014-06-16_Modul4A_Fingolimod.pdf2025-12-03T11:04:30.582Z"d2b2992560021b6648e980c2b43c45f2"6623830STANDARD2206203922062039Normalmedia/2014-06-18_Analyse-Schiedsspruch-Lixisenatid.pdf2025-12-03T11:45:12.759Z"c00e4ace1e4f3613c19319ac21b17e64"115200STANDARD2206203922062039Normalmedia/2014-06-18_Schiedsspruch_1-14_Lixisenatid_Lyxumia_007.pdf2025-12-03T11:45:19.729Z"319400802c72af66532a01a7b643d669"3590658STANDARD2206203922062039Normalmedia/2014-06-19_AM-RL-XII_Radium-223_2014-01-01-D-094_BAnz.pdf2025-12-03T11:03:51.746Z"44223f9707d6203527cb41868fc8f2bc"587977STANDARD2206203922062039Normalmedia/2014-06-19_AM-RL-XII_Radium-223_2014-01-01-D-094_TrG.pdf2025-12-03T11:03:49.899Z"d1d2014966ebec0dbb2f235cb71f2001"294193STANDARD2206203922062039Normalmedia/2014-06-19_AM-RL-XII_Rilpivirin-Kombi_2014-01-01-D-089_BAnz.pdf2025-12-03T11:03:46.653Z"f1ebff1a2085e892bb33ef4fd161962f"550319STANDARD2206203922062039Normalmedia/2014-06-19_AM-RL-XII_Rilpivirin-Kombi_2014-01-01-D-089_TrG.pdf2025-12-03T11:03:47.864Z"a6e2f5c1365408fd0697a0ecf749ec3a"123304STANDARD2206203922062039Normalmedia/2014-06-19_AM-RL-XII_Trastuzumab-Emtansin_2014-01-01-D-084_BAnz.pdf2025-12-03T11:03:53.551Z"8d174fedc873ff7cfbc8b14fd83c64b1"658581STANDARD2206203922062039Normalmedia/2014-06-19_AM-RL-XII_Trastuzumab-Emtansin_2014-01-01-D-084_TrG.pdf2025-12-03T11:03:51.960Z"6f41354c39f70a19e1a90b20350660b7"153922STANDARD2206203922062039Normalmedia/2014-06-24_Wortprotokoll_end_Dapagliflozin-Metformin.pdf2025-12-03T11:04:01.355Z"e7cda159b3ae1d3112a45df74a116834"322567STANDARD2206203922062039Normalmedia/2014-06-24_Wortprotokoll_end_Dolutegravir.pdf2025-12-03T11:03:59.142Z"7088b189eb4ebf0944cffd59bee62d8b"308501STANDARD2206203922062039Normalmedia/2014-06-27_Info_zur_zVT_Cobicistat.pdf2025-12-03T11:04:02.564Z"d6906f74691624b7159c35d73105786c"63947STANDARD2206203922062039Normalmedia/2014-06-27_Nutzenbewertung_20G-BA_Cobicistat.pdf2025-12-03T11:04:02.960Z"c8267de110ba0bd46a2eff0c3b50c464"67220STANDARD2206203922062039Normalmedia/2014-07-01-D-116_Fingolimod_Addendum.pdf2025-12-03T11:04:28.982Z"a13701779cdc3ed6cb11ea658444e272"135064STANDARD2206203922062039Normalmedia/2014-07-01_Informationen_zur_zVT_D-116_Fingolimod.pdf2025-12-03T11:04:28.157Z"154d12c57af3ba49eba510019f852519"199501STANDARD2206203922062039Normalmedia/2014-07-03_AM-RL-XII_Retigabin_2014-01-15-D-098_BAnz.pdf2025-12-03T11:03:54.545Z"72923410cbc75ef69f9e31c1cad96bbe"545115STANDARD2206203922062039Normalmedia/2014-07-03_AM-RL-XII_Retigabin_2014-01-15-D-098_TrG.pdf2025-12-03T11:03:54.943Z"f94aed5b4607f6a1fb54f353de4651e9"99215STANDARD2206203922062039Normalmedia/2014-07-03_AM-RL-XII_Turoctocog_20alfa_2014-01-15-D-092_BAnz.pdf2025-12-03T11:03:51.740Z"8eac9266a23e826db1a9caf3b141b3c7"133565STANDARD2206203922062039Normalmedia/2014-07-03_AM-RL-XII_Turoctocog_20alfa_2014-01-15-D-092_TrG.pdf2025-12-03T11:03:52.097Z"acfcbb12b294cb486b9a6e7a68b7ee3a"110456STANDARD2206203922062039Normalmedia/2014-07-10_Analyse-Schiedsspruch-Linaclotid.pdf2025-12-03T11:45:18.120Z"f9fb05c17b4a4a9388bcd8570bb13b55"118356STANDARD2206203922062039Normalmedia/2014-07-10_Modul1_Vedolizumab.pdf2025-12-03T11:04:30.223Z"01a5325e5d8ea6faf5e8f15441fcb241"618778STANDARD2206203922062039Normalmedia/2014-07-10_Modul4A_Umeclidinium-Vilanterol.pdf2025-12-03T11:04:37.751Z"e1d600eeef72b76fd705f4e416cedbe1-4"25455073STANDARD2206203922062039Normalmedia/2014-07-10_Modul4A_Vedolizumab.pdf2025-12-03T11:04:32.568Z"833b1271781ebf05b246eb5143d38ba0"4368280STANDARD2206203922062039Normalmedia/2014-07-10_Modul4B_Vedolizumab.pdf2025-12-03T11:04:32.663Z"3ea736f83e81d89501cbc2ed05cc7458"4561495STANDARD2206203922062039Normalmedia/2014-07-10_Schiedsspruch_5-14_Linaclotid_Constella_008.pdf2025-12-03T11:45:13.797Z"924179dffbaa89e79da9d9fdae2af5cc"2359821STANDARD2206203922062039Normalmedia/2014-07-11_Modul1_Umeclidimiun-Vilanterol.pdf2025-12-03T11:04:33.562Z"4d216bf7a1e7f49d7b2e97aac98ae8ce"469447STANDARD2206203922062039Normalmedia/2014-07-15-D-117_Umeclidinium-Vilanterol_Addendum.pdf2025-12-03T11:04:37.842Z"c5be311fb2807908918479c0dfd6e5f1"191636STANDARD2206203922062039Normalmedia/2014-07-15_Informationen_zur_zVT_Vedolizumab_Colitis-ulcerosa_Morbus-Crohn.pdf2025-12-03T11:04:30.860Z"d444c8d170c91c162367fdf479b25f92"1474710STANDARD2206203922062039Normalmedia/2014-07-15_Nutzenbewertung-35a-SGB-V_Umeclidinium-Vilanterol.pdf2025-12-03T11:04:33.255Z"330cb53c9b79177c8551f1799f7d979d"548840STANDARD2206203922062039Normalmedia/2014-07-17_AM-RL-IX-XII_Beta2-Sympathomimetika_inhalativ_Eingr_Olodaterol_Gr1_BAnz.pdf2025-12-03T11:04:23.963Z"15d2639d400d2c32939cb81b094e7025"64167STANDARD2206203922062039Normalmedia/2014-07-17_AM-RL-IX-XII_Beta2-Sympathomimetika_inhalativ_Eingr_Olodaterol_Gr1_TrG.pdf2025-12-03T11:04:28.021Z"9e3791157df340a908d9b4ccb2328602"6796013STANDARD2206203922062039Normalmedia/2014-07-17_AM-RL-XII_Macitentan_2014-02-01-D-096_BAnz.pdf2025-12-03T11:03:55.342Z"96e0e44bf6980b89d0b75d9343f17c09"123897STANDARD2206203922062039Normalmedia/2014-07-17_AM-RL-XII_Macitentan_2014-02-01-D-096_TrG.pdf2025-12-03T11:03:55.457Z"37a84708256389be2ead0890f22bd8ba"118664STANDARD2206203922062039Normalmedia/2014-07-17_AM-RL-XII_Sofosbuvir_2014-02-01-D-091_BAnz.pdf2025-12-03T11:03:59.601Z"9f102fd871503cbab4ff3802e24d2ff9"699617STANDARD2206203922062039Normalmedia/2014-07-17_AM-RL-XII_Sofosbuvir_2014-02-01-D-091_TrG.pdf2025-12-03T11:04:00.054Z"ad629c72a797f7aa3c852e522d18386e"171598STANDARD2206203922062039Normalmedia/2014-07-17_Macitentan-Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG.pdf2025-12-03T11:03:56.257Z"80044e938654fef643b6ec0059ad4ab8"122032STANDARD2206203922062039Normalmedia/2014-07-18_Modul1_Eribulin.pdf2025-12-03T11:04:33.960Z"cf87edf1d6aadaa9ed4959d58a718001"623753STANDARD2206203922062039Normalmedia/2014-07-18_Modul4A_Eribulin.pdf2025-12-03T11:04:51.190Z"d1935635e42909300278b20683b73e91-5"37165823STANDARD2206203922062039Normalmedia/2014-07-21_Modul1_Cabozantinib.pdf2025-12-03T11:04:37.651Z"e760ecc4ca0d70f3e0a96c5729d598b6"351806STANDARD2206203922062039Normalmedia/2014-07-21_Modul4A_Cabozantinib.pdf2025-12-03T11:04:50.219Z"2272265526df0161b324b0e2dd4acc22-5"37992113STANDARD2206203922062039Normalmedia/2014-07-22_Wortprotokoll_22-02-2014_Canagliflozin.pdf2025-12-03T11:04:04.368Z"8ea0cb76638d9d485db046790a275d4d"264315STANDARD2206203922062039Normalmedia/2014-07-28_Modul1_Obinutuzumab.pdf2025-12-03T11:04:49.220Z"5c20864c8f78d1b606a9d1987dc63134"286087STANDARD2206203922062039Normalmedia/2014-07-28_Modul4A_Obinutuzumab.pdf2025-12-03T11:46:57.948Z"3265a82942a7dee5a42e870745d60205"2062703STANDARD2206203922062039Normalmedia/2014-07-30_A14-13_Insulin-degludec_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:04:11.864Z"6bbe6cfa744265077b148d9a8331a5d5"561262STANDARD2206203922062039Normalmedia/2014-08-01-D-125_Eribulin_Addendum.pdf2025-12-03T11:04:34.368Z"42db828c454317478ed02299bd36fbaa"194128STANDARD2206203922062039Normalmedia/2014-08-01_Information_zur0zVT_Eribulin_2014-B-033.pdf2025-12-03T11:04:34.166Z"6f32a84b6cad5d11a7bec45710f7aaaa"618086STANDARD2206203922062039Normalmedia/2014-08-01_Nutzenbewertung_Cabozantinib-G-BA.pdf2025-12-03T11:04:39.249Z"5500fc6ab3dfb3f6ed6f3cf4011ad383"1469154STANDARD2206203922062039Normalmedia/2014-08-07_AM-RL-XII_Dapagliflozin_Metformin_2014-02-15-D-097_BAnz.pdf2025-12-03T11:03:59.745Z"0240d014c5243088023eb57345b7414b"147763STANDARD2206203922062039Normalmedia/2014-08-07_AM-RL-XII_Dapagliflozin_Metformin_2014-02-15-D-097_TrG.pdf2025-12-03T11:04:00.047Z"4ead75c3f07b45f084be5adb719fb810"173151STANDARD2206203922062039Normalmedia/2014-08-07_AM-RL-XII_Dolutegravir_2014-02-15-D-099_BAnz.pdf2025-12-03T11:03:57.146Z"934c902ce7a62fac6bb67c5d01d40ba9"233535STANDARD2206203922062039Normalmedia/2014-08-07_AM-RL-XII_Dolutegravir_2014-02-15-D-099_TrG.pdf2025-12-03T11:03:57.157Z"356aa6d69430ae2bb0bd62ea39300193"181919STANDARD2206203922062039Normalmedia/2014-08-12_Wortprotokoll_end_Cobicistat.pdf2025-12-03T11:04:03.844Z"8a29dd3124f3e755121e48581b097e97"54821STANDARD2206203922062039Normalmedia/2014-08-13_A14-16_Perampanel_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:04:17.368Z"ebe88d7e3dbe131e21256157037b8a51"299398STANDARD2206203922062039Normalmedia/2014-08-13_Modul1_Canagliflozin-Metformin-FDC.pdf2025-12-03T11:04:39.963Z"4492de2db2d37257c1089af21e9659d1"1193418STANDARD2206203922062039Normalmedia/2014-08-13_Modul4A_Canagliflozin-Metformin-FDC.pdf2025-12-03T11:04:46.175Z"00357fd0d75526f6119f8d9e643403d7-2"8459639STANDARD2206203922062039Normalmedia/2014-08-13_Modul4B_Canagliflozin-Metformin-FDC.pdf2025-12-03T11:04:43.169Z"7ade36b176c32fbd58b1a750174047b0"4029731STANDARD2206203922062039Normalmedia/2014-08-13_Modul4C_Canagliflozin-Metformin-FDC.pdf2025-12-03T11:04:42.187Z"20e18d12c0610a0c92f7963ec7283ce6"1752868STANDARD2206203922062039Normalmedia/2014-08-13_Nutzenbewertung_20IQWIG_Ruxolitinib.pdf2025-12-03T11:04:13.943Z"beab5ae08cf4191e52dc8cccfc755608"779027STANDARD2206203922062039Normalmedia/2014-08-14_Info_zur_zVT_Ruxolitinib.pdf2025-12-03T11:04:14.756Z"eb90609880be0da92e731d211f1e8ff1"922734STANDARD2206203922062039Normalmedia/2014-08-14_Modul1_Empagliflozin.pdf2025-12-03T11:04:47.703Z"0357aae5c8dbb984ec31f9e8ed68bdb7"374911STANDARD2206203922062039Normalmedia/2014-08-14_Modul4A_Empagliflozin.pdf2025-12-03T11:04:42.152Z"bb1a1fbf9402e0b0f346863e6493493f"1116986STANDARD2206203922062039Normalmedia/2014-08-14_Modul4B_Empagliflozin.pdf2025-12-03T11:04:44.177Z"ad6c75352c01b0ba5b871423baeed48d"5168894STANDARD2206203922062039Normalmedia/2014-08-14_Modul4C_Empagliflozin.pdf2025-12-03T11:04:48.118Z"8161ae54d0bf611edba2a8ed96ead4c5"3097733STANDARD2206203922062039Normalmedia/2014-08-15-D-123_Empagliflozin_Addendum.pdf2025-12-03T11:04:48.533Z"20288c1348d1b1ee0baa85b0d6cfab4d"227488STANDARD2206203922062039Normalmedia/2014-08-15_Nutzenbewertung_G-BA_Cholsaeure.pdf2025-12-03T11:04:16.283Z"3e4e5a9765694973393bee893b5d27c7"692488STANDARD2206203922062039Normalmedia/2014-08-15_Nutzenbewertung_G-BA_Obinutuzumab.pdf2025-12-03T11:04:50.380Z"d0010e6f2faad6a7de29e5ab32239796"1219510STANDARD2206203922062039Normalmedia/2014-08-20_Analyse-Schiedsspruch-Vildagliptin.pdf2025-12-03T11:45:19.498Z"54b5520f5810a86a6eb432ab2de9e69a"115026STANDARD2206203922062039Normalmedia/2014-08-20_Schiedsspruch_4-14_Vildagliptin_Galvus_009.pdf2025-12-03T11:45:14.670Z"ef434250da90a21d58f0888ef27963bd"5091157STANDARD2206203922062039Normalmedia/2014-08-21_35a_Einstellung-Verfahren-Bedaquilin_D-112_BAnz.pdf2025-12-03T11:22:46.483Z"6d25490db1a51e5e4f8710d4049e9553"50248STANDARD2206203922062039Normalmedia/2014-08-21_35a_Einstellung-Verfahren-Bedaquilin_D-112_TrG.pdf2025-12-03T11:22:47.151Z"2c0cac576c579c6f61b9b8df7b3815e0"55383STANDARD2206203922062039Normalmedia/2014-08-22_Modul1_Apixaban.pdf2025-12-03T11:04:51.449Z"f37890f86f1077bcc9b8d5f66172b663"210033STANDARD2206203922062039Normalmedia/2014-08-22_Modul1_Ivacaftor.pdf2025-12-03T11:04:52.354Z"acca6e1c2f92a4dc236f4fe429ce8301"580350STANDARD2206203922062039Normalmedia/2014-08-22_Modul4B_Ivacaftor.pdf2025-12-03T11:46:58.456Z"792d939643f4ddd57783b9ca7fe1b957"3654482STANDARD2206203922062039Normalmedia/2014-08-22_Modul4D_Apixaban.pdf2025-12-03T11:04:53.686Z"ef64fe9306cf908f27777a44debb6ef5"5366659STANDARD2206203922062039Normalmedia/2014-08-25_Analyse-Schiedsspruch-Vildagliptin-Metformin.pdf2025-12-03T11:45:14.973Z"8cda33e0edec4e8ce8690dc3238128e9"116048STANDARD2206203922062039Normalmedia/2014-08-25_Schiedsspruch_3-14_Vildagliptin-Metformin_Eucreas_010.pdf2025-12-03T11:45:21.692Z"b76b47ded39cec52062d9d4f121bcb29"5094790STANDARD2206203922062039Normalmedia/2014-08-28_Mirabegron_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:04:20.849Z"b6561feaaea69c63348a9e8ce7d8b691"729992STANDARD2206203922062039Normalmedia/2014-08-28_Modul1_Nalmefen.pdf2025-12-03T11:04:54.411Z"59db15dbffe641a005c7d38384c98a0e"230881STANDARD2206203922062039Normalmedia/2014-08-28_Modul1_Teduglutid.pdf2025-12-03T11:05:00.590Z"a8ebe0b82e19a8388f2d3e3bc13d0470"131085STANDARD2206203922062039Normalmedia/2014-08-28_Modul4A_Nalmefen.pdf2025-12-03T11:04:55.179Z"22bdbcdb35be2aae4b0c12f4a8738d87-2"9671289STANDARD2206203922062039Normalmedia/2014-08-28_Modul4A_Teduglutid.pdf2025-12-03T11:05:00.551Z"2e454533e1abebf199cdb5719173e726"2202689STANDARD2206203922062039Normalmedia/2014-08-29_Modul1_Daclatasvir.pdf2025-12-03T11:04:58.696Z"fda3469e2a6d12b1c5ed3bcadae93439"661935STANDARD2206203922062039Normalmedia/2014-08-29_Modul1_Propranolol.pdf2025-12-03T11:04:55.961Z"90a5b77c045061589d6fca8cf2e5f5aa"482112STANDARD2206203922062039Normalmedia/2014-08-29_Modul4A_Propranolol.pdf2025-12-03T11:04:57.384Z"d532b4e93afd6ca7da9b85bea86798a9"3893787STANDARD2206203922062039Normalmedia/2014-08-29_Modul4_Daclatasvir.pdf2025-12-03T11:05:02.775Z"0d08f6ed3bc6ec20785e0e7ceb6b2fca-2"14038231STANDARD2206203922062039Normalmedia/2014-09-01-D-129_Daclatasvir_Addendum.pdf2025-12-03T11:04:58.570Z"612eb43a8928c850c02ff40aa5179ce4"116005STANDARD2206203922062039Normalmedia/2014-09-01_Informationen-zur-zweckmaessigen-Vergleichstherapie_Daclatasvir.pdf2025-12-03T11:04:59.063Z"59627e1db0fb219550238326a9831230"1156438STANDARD2206203922062039Normalmedia/2014-09-01_Informationen_zur_zVT_Apixaban_nAWG_D-126.pdf2025-12-03T11:04:52.158Z"f286482ac322bc9ca670014bd788a408"1229862STANDARD2206203922062039Normalmedia/2014-09-01_Informationen_zur_zVT_D-128_Propranolol.pdf2025-12-03T11:04:55.552Z"dfe3174497326b1213e631e472cd30f0"200238STANDARD2206203922062039Normalmedia/2014-09-01_Informationen_zur_zVT_D-134_Regorafenib_nAWG.pdf2025-12-03T11:04:57.325Z"638c9c51289a496cf36ceb0ac1e28384"91208STANDARD2206203922062039Normalmedia/2014-09-01_Informationen_zur_zVT_Lebende_Larven.pdf2025-12-03T11:04:18.019Z"454b3d39aa420275ced71f67572ddc2c"510448STANDARD2206203922062039Normalmedia/2014-09-01_Informationen_zur_zVT_b_Nalmefen.pdf2025-12-03T11:04:55.142Z"6785dae3c0d6a71fad166ecfd5527163"461655STANDARD2206203922062039Normalmedia/2014-09-01_Nutzenbewertung_20G-BA_Lebende_20Larven.pdf2025-12-03T11:04:20.041Z"b2c5ef52986ff63123e3453ce99345cb"112032STANDARD2206203922062039Normalmedia/2014-09-01_Nutzenbewertung_G-BA.PDF2025-12-03T11:04:23.253Z"a8296b397d2bcdc5f0004b70175970ff"1077263STANDARD2206203922062039Normalmedia/2014-09-02_Modul1_Aflibercept.pdf2025-12-03T11:05:01.783Z"ad59c3cf14f3af994667661f3dedb08c"437060STANDARD2206203922062039Normalmedia/2014-09-02_Modul4C_Aflibercept.pdf2025-12-03T11:05:06.247Z"24d70b02053645d00d3a368a489c85a4-3"19684483STANDARD2206203922062039Normalmedia/2014-09-04_AM-RL-XII_Canagliflozin_2014-03-15-D-101.pdf2025-12-03T11:04:06.245Z"fe60ea049c35ddd2c07112269e65052d"165683STANDARD2206203922062039Normalmedia/2014-09-04_AM-RL-XII_Canagliflozin_2014-03-15-D-101_TrG.pdf2025-12-03T11:04:06.450Z"e98c03439ad0458b6d910d91f43d9ff9"150599STANDARD2206203922062039Normalmedia/2014-09-08_Analyse-Schiedsspruch-Elvitegravier-Kombi.pdf2025-12-03T11:45:17.365Z"2371f4d7afdf9440268623d1ffc2d4b0"115484STANDARD2206203922062039Normalmedia/2014-09-08_Schiedsspruch_6-14_Elvitegravir-Cobiclstat-Emtricitabin-Tenofovirdisoproxil_S_uMMAjpp.pdf2026-03-21T13:57:26.142Z"52dda35f5b44d131a9a902fd615c8b0e"2902672STANDARD2206203922062039Normalmedia/2014-09-08_Schiedsspruch_6-14_Elvitegravir-Cobiclstat-Emtricitabin-Tenofovirdisoproxil_Stribild_011.pdf2025-12-03T11:45:21.026Z"52dda35f5b44d131a9a902fd615c8b0e"2902672STANDARD2206203922062039Normalmedia/2014-09-08_Wortprotokoll_end_Dimethylfumarat.pdf2025-12-03T11:04:11.192Z"3cbe48c4eddd9f07e3f4c83047e6f776"215815STANDARD2206203922062039Normalmedia/2014-09-08_Wortprotokoll_end_Insulin_20degludec.pdf2025-12-03T11:04:11.744Z"59474a19b58fc1156b3a37d91108ffe4"101232STANDARD2206203922062039Normalmedia/2014-09-08_Wortprotokoll_end_Riociguat.pdf2025-12-03T11:04:12.650Z"6971add05902d7b598c90ec9d17dfee6"168703STANDARD2206203922062039Normalmedia/2014-09-11_Modul1_Dolutegravir-Abacavir-Lamivudin.pdf2025-12-03T11:46:57.920Z"5a46c9f4b971b2bbe9c1ab1d01a8be5f"406906STANDARD2206203922062039Normalmedia/2014-09-11_Modul4A_DolutegravirAbacavirLamivudin.pdf2025-12-03T11:05:11.965Z"3beb198d0aa6c417e79c0f2484ae8cd7"5973211STANDARD2206203922062039Normalmedia/2014-09-15-D-137_Aflibercept_Addendum.pdf2025-12-03T11:05:07.082Z"ec4c164277ffa9bd1c1722fbc46f677d"178891STANDARD2206203922062039Normalmedia/2014-09-15_Nutzenbewertung_G-BA_Insulin_degludec_nAWG.pdf2025-12-03T11:04:26.256Z"58b6d821bb33ab8494a29bb7a04a3869"133103STANDARD2206203922062039Normalmedia/2014-09-15_Nutzenbewertung_IQWiG_D-137_Aflibercept-nAWG.pdf2025-12-03T11:05:03.371Z"b4d020be13e6c45d96b13a2ecbb12908"805149STANDARD2206203922062039Normalmedia/2014-09-18_AM-RL-XII_Cobicistat_2014-04-01-D-104_BAnz.pdf2025-12-03T11:04:02.178Z"bdb0781a876ad5fc4bc3514ed9ec95ba"97433STANDARD2206203922062039Normalmedia/2014-09-18_AM-RL-XII_Cobicistat_2014-04-01-D-104_TrG.pdf2025-12-03T11:04:02.457Z"a09f23a40b3373b75d08c43a14e3cd9f"81398STANDARD2206203922062039Normalmedia/2014-09-22_Modul1_Idelalisib.pdf2025-12-03T11:05:04.867Z"0e0366b7d01fdc4e3c9e7a7ad7061c25"213643STANDARD2206203922062039Normalmedia/2014-09-22_Modul4A_Idelalisib.pdf2025-12-03T11:05:07.480Z"c2212156dea18df589629fa51facaf39"6232649STANDARD2206203922062039Normalmedia/2014-09-22_Modul4B_Idelalisib.pdf2025-12-03T11:05:03.943Z"29b5dd70c43cad052ef6caad91f97840"3213083STANDARD2206203922062039Normalmedia/2014-09-22_Wortprotokoll_End_Ruxolitinib.pdf2025-12-03T11:04:13.876Z"f7cba5f0128158d644d245bd26fbd567"115394STANDARD2206203922062039Normalmedia/2014-09-22_Wortprotokoll_Perampanel.pdf2025-12-03T11:04:17.539Z"b0a18d21886144cc79d30166e08ea5cc"211593STANDARD2206203922062039Normalmedia/2014-09-22_Wortprotokoll_end_Chols_C3_A4ure.pdf2025-12-03T11:04:15.787Z"14a865e985b1e13915994d19284575e3"150548STANDARD2206203922062039Normalmedia/2014-09-29_A14-21_Fingolimod-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:04:30.326Z"6b702bd0cdfe68f261879ab896f2cf50"658470STANDARD2206203922062039Normalmedia/2014-09-29_Modul1_Abliglutid.pdf2025-12-03T11:05:14.192Z"2e10bc4c619fbdc893600014e56f2db0"631498STANDARD2206203922062039Normalmedia/2014-09-29_Modul4A_Albiglutid.pdf2025-12-03T11:05:12.509Z"afe1896f40745eba8f1b41f2c0f7ed64"758265STANDARD2206203922062039Normalmedia/2014-09-29_Modul4B_Albiglutid.pdf2025-12-03T11:05:13.717Z"20cf8b45c693055d7626c44effa76587"6540103STANDARD2206203922062039Normalmedia/2014-09-29_Modul4C_Albiglutid.pdf2025-12-03T11:05:12.773Z"9e232ee5c7524be10eb8337c7b44bf63"769574STANDARD2206203922062039Normalmedia/2014-09-29_Modul4D_Albiglutid.pdf2025-12-03T11:05:12.960Z"2ebd8318ae0058fab2feb1aa4f8f80de"767233STANDARD2206203922062039Normalmedia/2014-09-30_Modul1_Sipuleucel-T.pdf2025-12-03T11:05:06.556Z"ed1f2adc82731234a8ce6089e4f3a4a3"386403STANDARD2206203922062039Normalmedia/2014-09-30_Modul4A_Sipuleucel-T.pdf2025-12-03T11:05:08.414Z"76fb0699fa81501e9a02adb0f39fd2d4"5139742STANDARD2206203922062039Normalmedia/2014-10-01-D-131_Info_zur_zVT_Dolutegravir-Kombi.pdf2025-12-03T11:05:10.764Z"e8f3dc6553c6a464d6d0044aa95f1b9e"738869STANDARD2206203922062039Normalmedia/2014-10-01-D-139_Sipuleucel-T_Addendum.pdf2025-12-03T11:05:06.891Z"9d6c26ed4cae77d897aa71e78e1f5b7f"279118STANDARD2206203922062039Normalmedia/2014-10-01_Info_zu_zVT_Sucroferric-D-136.pdf2025-12-03T11:05:09.252Z"10ac1e496da63923a993803642d4feeb"531893STANDARD2206203922062039Normalmedia/2014-10-01_Modul1_Sucroferric_Oxyhydroxide.pdf2025-12-03T11:05:08.565Z"fcbc60a002044a543482ea5e0b5c08f1"149055STANDARD2206203922062039Normalmedia/2014-10-01_Modul4A_Sucroferric_Oxyhydroxide.pdf2025-12-03T11:05:11.399Z"dd8c1fedaccd0ea6a23b4c0cf7928d27-3"20946160STANDARD2206203922062039Normalmedia/2014-10-06_Wortprotokoll_end_Elosulfase_alfa.pdf2025-12-03T11:04:22.422Z"696dc9aa849f8170930fec94b4b6d306"178442STANDARD2206203922062039Normalmedia/2014-10-06_Wortprotokoll_end_Mirabegron.pdf2025-12-03T11:04:21.158Z"24f9e544065623ada4bb1c82783cf653"221013STANDARD2206203922062039Normalmedia/2014-10-06_Wortprotokoll_end_Simeprevir.pdf2025-12-03T11:04:24.953Z"79f630a6e18802d3a2fc950b9b631b57"169167STANDARD2206203922062039Normalmedia/2014-10-06_Wortprotokoll_end_lebende_20Larven_20von_20Lucilia_20sericata.pdf2025-12-03T11:04:18.138Z"880dfdd285d89e7a8a7412edabae68ae"71305STANDARD2206203922062039Normalmedia/2014-10-13_A14-23_Vedolizumab_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:04:30.332Z"de13b58423aae55d369cf701d6ec4f55"730993STANDARD2206203922062039Normalmedia/2014-10-15_Umeclidinium_Vilanterol_Informationen_zur_zweckmaessigen_Vergleichstherapie.pdf2025-12-03T11:04:38.454Z"5358db3fae18687706719dd08f963a47"587326STANDARD2206203922062039Normalmedia/2014-10-16_AM-RL-XII_Dimethylfumarat_2014-05-01-D-100.pdf2025-12-03T11:04:11.951Z"79be9bd422055302699bcc0497abf1c7"76037STANDARD2206203922062039Normalmedia/2014-10-16_AM-RL-XII_Dimethylfumarat_2014-05-01-D-100_TrG.pdf2025-12-03T11:04:12.250Z"80b3373e859286477ca6a378a8017c41"192543STANDARD2206203922062039Normalmedia/2014-10-16_AM-RL-XII_Insulin_20degludec_2014-05-01-D-109.pdf2025-12-03T11:04:09.582Z"b358b4e78b9f0b09f62f26860c114a12"200466STANDARD2206203922062039Normalmedia/2014-10-16_AM-RL-XII_Insulin_20degludec_2014-05-01-D-109_TrG.pdf2025-12-03T11:04:10.067Z"cdb8967d11536d7a1eb78fa940443b98"156167STANDARD2206203922062039Normalmedia/2014-10-16_AM-RL-XII_Riociguat_2014-05-01-D-103.pdf2025-12-03T11:04:06.660Z"a77a2913e0d4282bb409aa053ee09d4e"132904STANDARD2206203922062039Normalmedia/2014-10-16_AM-RL-XII_Riociguat_2014-05-01-D-103_TrG.pdf2025-12-03T11:04:07.176Z"d593e69a80cedc4e80d520a63f707a6d"135013STANDARD2206203922062039Normalmedia/2014-10-16_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_Riociguat.pdf2025-12-03T11:04:07.201Z"55125f71864d46f448b68189dd699142"155878STANDARD2206203922062039Normalmedia/2014-10-22_Modul1_Ibrutinib.pdf2025-12-03T11:05:15.367Z"b926e09999296daf6f39d213a543f6f3"356995STANDARD2206203922062039Normalmedia/2014-10-22_Modul4A_Ibrutinib.pdf2025-12-03T11:05:14.760Z"86c747e03941e383a2682328ea2f151d"3046308STANDARD2206203922062039Normalmedia/2014-10-22_Modul4B_Ibrutinib.pdf2025-12-03T11:05:14.879Z"36a0f14ca748a0b29a76ff14ebade92f"1181230STANDARD2206203922062039Normalmedia/2014-10-24_Modul1_Alipogentiparvovec.pdf2025-12-03T11:05:20.739Z"d0bcde30f507fbc83c46cc0fbed75075"136958STANDARD2206203922062039Normalmedia/2014-10-24_Modul4A_Alipogentiparvovec.pdf2025-12-03T11:05:20.063Z"b095a7b08cf438754de69db5d6bb1e38"1730377STANDARD2206203922062039Normalmedia/2014-10-28_Modul1_Simoctocog-alfa.pdf2025-12-03T11:05:18.088Z"334b990a436b6f89acec21af6c7d6eea"630926STANDARD2206203922062039Normalmedia/2014-10-28_Modul4_Simoctocog-alfa.pdf2025-12-03T11:05:20.854Z"1faab606d05fd7397c506e42d2c79b6c"5709192STANDARD2206203922062039Normalmedia/2014-10-28_Wortprotokoll_end_Insulin_20degludec_28nAWG_29.pdf2025-12-03T11:04:26.475Z"dda471ac6055e513d99650d550dbb6c5"112197STANDARD2206203922062039Normalmedia/2014-10-28_Wortprotokoll_end_Siltuximab.pdf2025-12-03T11:04:27.026Z"bf1ca2f4fcbd5072722d5b46ba3ae26b"164387STANDARD2206203922062039Normalmedia/2014-10-31_Modul1_Lurasidon.pdf2025-12-03T11:05:16.168Z"0f34795ffab2efbff944869f0cdeccf3"165436STANDARD2206203922062039Normalmedia/2014-10-31_Modul4A_Lurasidon.pdf2025-12-03T11:05:22.966Z"5cc762de2dd91ed67f1851c5c21197d5-5"36164623STANDARD2206203922062039Normalmedia/2014-10-31_Nutzenbewertung_20IQWiG_Eribulin.pdf2025-12-03T11:04:34.876Z"7ef7b3d603aaf59ed822ce004da095d5"1041225STANDARD2206203922062039Normalmedia/2014-11-06_AM-RL-XII_Cholsaeure_2014-05-15-D-105_BAnz.pdf2025-12-03T11:04:16.172Z"5847a6c4efffce4f2c3c8d6345e261d3"110512STANDARD2206203922062039Normalmedia/2014-11-06_AM-RL-XII_Cholsaeure_2014-05-15-D-105_TrG.pdf2025-12-03T11:04:17.608Z"974b5f0dfc751ce8fcbba08d365076da"98221STANDARD2206203922062039Normalmedia/2014-11-06_AM-RL-XII_Perampanel_2014-05-15-D-106.pdf2025-12-03T11:04:20.757Z"7527b3fc0b40d93e3a225be88e18fb90"100659STANDARD2206203922062039Normalmedia/2014-11-06_AM-RL-XII_Perampanel_2014-05-15-D-106_TrG.pdf2025-12-03T11:04:16.943Z"434c654c706cc534f867285e82ebfc65"106035STANDARD2206203922062039Normalmedia/2014-11-06_AM-RL-XII_Ruxolitinib_2014-05-15-D-108.pdf2025-12-03T11:04:13.153Z"5bb4e42e4c9e9c59866cc3e37e24a63b"120625STANDARD2206203922062039Normalmedia/2014-11-06_AM-RL-XII_Ruxolitinib_2014-05-15-D-108_TrG.pdf2025-12-03T11:04:13.352Z"ea49f738e3a6fff25f436b995d82ed64"119113STANDARD2206203922062039Normalmedia/2014-11-06_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_1.pdf2025-12-03T11:04:15.252Z"483d32a2f6507c5217ed941bfc615c44"151939STANDARD2206203922062039Normalmedia/2014-11-11_Wortprotokoll_end_Fingolimod_bf.pdf2025-12-03T11:04:29.145Z"0c1b4735acfa36aea555f69b739236dc"137214STANDARD2206203922062039Normalmedia/2014-11-13_A14-26_Empagliflozin_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:46:56.447Z"c1745ecfdc89fd3d2aa265f29550522b"642044STANDARD2206203922062039Normalmedia/2014-11-13_Info_zur_zVT_Canagliflozin-Metformin.pdf2025-12-03T11:04:39.759Z"6454a6f42f053e7bdfcc668755e14930"1438107STANDARD2206203922062039Normalmedia/2014-11-13_Info_zur_zVT_Empagliflozin.pdf2025-12-03T11:04:50.626Z"a311ec020b1e60549feb74778000352d"1436749STANDARD2206203922062039Normalmedia/2014-11-13_Nutzenbewertung_20IQWiG_Canagliflozin-Metformin.pdf2025-12-03T11:04:39.551Z"2c7379a06966c42d9335232d1996cd52"326899STANDARD2206203922062039Normalmedia/2014-11-15_Informationen-zVT_Simoctocog-alfa-D-140.pdf2025-12-03T11:05:18.270Z"5f9fedeafd3507da323a524aa6b45a9d"530167STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Elosulfase_20alfa_2014-06-01-D-114.pdf2025-12-03T11:04:21.997Z"3a0a41e23847f6966c5c85364f38c6b1"104044STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Elosulfase_20alfa_2014-06-01-D-114_TrG.pdf2025-12-03T11:04:22.494Z"8c180616370d03ac5b0cf98e58baf9ff"122962STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Lebende_20Larven_2014-06-01-D-115.pdf2025-12-03T11:04:18.280Z"5a92f68fddb19e21c0ef0585ee6e7c1b"82384STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Lebende_20Larven_2014-06-01-D-115_TrG.pdf2025-12-03T11:04:18.549Z"e25c57bc84514d5d660af8d95a00f0f5"78568STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Mirabegron_2014-06-01-D-110.pdf2025-12-03T11:04:18.574Z"431a5ce057db32ea7c77ea9457238479"109184STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Mirabegron_2014-06-01-D-110_TrG.pdf2025-12-03T11:04:19.966Z"988d289d06ebbf011d5eb47eb045c95d"90743STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Simeprevir_2014-06-01-D-113.pdf2025-12-03T11:04:22.757Z"52f911f09c3a80c7cf3883921c561ca9"361963STANDARD2206203922062039Normalmedia/2014-11-20_AM-RL-XII_Simeprevir_2014-06-01-D-113_TrG.pdf2025-12-03T11:04:25.066Z"808f99458dfd203f2aa988e9f7703ef6"206709STANDARD2206203922062039Normalmedia/2014-11-20_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG.pdf2025-12-03T11:04:24.660Z"508928509d5891c38fa97e62a59720c1"125522STANDARD2206203922062039Normalmedia/2014-11-20_Modul1_Ledipasvir-Sofosbuvir.pdf2025-12-03T11:46:56.942Z"0ab94b0cd185b579e7a0dccbb3bfc9ab"360625STANDARD2206203922062039Normalmedia/2014-11-20_Modul4A_Ledipasvir-Sofosbuvir.pdf2025-12-03T11:05:24.840Z"4a8b7940c418b8c88864a1712ff6997c-2"9693864STANDARD2206203922062039Normalmedia/2014-11-24_Modul1_Ataluren.pdf2025-12-03T11:05:25.462Z"49a8ff2068c601eeed65a6666356532a"400166STANDARD2206203922062039Normalmedia/2014-11-24_Modul4_Ataluren.pdf2025-12-03T11:05:26.147Z"f0d5ba9055be616f7d1ecc8959e7b815"2459277STANDARD2206203922062039Normalmedia/2014-11-25_Informationen-zVT_Tiotropium-Olodaterol.pdf2025-12-03T11:06:26.857Z"bba00c0874e98ded5c9bd33c57f473ab"592118STANDARD2206203922062039Normalmedia/2014-11-25_Wortprotokoll_end_Umeclidinium_Vilanterol.pdf2025-12-03T11:04:33.458Z"d1e7e4ddb5bf9594809d2e4c7df17146"198614STANDARD2206203922062039Normalmedia/2014-11-25_Wortprotokoll_end_Vedolizumab.pdf2025-12-03T11:04:30.028Z"dfba7bc9e86c203ab7694f658add7d49"229996STANDARD2206203922062039Normalmedia/2014-11-26_Analyse-Schiedsspruch-Pomalidomid.pdf2025-12-03T11:45:18.237Z"ef1c6c676f8c0c3b8c59ee31282174f3"114395STANDARD2206203922062039Normalmedia/2014-11-26_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_Teduglutid.pdf2025-12-03T11:05:01.650Z"ab6c0718a484886454aa2a0c361c9d9f"119492STANDARD2206203922062039Normalmedia/2014-11-26_G14-09_Ivacaftor_nAWG_Bewertung-35a-Abs1-Satz10-SGB-V.pdf2025-12-03T11:04:52.752Z"be3ab5be4ab0e92295244a47e5ed6b03"132238STANDARD2206203922062039Normalmedia/2014-11-26_Nutzenbewertung_20IQWiG_Apixaban_nAWG.pdf2025-12-03T11:04:51.573Z"a640e69df29b1520cf63b5e15c15683a"623849STANDARD2206203922062039Normalmedia/2014-11-26_Schiedsspruch_7-14_Pomalidomid_Imnovid_012.pdf2025-12-03T11:45:18.685Z"a67341e82139c4d8f6da77a2c36f477a"1570929STANDARD2206203922062039Normalmedia/2014-11-27_Modul1_Vildagliptin.pdf2025-12-03T11:05:24.797Z"e97250110860fc07b76b5ffdf46787cd"236678STANDARD2206203922062039Normalmedia/2014-11-27_Modul4A_Vildagliptin.pdf2025-12-03T11:05:25.426Z"dbae60c7a6f2fd4c7a29bb6f8e011b30"2120201STANDARD2206203922062039Normalmedia/2014-11-27_Nutzenbewertung_20IQWiG_Daclatasvir.pdf2025-12-03T11:04:58.704Z"9dcb8302fd930fc49c6a5b75a565851c"551243STANDARD2206203922062039Normalmedia/2014-11-27_Nutzenbewertung_IQWiG_Propranolol.pdf2025-12-03T11:04:55.948Z"68f60503faa4f6bac151a0d8f73d27ef"660500STANDARD2206203922062039Normalmedia/2014-12-01-D-143_LedipasvirSofosbuvir_Addendum.pdf2025-12-03T11:05:22.673Z"a4608e031d4433a56c49504dddf2db8f"212140STANDARD2206203922062039Normalmedia/2014-12-01-D-145_Info-zur-zVT_Vildagliptin.pdf2025-12-03T11:05:24.952Z"794b7f48ed6b136116440e2c952ded89"1450059STANDARD2206203922062039Normalmedia/2014-12-01_Informationen-zur-zVT_Ledipasvor-Sofosbuvir.pdf2025-12-03T11:05:23.357Z"28565731fadc48d28ee1c0b01d6d843b"1094883STANDARD2206203922062039Normalmedia/2014-12-01_Ivacaftor_nAWG_Nutzenbewertung.pdf2025-12-03T11:04:52.573Z"0e5cf402e4fae3da2ecc06a162274436"478668STANDARD2206203922062039Normalmedia/2014-12-01_Nalmefen_Nutzenbewertung_IQWiG.pdf2025-12-03T11:04:55.147Z"49c34c033238c6ec78e6e771de2fe8c4"374271STANDARD2206203922062039Normalmedia/2014-12-01_Nutzenbewertung_20G-BA_Regorafenib_nAWG.pdf2025-12-03T11:04:57.343Z"72d132e6d6fa0ee14ac7c3b3e71e985e"135765STANDARD2206203922062039Normalmedia/2014-12-01_Nutzenbewertung_20G-BA_Teduglutid.pdf2025-12-03T11:05:00.866Z"c958a87b55d41a09788024940a400457"396479STANDARD2206203922062039Normalmedia/2014-12-01_Wortprotokoll_D-145_Vildagliptin_erneute_NB.pdf2025-12-03T11:05:24.369Z"c99038a791a1e24aaa94610820c032c0"150842STANDARD2206203922062039Normalmedia/2014-12-04_AM-RL-XII_Insulin-degludec_nAWG_2014-06-15-D-118.pdf2025-12-03T11:04:24.961Z"485ff340fa3f55cabdf03390870d3331"98571STANDARD2206203922062039Normalmedia/2014-12-04_AM-RL-XII_Insulin-degludec_nAWG_2014-06-15-D-118_TrG.pdf2025-12-03T11:04:25.139Z"cbe68da4bb3753fbaa76a0c18f29d00a"93460STANDARD2206203922062039Normalmedia/2014-12-04_AM-RL-XII_Siltuximab_2014-06-15-D-119.pdf2025-12-03T11:04:27.257Z"6ac20a1181187c0a16b0b922a2b69b7d"155177STANDARD2206203922062039Normalmedia/2014-12-04_AM-RL-XII_Siltuximab_2014-06-15-D-119_TrG.pdf2025-12-03T11:46:57.160Z"98da77548c22b6df4070056e41d0d06a"152715STANDARD2206203922062039Normalmedia/2014-12-04_Bewertung_der_Kosten_und_Patientenzahlen_IQWiG_Siltuximab.pdf2025-12-03T11:04:27.315Z"393e09691b45499fc5cfefd8692875d2"130337STANDARD2206203922062039Normalmedia/2014-12-09_Wortprotokoll_15-12-2014_Cabozantinib.pdf2025-12-03T11:04:37.667Z"10df09b3b8801a2640f8b020bd55fc45"174657STANDARD2206203922062039Normalmedia/2014-12-09_Wortprotokoll_end_Eribulin_bf.pdf2025-12-03T11:04:34.948Z"95cef41d9418f8746b6d2e5407efe52f"213317STANDARD2206203922062039Normalmedia/2014-12-15_Info-zur-zVT_Aflibercept_nAWG.pdf2025-12-03T11:05:02.411Z"b843bda71c0c6d8923a22ec4e1ef4583"748502STANDARD2206203922062039Normalmedia/2014-12-15_Modul1_Pasireotid.pdf2025-12-03T11:05:32.329Z"c0c4d75ad9fc77cbab302951c463004a"468137STANDARD2206203922062039Normalmedia/2014-12-15_Modul4A_Pasireotid.pdf2025-12-03T11:05:33.273Z"a83adfdff55bc3790bd21d4079c64086"1622687STANDARD2206203922062039Normalmedia/2014-12-18_AM-RL-XII_Fingolimod_nAWG_2014-07-01-D-116.pdf2025-12-03T11:04:32.971Z"2d54cb1348b6aab7d866513966390dc5"203245STANDARD2206203922062039Normalmedia/2014-12-18_AM-RL-XII_Fingolimod_nAWG_2014-07-01-D-116_TrG.pdf2025-12-03T11:04:28.056Z"e11727832d72fad353ab4a561f7d6b70"135863STANDARD2206203922062039Normalmedia/2014-12-18_Modul1_Enzalutamid.pdf2025-12-03T11:05:28.033Z"98fb94dd18bb14b909326951d685ff86"471163STANDARD2206203922062039Normalmedia/2014-12-18_Modul4A_Enzalutamid.pdf2025-12-03T11:05:30.826Z"1fe6ba74e518f088dd35501cdf98e66d-3"18509561STANDARD2206203922062039Normalmedia/2014-12-19_Modul1_Nintedanib.pdf2025-12-03T11:05:30.773Z"ac9d02051381e99961f4a62bf5be082e"197616STANDARD2206203922062039Normalmedia/2014-12-19_Modul4A_Nintedanib.pdf2025-12-03T11:05:30.906Z"acbffc84fdcc79bcfa0883be44b84975"1892741STANDARD2206203922062039Normalmedia/2014-12-19_Nutzenbewertung_20IQWiG_Dolutegravir-Abacavir-Lamivudin.pdf2025-12-03T11:05:10.657Z"d59b7787c49ef42989217b651f008f75"583658STANDARD2206203922062039Normalmedia/2014-12-19_Wortprotokoll_Canagliflozin-Metformin_D-124.pdf2025-12-03T11:04:39.951Z"6a046d4a61d054ce52daeb59a7fc40da"65403STANDARD2206203922062039Normalmedia/2014-12-19_Wortprotokoll_end_Empagliflozin_bf.pdf2025-12-03T11:04:48.788Z"20a852736381a2a4fa9f864670737da7"201963STANDARD2206203922062039Normalmedia/2014-12-19_Wortprotokoll_end_Obinutuzumab_bf.pdf2025-12-03T11:04:49.719Z"c288e90f7b76402d2f85df60d263d5e2"123208STANDARD2206203922062039Normalmedia/2014-12-22_Nutzenbewertung-IQWiG_Sucroferric-Oxyhydroxid.pdf2025-12-03T11:05:09.269Z"f25610754499e1ef53984a69b0a75c46"389955STANDARD2206203922062039Normalmedia/2014-12-22_Nutzenbewertung_20IQWiG_Idelalisib_2014-10-01-D-135.pdf2025-12-03T11:05:05.937Z"3d78f2e998d76781f4412651e7d0c9a1"604299STANDARD2206203922062039Normalmedia/2014-12-23_Nutzenbewertung-IQWiG_Albiglutid.pdf2025-12-03T11:05:13.577Z"e24e0abf99776c78d52a9ddf50d075a4"696862STANDARD2206203922062039Normalmedia/2014-12-23_Nutzenbewertung-IQWiG_Sipuleucel-T.pdf2025-12-03T11:05:06.822Z"af7ccffbf5ef4f03459e031a9db7dac2"893234STANDARD2206203922062039Normalmedia/2014-12-29_Info_zur_zVT_Albiglutid.pdf2025-12-03T11:05:13.645Z"a311f165cdad69aa23945161b2dcb684"1436911STANDARD2206203922062039Normalmedia/2014-12-30_Info_zur_zVT_Idelalisib_2014-10-01-D-135_Master.pdf2025-12-03T11:05:05.634Z"8662496fb93d8572356fe7b67b21ab09"1547912STANDARD2206203922062039Normalmedia/2014_02_01_Modul4A_Sofosbuvir.pdf2025-12-03T11:04:04.753Z"1834e0d7e9260dc8c95893e161f81180-2"13234392STANDARD2206203922062039Normalmedia/2014_05_01_Modul4_Dimethylfumarat.pdf2025-12-03T11:04:18.650Z"27e81b74b4d13ae1b9d52eeaa2add35b-2"14446875STANDARD2206203922062039Normalmedia/2015-01-01-D-144_Tafluprost-Timolol_Addendum.pdf2025-12-03T11:05:27.182Z"a96c9c0c68544b1d5ec1f0d8b45275de"73184STANDARD2206203922062039Normalmedia/2015-01-01_Informationen_zur_zVT_D-144_Tafluprost_Timolol.pdf2025-12-03T11:05:27.271Z"1e59b7ef8443a254c4aca101b487b842"309383STANDARD2206203922062039Normalmedia/2015-01-01_Informationen_zur_zVT_D-146_Enzalutamid_nAWG.pdf2025-12-03T11:05:28.382Z"a89afd739b748b718aa9d0e074d56b3a"378034STANDARD2206203922062039Normalmedia/2015-01-01_Modul1_Tafluprost_Timolol.pdf2025-12-03T11:05:26.697Z"3795f79c5fcd28d5c79f9100fdea262d"466590STANDARD2206203922062039Normalmedia/2015-01-01_Modul4A_Tafluprost___Timolol.pdf2025-12-03T11:05:28.002Z"e73d3dfaaa1af9a51bebb6288bb9ee3d"1526169STANDARD2206203922062039Normalmedia/2015-01-01_Nintedanib_Informationen_zur_zVT.pdf2025-12-03T11:05:32.605Z"82fdefd23fafc8d9afe6e5914e68ebdc-2"11391922STANDARD2206203922062039Normalmedia/2015-01-01_Nutzenbewertung_IQWiG_Enzalutamid_nAWG.pdf2025-12-03T11:05:29.489Z"5783bb01202c868ed678c29f71d9c9f5"1826583STANDARD2206203922062039Normalmedia/2015-01-02_Info_zur_zVT_Sipuleucel-T.pdf2025-12-03T11:46:57.574Z"8c24275615b9d68dd8b0dd460c6143f2"396301STANDARD2206203922062039Normalmedia/2015-01-08_AM-RL-XII_Umeclidinium-Vilanterol_2014-07-15-D-117.pdf2025-12-03T11:04:31.666Z"d1ab8202c1260288d4057b11618f46b0"127260STANDARD2206203922062039Normalmedia/2015-01-08_AM-RL-XII_Umeclidinium-Vilanterol_2014-07-15-D-117_TrG.pdf2025-12-03T11:04:31.945Z"393241f49091f60e7edab965ff3d3657"143146STANDARD2206203922062039Normalmedia/2015-01-08_AM-RL-XII_Vedolizumab_2014-07-15-D-122.pdf2025-12-03T11:04:30.408Z"468f9d85cdd2096ea2d8850eda0531d4"151732STANDARD2206203922062039Normalmedia/2015-01-08_AM-RL-XII_Vedolizumab_2014-07-15-D-122_TrG.pdf2025-12-03T11:04:32.452Z"8209080f902ebacc0ca8b14d224387c1"174660STANDARD2206203922062039Normalmedia/2015-01-12_Wortprotokoll_Nalmefen.pdf2025-12-03T11:04:55.029Z"6d499b2bec70007be1d9a2f66cdbbb0f"146417STANDARD2206203922062039Normalmedia/2015-01-12_Wortprotokoll_Regorafenib_nAWG.pdf2025-12-03T11:04:57.383Z"42dfaf1d373eb8af44b538e4b9e44ba7"87438STANDARD2206203922062039Normalmedia/2015-01-12_Wortprotokoll_end_Daclatasvir.pdf2025-12-03T11:04:58.590Z"3d9520e5c17326c73e96b8534efde94f"122959STANDARD2206203922062039Normalmedia/2015-01-12_Wortprotokoll_end_Ivacaftor-nAWG.pdf2025-12-03T11:04:53.176Z"b282195bcd3c819cb9d766d6daa02851"95189STANDARD2206203922062039Normalmedia/2015-01-12_Wortprotokoll_end_Propranolol.pdf2025-12-03T11:04:55.951Z"627ddf80b34a72159fbabaecfa91100f"123356STANDARD2206203922062039Normalmedia/2015-01-19_Modul1_Dasabuvir.pdf2025-12-03T11:05:37.377Z"d4d7e700d7bdaf81804f601b68d6bbc6"842860STANDARD2206203922062039Normalmedia/2015-01-19_Modul1_Ombitasvir-Paritaprevir-Ritonavir.pdf2025-12-03T11:05:41.076Z"f0913c9b49dd3657a234d32421972e26"924249STANDARD2206203922062039Normalmedia/2015-01-19_Modul4A_Dasabuvir.pdf2025-12-03T11:05:40.299Z"71d555465a2e91757c7ab04217b27966"7396834STANDARD2206203922062039Normalmedia/2015-01-19_Modul4A_Ombitasvir-Paritaprevir-Ritonavir.pdf2025-12-03T11:05:44.048Z"1c8e3d45818d3d4e735112baca8fec0a-2"8623739STANDARD2206203922062039Normalmedia/2015-01-22_AM-RL-XII_Cabozantinib_2014-08-01-D-121.pdf2025-12-03T11:04:37.233Z"9719ee19518b1d8794884cd3cce3b000"148973STANDARD2206203922062039Normalmedia/2015-01-22_AM-RL-XII_Cabozantinib_2014-08-01-D-121_TrG.pdf2025-12-03T11:04:37.058Z"002d59f59f4941eafc8c9a7e0316f589"115611STANDARD2206203922062039Normalmedia/2015-01-22_AM-RL-XII_Eribulin_2014-08-01-D-125.pdf2025-12-03T11:04:35.056Z"b54587b4b74c25f89dc4dc276d1663bc"186540STANDARD2206203922062039Normalmedia/2015-01-22_AM-RL-XII_Eribulin_2014-08-01-D-125_TrG.pdf2025-12-03T11:04:35.375Z"7ab6a692df77d7830e28a0f18ee58694"156306STANDARD2206203922062039Normalmedia/2015-01-22_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWIG_Kopie.pdf2025-12-03T11:04:38.954Z"49120cffecd8a131cf4ddfbe8b9523bb"136089STANDARD2206203922062039Normalmedia/2015-01-27_Bewertung-der-Therapiekosten-und-Patientenzahlen-IQWiG_Alipogentiparvovec.pdf2025-12-03T11:05:26.175Z"2d1a6ed9a952e4cde0faf49f85a6c1a8"106722STANDARD2206203922062039Normalmedia/2015-01-27_Bewertung-der-Therapiekosten-und-Patientenzahlen-IQWiG_Ibrutinib.pdf2025-12-03T11:05:15.678Z"5a895c54c0a686bf9545b2726fe917c0"217857STANDARD2206203922062039Normalmedia/2015-01-27_Wortprotokoll_end_Aflibercept.pdf2025-12-03T11:05:02.253Z"f5c7affb2b3ff4bcda9f10c8d6ff1c12"221711STANDARD2206203922062039Normalmedia/2015-01-29_Modul4A_Ibrutinib.pdf2025-12-03T11:07:23.810Z"baa4f16d946af40c1cd3328418934e07-3"18528286STANDARD2206203922062039Normalmedia/2015-01-30_Modul1_Aclidiniumbromid_Formoterol.pdf2025-12-03T11:05:33.626Z"c389feb68bdf8f7378049f243eed37dc"222216STANDARD2206203922062039Normalmedia/2015-01-30_Modul1_Dulaglutid.pdf2025-12-03T11:05:36.213Z"6cc8571ad816b9bf74d9d18d3e046e22"630304STANDARD2206203922062039Normalmedia/2015-01-30_Modul4A_Dulaglutid.pdf2025-12-03T11:05:34.965Z"5508c118e272dc23e64608d55900a86c"2333509STANDARD2206203922062039Normalmedia/2015-01-30_Modul4B_Dulaglutid.pdf2025-12-03T11:05:35.555Z"922df081ed4cc18d72ce2898468f8bfd"5903202STANDARD2206203922062039Normalmedia/2015-01-30_Modul4C_Dulaglutid.pdf2025-12-03T11:05:35.749Z"af40c4e992defc0aca23074848c72aa4"3739201STANDARD2206203922062039Normalmedia/2015-01-30_Modul4D_Dulaglutid.pdf2025-12-03T11:05:36.233Z"890641d6e6835f9c682ab676d39775b5"4506659STANDARD2206203922062039Normalmedia/2015-01-30_Modul_4A_Aclidiniumbromid_Formoterol.pdf2025-12-03T11:05:33.639Z"9db95669286f5f09298211485c9bad56"4750612STANDARD2206203922062039Normalmedia/2015-01_28_Nutzenbewertung-IQWiG_Lurasidon.pdf2025-12-03T11:05:16.449Z"ceb1134207517389fa3d9d94e2beec16"715343STANDARD2206203922062039Normalmedia/2015-02-01-D-152_Dasabuvir_Addendum.pdf2025-12-03T11:05:37.641Z"89971222baf8bf71ac187b8946346c36"563264STANDARD2206203922062039Normalmedia/2015-02-01-D-153_Ombitasvir-Paritaprevir-Ritonavir_Addendum.pdf2025-12-03T11:05:41.553Z"89971222baf8bf71ac187b8946346c36"563264STANDARD2206203922062039Normalmedia/2015-02-01-D-154_Dulaglutid_Addendum.pdf2025-12-03T11:05:36.883Z"349a38acfa6a48a108f260863e16bcbf"141654STANDARD2206203922062039Normalmedia/2015-02-01_Informationen-zur-zweckmaessigen-Vergleichstherapie_Dasabuvir.pdf2025-12-03T11:05:38.106Z"ec6a1332bdb140f114f842bfffaa5c37"885219STANDARD2206203922062039Normalmedia/2015-02-01_Informationen-zur-zweckmaessigen-Vergleichstherapie_Ombitasvir-Paritaprevir-Ritonavir.pdf2025-12-03T11:05:41.384Z"40a2e5c8182a8cf0f48c8fb0d1266a7a"886624STANDARD2206203922062039Normalmedia/2015-02-01_Modul1_RAMUCIRUMAB.pdf2025-12-03T11:05:40.762Z"de389a7b9bc5cbd888b56cfa69985e18"494611STANDARD2206203922062039Normalmedia/2015-02-01_Modul4A_RAMUCIRUMAB.pdf2025-12-03T11:05:39.350Z"1b2941c06b4cad6607bc58486114795e"3748693STANDARD2206203922062039Normalmedia/2015-02-01_Modul4B_RAMUCIRUMAB.pdf2025-12-03T11:05:39.744Z"093efc3d4ab8d45b4f8d9f333a837900"3255634STANDARD2206203922062039Normalmedia/2015-02-02_Analyse-Schiedsspruch-Perampanel_11-14.pdf2025-12-03T11:45:21.240Z"c741aaca1b1d827842f0372397525f8e"113064STANDARD2206203922062039Normalmedia/2015-02-02_Informationen-zur-zVT_Lurasidon.pdf2025-12-03T11:05:16.259Z"b3f595c7ca1e0cea42bcbcc298f9d341"498432STANDARD2206203922062039Normalmedia/2015-02-02_Nutzenbewertung-G-BA_Alipogentiparvovec_2014-11-01-D-138.pdf2025-12-03T11:05:21.849Z"89f449db5fb8c529c354b07066866d48"969030STANDARD2206203922062039Normalmedia/2015-02-02_Nutzenbewertung-G-BA_Ibrutinib_CLL.pdf2025-12-03T11:05:15.627Z"5e103923c3d462bffdc37bdda7984ff6"1401007STANDARD2206203922062039Normalmedia/2015-02-02_Nutzenbewertung-G-BA_Ibrutinib_MCL.pdf2025-12-03T11:05:15.775Z"66f543067519b2ca9eb6a0ed3521079a"1030292STANDARD2206203922062039Normalmedia/2015-02-02_Schiedsspruch_11-14_Perampanel_Fycompa_013.pdf2025-12-03T11:45:22.158Z"80ff36fd28f9243c74956579ae0abe3d"4915754STANDARD2206203922062039Normalmedia/2015-02-04_Analyse-Schiedsspruch-Perampanel_8-14.pdf2025-12-03T11:45:19.490Z"2c4da1564dff69affd5cc5b8e34bbece"113225STANDARD2206203922062039Normalmedia/2015-02-04_Schiedsspruch_8-14_Perampanel_Fycompa_014.pdf2025-12-03T11:45:23.916Z"e0524563836563d7df4d898fc5a47bcf"5122580STANDARD2206203922062039Normalmedia/2015-02-05_AM-RL-XII_CanagliflozinMetformin_2014-08-15-D-124.pdf2025-12-03T11:04:40.245Z"3fc9ea02398590c059d584af237c6098"130317STANDARD2206203922062039Normalmedia/2015-02-05_AM-RL-XII_CanagliflozinMetformin_2014-08-15-D-124_TrG.pdf2025-12-03T11:04:40.952Z"8262754f556c6b0c636f6bcbfb8d61d1"159009STANDARD2206203922062039Normalmedia/2015-02-05_AM-RL-XII_Empagliflozin_2014-08-15-D-123.pdf2025-12-03T11:04:48.358Z"f45444edee1e59b8644f25a0057d6e7e"194908STANDARD2206203922062039Normalmedia/2015-02-05_AM-RL-XII_Empagliflozin_2014-08-15-D-123_TrG.pdf2025-12-03T11:04:47.648Z"2c8e3586513e67ec9e122d37623ef722"172742STANDARD2206203922062039Normalmedia/2015-02-05_AM-RL-XII_Obinutuzumab_2014-08-15-D-120.pdf2025-12-03T11:04:51.358Z"2ff04c16d96d2167e8a6db863ae6d6de"109415STANDARD2206203922062039Normalmedia/2015-02-05_AM-RL-XII_Obinutuzumab_2014-08-15-D-120_TrG.pdf2025-12-03T11:04:50.705Z"d5b06f26679efd724368f9418cf42a21"120797STANDARD2206203922062039Normalmedia/2015-02-05_Bewertung_der_Therapiekosten_und_Patientenzahlen_IQWiG_Kopie_3.pdf2025-12-03T11:04:50.040Z"c3c230659769f9542e4239140aadbf72"130641STANDARD2206203922062039Normalmedia/2015-02-09_Wortprotokoll_end_Albiglutid.pdf2025-12-03T11:05:13.966Z"cf7d59a0006562e81bb54ddab24207c7"120506STANDARD2206203922062039Normalmedia/2015-02-09_Wortprotokoll_end_Dolutegravir_Abacavir_Lamivudin.pdf2025-12-03T11:05:11.358Z"38d97806922806a38db28d78c6a58d03"88859STANDARD2206203922062039Normalmedia/2015-02-09_Wortprotokoll_end_Idelalisib.pdf2025-12-03T11:05:06.042Z"689b6bddffa9fba917647f02c8e22685"166191STANDARD2206203922062039Normalmedia/2015-02-09_Wortprotokoll_end_Sipuleucel-T.pdf2025-12-03T11:05:07.259Z"fbe0bd281743691d3f74426774b66aa2"118578STANDARD2206203922062039Normalmedia/2015-02-09_Wortprotokoll_end_Sucroferric_Oxyhydroxide.pdf2025-12-03T11:05:09.924Z"4c2c3c4ff04fdb86dbd4b962ac8f9651"104243STANDARD2206203922062039Normalmedia/2015-02-11_A14-41_Simoctocog-alfa_Nutzenbewertung-35a-SGB-V.pdf2025-12-03T11:05:18.858Z"4e1196e202b79cefa2d53a676be602d5"417245STANDARD2206203922062039Normalmedia/2015-02-13_Modul1_Apremilast.pdf2025-12-03T11:05:43.752Z"aa79879cb94913ae9f0943d43230b4c6"322954STANDARD2206203922062039Normalmedia/2015-02-13_Modul4A_Apremilast.pdf2025-12-03T11:05:43.140Z"6cd6990ea58566de721e7448d33d8320"2543720STANDARD2206203922062039Normalmedia/2015-02-13_Modul4B_Apremilast.pdf2025-12-03T11:05:43.634Z"1d0c82b9b3a43cdab547ab5560d9054e"3957593STANDARD2206203922062039Normalmedia/2015-02-15_Informationen_zur_zVT-D-151_Apremilast.pdf2025-12-03T11:05:44.759Z"73c32a5052c13cecb1fcb26d45ce732e"2080985STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Apixaban_2014-09-01-D-126.pdf2025-12-03T11:04:52.451Z"bde5ebb328c659f9c91e5498ef38d84a"148426STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Apixaban_2014-09-01-D-126_TrG.pdf2025-12-03T11:04:51.177Z"bace1300328e759785f31ecb00acc142"137271STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Daclastavirr_2014-09-01-D-129.pdf2025-12-03T11:04:59.742Z"7e4070dcfd8567087d9cda5c73019f9e"297475STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Daclastavirr_2014-09-01-D-129_TrG.pdf2025-12-03T11:04:59.947Z"de5e592b7060e7c77e162f4a19e2fc30"172166STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Ivacaftor-nAWG_2014-09-01-D-133.pdf2025-12-03T11:04:53.271Z"fb4a6ed95778836a275d331ca939124b"83662STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Ivacaftor-nAWG_2014-09-01-D-133_TrG.pdf2025-12-03T11:04:53.561Z"db57bdc7e81ccc42f5fc3cd0d6b394fb"107453STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Nalmefen_2014-09-01-D-127.pdf2025-12-03T11:04:54.279Z"2ee7ba8195f8761f73af8b7056d5fd65"75703STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Nalmefen_2014-09-01-D-127_TrG.pdf2025-12-03T11:04:54.185Z"c6cf596d472d1891e79d79ff98527671"110143STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Propranolol_2014-09-01-D-128.pdf2025-12-03T11:04:56.058Z"a71189c7a4b74c7c2d58be9559dc563c"111526STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Propranolol_2014-09-01-D-128_TrG.pdf2025-12-03T11:04:56.661Z"8fdb51b5422b78fbd73d8b878f5fbb60"139179STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Regorafenib-nAWG_2014-09-01-D-134.pdf2025-12-03T11:04:56.663Z"274f147111284c69ed01c71c45a4b266"57379STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Regorafenib-nAWG_2014-09-01-D-134_TrG.pdf2025-12-03T11:04:56.751Z"7a9e80014649245227a2c99c89292b5c"86071STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Teduglutid_2014-09-01-D-130.pdf2025-12-03T11:05:00.241Z"3d140bf067451002a806d9ff55528db9"107527STANDARD2206203922062039Normalmedia/2015-02-19_AM-RL-XII_Teduglutid_2014-09-01-D-130_TrG.pdf2025-12-03T11:05:00.558Z"56d9bcebab6a164471a24566830a5b21"95521STANDARD2206203922062039Normalmedia/2015-02-23_Modul1_Fingolimod.pdf2025-12-03T11:05:50.139Z"b825403a2c1d49cef89d7cb1c6452bde"290615STANDARD2206203922062039Normalmedia/2015-02-24_Ataluren_Bewertung-der-Therapiekosten-und-Patientenzahlen-IQWIG.pdf2025-12-03T11:05:25.809Z"6a4d57ed3b4a525d766453d1d5bb3f76"124238STANDARD2206203922062039Normalmedia/2015-02-24_Modul4B_Fingolimod.pdf2025-12-03T11:05:52.827Z"49505720fd30a32ae9f30eb0f4e3f871"3451363STANDARD2206203922062039Normalmedia/2015-02-24_Modul4C_Fingolimod.pdf2025-12-03T11:05:52.915Z"dad8633a74ed62dc30383250170ccaaa"3509201STANDARD2206203922062039Normalmedia/2015-02-26_Modul1_Insulin_degludec.pdf2025-12-03T11:05:44.762Z"89f4c8fbb748ac946269b8de6f170d6e"421351STANDARD2206203922062039Normalmedia/2015-02-26_Modul4E_Insulin_degludec_final.pdf2025-12-03T11:05:46.616Z"f4cd3dbadb988112aad9384bc7f00fa4"3258187STANDARD2206203922062039Normalmedia/2015-02-26_Nutzenbewertung_IQWiG_Ledipasvir-Sofosbuvi.pdf2025-12-03T11:46:57.850Z"369f10d87f204c82eda3e0a71178a95f"1306635STANDARD2206203922062039Normalmedia/2015-02-26_Nutzenbewertung_IQWiG_Vildagliptin.pdf2025-12-03T11:05:25.063Z"9261e130ad82925dc888348fb8b0e09c"338945STANDARD2206203922062039Normalmedia/2015-02-27_Nutzenbewertung-G-BA_Ataluren.pdf2025-12-03T11:05:25.857Z"d7e2c966d0883e77eef4cb36c3b2466e"657322STANDARD2206203922062039Normalmedia/2015-03-01-D-158_Insulin_degludec_Addendum.pdf2025-12-03T11:05:44.822Z"5b696dd66bf9143f66c4885770c8e5c2"92275STANDARD2206203922062039Normalmedia/2015-03-01_Info_zur_zVT_Insulin_degludec_nAWG_D-158.pdf2025-12-03T11:05:45.756Z"083db84e395b96bef7dc782f80d5eb6e"980144STANDARD2206203922062039Normalmedia/2015-03-05_Aflibercept_nAWG_2014-09-15-D-137.pdf2025-12-03T11:05:02.750Z"c8a11887351108b66dfdbe54ca7c7e2b"177759STANDARD2206203922062039Normalmedia/2015-03-05_Aflibercept_nAWG_2014-09-15-D-137_TrG.pdf2025-12-03T11:05:02.783Z"be2c5d9573a4ef459f742fd9a7d6e513"140209STANDARD2206203922062039Normalmedia/2015-03-09_Modul1_Aflibercept.pdf2025-12-03T11:05:47.547Z"33c86b1a64c85f964d040a6d504a2244"481235STANDARD2206203922062039Normalmedia/2015-03-09_Modul4D_Aflibercept.pdf2025-12-03T11:05:49.120Z"cd0bb52d874d10ffcc251225d7d4998f"3858217STANDARD2206203922062039Normalmedia/2015-03-09_Wortprotokoll_Alipogentiparvovec.pdf2025-12-03T11:05:21.459Z"c95706e5d9d27205911fe5adab8cf675"107589STANDARD2206203922062039Normalmedia/2015-03-09_Wortprotokoll_Ibrutinib.pdf2025-12-03T11:05:15.951Z"45d9463e5d54d9502440d7c1b7e9da72"165611STANDARD2206203922062039Normalmedia/2015-03-09_Wortprotokoll_Lurasidon.pdf2025-12-03T11:05:16.569Z"4ef2e2be4b0d72b0ab2e2b90f069430c"69536STANDARD2206203922062039Normalmedia/2015-03-12_Modul1_Nintedanib.pdf2025-12-03T11:05:46.692Z"4d53d53774e23a921b48664dba4c40dd"164299STANDARD2206203922062039Normalmedia/2015-03-15_Informationen-zVT_Aflibercept-nAWG_D-160.pdf2025-12-03T11:05:48.072Z"59d2d20ead3a4c49de129ddcc796c9a4"1175118STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Albiglutid_2014-10-01-D-132.pdf2025-12-03T11:05:12.176Z"71be93282fbcb3b1cbe13ecec9cd8fb6"209238STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Albiglutid_2014-10-01-D-132_TrG.pdf2025-12-03T11:05:12.266Z"fc53050c89853e7b46e425cad87a41ef"172778STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Dolutegravir-Kombi_2014-10-01-D-131.pdf2025-12-03T11:05:11.850Z"d35c2457da1441c58a9c7566cf48af64"180086STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Dolutegravir-Kombi_2014-10-01-D-131_TrG.pdf2025-12-03T11:05:11.854Z"8868db30cd7a5c7a2d42aac6f033c52a"171874STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Idelalisib_2014-10-01-D-135.pdf2025-12-03T11:05:03.996Z"3ea7f84ef38ea4b994445929b7abf21b"156477STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Idelalisib_2014-10-01-D-135_TrG.pdf2025-12-03T11:05:04.445Z"dfd0468dbcf172f7abfa1e9d3e71abf7"197922STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Sipuleucel-T_2014-10-01-D-139.pdf2025-12-03T11:05:07.660Z"de6c6de1a41778eb9d9eab55f0e6efcc"123120STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Sipuleucel-T_2014-10-01-D-139_TrG.pdf2025-12-03T11:05:07.857Z"0062e7ef34702ef156ff34baf54326ca"153278STANDARD2206203922062039Normalmedia/2015-03-19_AM-RL-XII_Sipuleucel-T_2014-10-01-D-139_TrG.pdf